




INVESTIGATING THE MECHANISMS OF p35-MEDIATED 













A dissertation submitted to Johns Hopkins University in conformity with the requirements for 














 Aging and adult-onset neurodegenerative diseases (NDDs) share multiple cellular 
phenotypes stemming from dysfunction of an overlapping set of molecular mechanisms; 
however, aging by itself fails to cause neurodegeneration in all individuals, indicating that NDDs 
are the result of more than brain aging alone.  Thus, while aging is the greatest risk factor for 
NDDs, a complete understanding of NDD etiology and pathogenesis will require the full 
elucidation of the relationship between aging and degeneration.  My thesis project investigates 
this relationship by probing the mechanisms underlying a model of adult-onset 
neurodegeneration in Drosophila.  In humans, cyclin dependent kinase 5 (Cdk5) has been linked 
to multiple NDDs, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral 
sclerosis.  Cdk5 activity requires binding an activator subunit; in Drosophila, the sole activator is 
the neuron-specific p35.  We develop a comprehensive metric for physiological age in 
Drosophila based on genome-wide expression profiling, and show that loss (mutant) or 
overexpression (OE) of p35 in young, presymptomatic flies accelerates the intrinsic rate of aging 
of brain and thorax tissue.  Gene ontology analysis revealed that biological processes affected by 
altered p35 levels are also affected by aging.  Further, modulation of p35 leads to degenerative 
phenotypes including impaired autophagy, loss of central brain neurons, motor defects, and 
shortened lifespan, all of which are observed in human ND diseases.  These findings suggest that 
neuronal dysfunction can cause accelerated aging, which then acts as a driving mechanism to 
induce neurodegeneration. 
In parallel work, we also investigated the regulatory role of p35 in regards to the axon 
initial segment (AIS) and its potential link to neurodegeneration.  p35 activity modulates the size 
of the AIS of mushroom body (MB) neurons, and deletion of p35 results in swelling of the 
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proximal axon in the vicinity of the AIS; furthermore, p35-mutant flies exhibited an accelerated 
loss of MB neurons.  Thus, we sought to investigate whether perturbation of the AIS contributed 
to p35-mediated neurodegeneration.  We identified a novel regulator that robustly modulates the 
AIS independently of p35, and showed that shortening of the AIS may be sufficient to induce 
MB neurodegeneration.  Taken together, our results suggest p35-mediated neurodegeneration 
results from accelerated aging effects in combination with cell-autonomous neuronal insults.  
These data fundamentally recast our picture of the relationship between neurodegenerative 
processes and their most prominent risk factor, natural aging, and have profound implications for 
identifying which aspects of NDDs could be productive targets for therapy. 
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Chapter 1.  Introduction 
Recent literature has estimated that the global population of people over 80 years old will 
triple in the next 30 years (Fontana et al, 2014).  As populations are aging longer and longer, 
they are becoming more at risk for a variety of diseases.  Detrimental changes occur with age, 
leading to an ever-increasing vulnerability and reduction in healthspan.  The vast majority of 
elderly people over the age of 65 have multiple comorbidities, ranging from arthritis to cancer to 
neurodegenerative diseases (NDDs) (Hung, Ross et al. 2011).  Indeed, aging has long been 
recognized as the greatest risk factor for multiple NDDs, including Alzheimer’s disease (AD), 
Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).  Nearly half of people over 
the age of 85 have AD (Podtelezhnikov, Tanis et al. 2011), while the prevalence of PD, the 
second most common age-related NDD, quintuples in individuals older than 85, relative to the 60 
years or older cohort (Reeve, Simcox et al. 2014).  ALS rarely affects people under the age of 40, 
but its prevalence increases exponentially in older individuals, with 70-79 year olds having the 
highest incidence of the disease (Ingre, Roos et al. 2015).  While aging very obviously plays a 
role in each of these diseases, the underlying age-related factors that predispose some individuals 
to disease remains unknown.  It is therefore essential to elucidate the relationship between 
degeneration and aging to progress forward in the development of therapeutic strategies. 
 Although some cases of adult-onset NDDs are related to specific genetic risk factors, and 
thus proceed through hallmark mechanisms, most instances of NDD are a sporadic form.  NDDs 
generally present with some combination of molecular and cellular phenotypes that are shared 
amongst multiple diseases; these phenotypes interconnect and modulate one another, eventually 
leading to cellular dysfunction and neurodegeneration.  These pathologies will be discussed in 
detail below.   
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1.1 Pathologies of Neurodegeneration 
Protein aggregation and proteostatic defects 
Many protein aggregates contain misfolded protein.  Proper protein folding is required 
for normal function, so misfolded proteins must either be re-folded in the appropriate 
conformation, or degraded and removed.  Proteins can be highly dynamic, however, frequently 
changing conformation as they interact with other proteins, form complexes, or translocate 
across membranes.  Thus, there is an ever-present risk for misfolding to occur.  To combat this, 
cells utilize multiple mechanisms to ensure correct folding.  Chaperone proteins assist folding at 
multiple steps.   The most notable chaperones are the highly conserved heat-shock family of 
proteins.  HSP60 and HSP70 are more promiscuous, interacting with a wide range of proteins, 
while other members exhibit more specialized localization and targeting.  As polypeptides are 
translated in either the cytosol or the ER lumen, some chaperones assist in the initial folding 
(Koga, Kaushik et al. 2011).  Other chaperones are located near organelle membranes to aid in 
protein refolding after translocation, and throughout the cytosol to help with refolding or 
disaggregation as needed.  Notably, many proteins associated with NDDs are intrinsically 
disordered and therefore carry a higher risk of misfolding into a pathologic conformation 
(Uversky 2009).  If the chaperone is unable to correct the misfolding or aggregation, it will target 
the dysfunctional protein for lysosomal or proteasomal degradation.   
AD, PD, and ALS, among others, are all associated with improper protein aggregation 
(Ross and Poirier 2004).  AD is characterized by the accumulation of amyloid beta peptide and 
hyperphosphorylated tau (Bloom 2014), PD is linked to a-synuclein (α-syn) deposits (Davie 
2008), and ALS sometimes results in aggregates of superoxide dismutase 1 (SOD1) (Bruijn, 
Houseweart et al. 1998).  The aggregates inhibit normal processing and function of the proteins 
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involved, and can further promote disease by sequestering additional interactors.  Aggregates can 
also be deposited extracellularly, where they can cause neuronal injury (Zhao, Beers et al. 2010).  
Extracellular aggregates can induce aggregation in neighboring, unaffected cells, further 
propagating the detrimental effects (Desplats, Lee et al. 2009, Frost, Jacks et al. 2009, Luk, Song 
et al. 2009). 
Proteasomal degradation occurs through chaperone-mediated autophagy (CMA) or via 
the ubiquitin proteasome system (UPS).  A subset of heat shock proteins (Hsc70 and Hsp90) 
acquire post-translational modifications that are exclusively associated with CMA (Kaushik, 
Bandyopadhyay et al. 2011).  Hsc70 recognizes and binds misfolded proteins exposing a 
KFERQ-like motif, and transports them to lysosomes expressing lysosome-associated membrane 
protein 2 (LAMP-2A).  Intralumenal lys-Hsc70 facilitates the formation of a translocation 
complex and the transport of the protein into the lysosome, where it is degraded.  Wild-type a-
syn is typically degraded via CMA; certain mutated forms of a-syn, however, bind more 
strongly to LAMP-2A, but do not get translocated into the lysosome for degradation (Cuervo, 
Stefanis et al. 2004).  Thus, mutant a-syn itself does not get degraded, and it prevents the 
degradation of wild-type a-syn, leading to toxic gain of function conditions.   
While CMA is specific to mammals, the UPS is conserved among eukaryotes, with 
analogous mechanisms even found in archaea (Fu, Liu et al. 2016).  The 26S proteasome 
comprises a catalytic core (20S core particle) sandwiched between two regulatory complexes 
(19S regulatory particle) (Koga, Kaushik et al. 2011).  Polyubiquitinated proteins targeted for 
degradation are recognized by the regulatory subunits.  The ubiquitin chains are removed by 
deubiquitinases and unfoldases straighten the substrate, which is then fed into the catalytic 
barrel.  The substrate is proteolyzed into shorter polypeptides, which are released back into the 
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cytoplasm.  Multiple types of NDD brain samples exhibit polyubiquitination of protein 
aggregates, as well as an accumulation of oxidized proteins, hinting at impaired ubiquitin-
dependent proteolysis (Lim 2007, Oddo 2008, Lehman 2009).  Further, treatment with a 
selective proteasome inhibitor is sufficient to induce neurodegeneration, and is accompanied by 
the formation of a-syn aggregates (McNaught, Björklund et al. 2002, Fornai, Lenzi et al. 2003, 
Miwa, Kubo et al. 2005).  a-syn can also directly interact with proteasome subunits and 
potentially block polyubiquitin recognition (Ghee, Fournier et al. 2000, Paul 2008).  Thus, 
impaired UPS function can contribute to protein aggregation, which can then further inhibit UPS 
function, leading to enhanced accumulation of aggregates.  It remains to be seen if protein 
aggregation typically causes UPS dysfunction through direct interactions, through overloading 
the system, or through alternative mechanisms, or more likely, a context-dependent combination 
thereof.   
 
Mitochondrial dysfunction 
As the primary source of ATP, mitochondria are vital to cellular function.  Notably, 
mitochondria are not static organelles, but are rather part of a dynamic network that rapidly 
divides and fuses.  Through these processes, there is regular exchange of mitochondrial DNA 
(mtDNA), lipids, and proteins needed for normal function (Kowald and Kirkwood 2011).  
Additionally, fission allows for dysfunctional mitochondria to be separated from the network and 
selectively degraded through mitophagy, protecting the remaining mitochondria (Wang and 
Klionsky 2011).   
The most susceptible mitochondrial components are mtDNA and the respiratory chain 
enzymes.  mtDNA encodes thirteen peptide subunits of the electron transport chain complexes, 
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and includes tRNA and rRNA genes (Taanman 1999).  Mitochondrial DNA is more vulnerable 
to damage than nuclear DNA as mitochondria lack histones, which offer some protection, and 
because mitochondria do not possess the complete repertoire of repair machinery found in the 
nucleus.  Given the high number of mitochondria within a cell, the detrimental consequences of 
mutations can initially be suppressed by the abundance of non-mutated mtDNA.  Over time, 
however, clonal expansion of the mutated mtDNA can lead to dysfunctional mitochondria and 
respiratory deficiency (Winklhofer and Haass 2010).  Alzheimer’s patients show significant 
accumulation of mtDNA mutations, as well as reductions in mRNA levels (Coskun, Beal et al. 
2004, Leuner, Hauptmann et al. 2007, Jellinger 2010).  Substantia nigral neurons from PD 
patients were found to have an increased number of mtDNA mutations relative to age-matched 
controls (Bender, Krishnan et al. 2006), and maternally-inherited mtDNA mutations have been 
associated with L-DOPA-responsive parkinsonism (Lin and Beal 2006).  Mutations in the 
control region can lead to altered expression of mtDNA genes, while mutations in coding 
sequences can generate peptides that do not fold or complex properly and have altered activity.   
The respiratory chain comprises Complexes I-V, located in the inner mitochondrial 
membrane; as electrons are transferred from one complex to the next, protons are transported 
across the membrane, generating a proton electrochemical gradient.  This gradient drives energy 
production via Complex V, which is an ATP synthase.  As protons flow through the complex 
back into the mitochondrial matrix, the free energy powers the oxidative phosphorylation of 
ADP into ATP.  Dysfunction of these complexes arises from stoichiometric imbalances and 
changes in individual complex concentrations, as well as declines in specific complex efficiency 
(Leuner, Hauptmann et al. 2007).  AD brain tissue exhibits significant reductions in multiple 
respiratory chain complexes, and Aβ was found to inhibit cytochrome oxidase (Complex IV), as 
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well as α-ketoglutarate dehydrogenase and pyruvate dehydrogenase (Casley, Canevari et al. 
2002, Terni, Boada et al. 2010).  PD is largely associated with deficiencies in Complex I activity, 
although the underlying causative mechanisms remain to be completely elucidated (Winklhofer 
and Haass 2010).  Additionally, α-syn binds to Complex IV, which may interfere with 
respiratory complex activity in PD (Elkon, Don et al. 2002).  In ALS, SOD1 mutants are 
associated with decreased respiratory efficiency (Borthwick, Johnson et al. 1999).  
 Additional causes of mitochondrial dysfunction include the formation of the 
mitochondrial permeability transition pore (mPTP) and perturbation of mitochondrial dynamics.  
Under certain pathological conditions, the mPTP forms in the mitochondrial membranes, 
creating a path from the mitochondrial matrix to the cytosol (Du and Yan 2010).  Formation of 
the mPTP is associated with Aβ, as Aβ directly interacts with cyclophilin D (cypD), a major 
constituent of the mPTP (Du, Guo et al. 2008).  Further, AD brains showed elevated levels of the 
Aβ-cypD complex, which was absent in control brains.  Ultimately, the mPTP causes 
mitochondrial swelling, loss of membrane potential, and damage to the respiratory transport 
chain (Du and Yan 2010).   
Mitochondrial fusion and fission are necessary for determining mitochondrial size, 
regulating mitochondrial degradation, and maintaining proper distribution (Itoh, Nakamura et al. 
2013).  Fusion proteins OPA1, Mfn1, and Mfn2 were found to be decreased in AD samples, 
while the fission protein Fis1 was upregulated (Wang, Su et al. 2009).  PINK1 and Parkin, two 
proteins commonly dysregulated in PD, function in mitochondrial fission (Poole, Thomas et al. 
2008) and degradation via mitophagy (Pickrell and Youle 2015).  Additional PD-related proteins 
are also involved with impaired mitochondrial dynamics, as both α-syn and LRRK2 are 
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associated with mitochondrial fragmentation (Nakamura, Nemani et al. 2011, Wang, Yan et al. 
2012).   
Mitochondrial dysfunction results in a notable decline in energy metabolism as ATP 
production is significantly decreased.  Lower ATP levels put an additional strain on cells, as 
many processes compete for available ATP.  One such process is the UPS, which requires ATP 
at multiple steps.  Thus, mitochondrial dysfunction can cause proteostatic defects, further 
perturbing cellular homeostasis.  Mitochondrial dysfunction also results in impaired calcium 
homeostasis, and increased generation of reactive oxygen species (ROS) (Celsi, Pizzo et al. 
2009).  Notably, ~90% of cellular ROS is generated by the mitochondria (Balaban, Nemoto et al. 
2005).   
 
Oxidative Stress 
 Elevated production of ROS and other free radicals causes oxidative stress, leading to a 
host of detrimental consequences, including DNA mutations; damaged proteins, lipids, and 
nucleic acids; uncoupling of oxidative phosphorylation; induction of the mitochondrial 
permeability transition; and disrupted calcium homeostasis (Leuner, Hauptmann et al. 2007).  
Cells employ multiple antioxidant mechanisms to deal with oxidative stress.  These mechanisms 
include enzymes such as superoxide dismutases, catalase, glutathione-S-transferases, glutathione 
peroxidase, and glutathione reductase, as well as a variety of non-enzymatic antioxidants like 
glutathione, vitamins, and β-carotene (Birben, Sahiner et al. 2012).  Once the generation of free 
radicals exceeds the capabilities of the antioxidant defense mechanisms, oxidative stress occurs. 
Neurons are notable for their extremely high energy and oxygen consumption (Raichle 
and Gusnard 2002).  Indeed, neurons have a higher relative content of mitochondria to meet this 
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energy demand (Leuner, Hauptmann et al. 2007).  Consequently, neurons generate a significant 
amount of ROS and are particularly vulnerable to oxidative stress.  Further, neurons have a high 
concentration of unsaturated fatty acids that are more susceptible to lipid peroxidation (Coyle 
and Puttfarcken 1993), in combination with a relatively low concentration of antioxidant 
enzymes (Mattson, Chan et al. 2002).  As with other cell types, neurons are also subject to 
genomic instability (Chow and Herrup 2015) and proteostatic defects (Powers, Morimoto et al. 
2009), leading to an overall decline in neuronal function and decreased cognitive function.   
 Oxidative stress has been identified in many diseases, including AD, PD, and ALS 
(Uttara, Singh et al. 2009).  Various markers of oxidative stress, such as lipid peroxidation 
products, oxidative modifications of proteins, and oxidized rRNA and mRNAs, have all been 
found to be elevated in multiple brain regions of AD patients (Kim, Kim et al. 2015).  These 
increases are preceded by decreases in antioxidant enzyme activity and lower levels of non-
enzymatic antioxidants, suggesting that an oxidative imbalance occurs at the earliest stages of 
AD (Wang, Wang et al. 2014).  Similarly, there is elevated oxidative stress accompanied by a 
decrease in glutathione levels and glutathione peroxidase activity in PD (Martin and Teismann 
2009).  Of note, oxidative stress was found to be sufficient to induce α-syn aggregation 
(Hashimoto, Hsu et al. 1999).  Evidence of oxidative stress, including elevated protein carbonyl 
levels, lipid oxidation, and oxidized DNA, has also been found in tissues from patients with 
either familial or spontaneous ALS (Barber and Shaw 2010).   
 The detrimental effects of oxidative stress are exacerbated by its feedback on multiple 
pathways regulating cellular homeostasis.  mtDNA and mitochondrial proteins are all targets of 
oxidative stress, and their dysfunction can result in further generation of ROS, creating a cycle of 
increased stress accompanied by mitochondrial dysfunction (Winklhofer and Haass 2010, 
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Swerdlow 2011).  Levels and activity of antioxidant enzymes can also suffer from oxidative 
stress, diminishing the cell’s capacity of dealing with increased ROS levels.  Accumulation of 
ROS leads to a higher number of damaged and misfolded proteins, which not only affects protein 
function but also puts an added strain on proteostasis.  Further, oxidation of various potassium 
channels is suspected to alter channel activity, which could lead to perturbed electrophysiology 
(Sesti 2016).   
 
Immune dysfunction 
Multiple NDDs are associated with chronic activation of the immune system, which 
includes activation of microglia and astrocytes, increased pro-inflammatory signaling, and T-cell 
infiltration.  Under normal conditions, microglia monitor the brain milieu to protect against 
invading pathogens or to identify and repair tissue damage.  Microglia perform a host of 
functions to accomplish these tasks.  Microglia will phagocytose foreign material, damaged or 
apoptotic cells, cellular debris, neurofibrillary tangles, and amyloid plaques.  Microglia can also 
secrete cytokines to activate additional microglia, recruit other immune cells, promote B-cell 
maturation, and upregulate pro-inflammatory signaling (Graeber and Streit 2010).  As a 
controlled response, these functions are neuroprotective; chronic microglial activation, however, 
can become detrimental to neurons and contribute to neurodegeneration.   
Activated microglia have been found to localize around extracellular protein aggregates 
in post-mortem analysis of AD (Ishizuka, Kimura et al. 1997), PD (Yamada, McGeer et al. 
1992), and ALS (Zhao, Beers et al. 2010) samples.  Aβ has been shown to recruit and activate 
microglia by stimulating the release of CCL2 from astrocytes, neurons, oligodendrocytes, and 
microglial cells themselves (Guillot-Sestier and Town 2013); decreased levels of CCR2, the 
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receptor for CCL2, result in decreased microglia accumulation in response to elevated Aβ (El 
Khoury, Toft et al. 2007).  Activated microglia also secrete a number of pro-inflammatory 
cytokines such as TNF-α, IL-6, IL-1α, and GM-CSF, as evidenced by elevated cytokine levels in 
transgenic mouse models and tissue samples from AD and PD patients (Patel, Paris et al. 2005, 
Long-Smith, Sullivan et al. 2009).  Further, AD patients show elevated circulating levels of 
macrophage colony-stimulating factor (M-CSF), a chemokine that attracts monocytes and is 
produced by microglia (Laske, Stransky et al. 2010).  The neurotoxic effects of extracellular 
SOD1 in ALS are suggested to be microglia-dependent, as blocking microglia activation failed to 
induce neurodegeneration in a cell-culture model (Zhao, Beers et al. 2010).  Microglia are also 
known to secrete ROS, which can serve as an inflammatory signal by amplifying cytokine 
release (Giunta, Fernandez et al. 2008); chronic secretion of ROS can contribute to oxidative 
stress, as previously discussed. 
Secreted cytokines and chemokines can disrupt the blood brain barrier (BBB) and attract 
other immune cells to the site of microglia activation.  Both AD and PD patients exhibit 
increased BBB permeability, and an influx of activated T cells into the brain (Desai, Monahan et 
al. 2007, Amor, Puentes et al. 2010).  T cell infiltration plays a significant role in dopaminergic 
neurodegeneration: in multiple mouse models, reducing levels of CD4+ T cells attenuates cell 
loss (Brochard, Combadiere et al. 2009).  Reynolds et al demonstrated that T cells could 
recognize α-syn modified by oxidative stress and exacerbated the neurotoxic effects of microglia 





Defects in axonal transport and axonal swelling 
 Proper neuronal function requires an established microtubule network that connects each 
of the subcellular compartments and permits the transport of cargo between regions.  Neurons 
are organized such that the stable, minus-end of microtubules is located in the cell body, while 
the more dynamic plus-end of microtubules extends into the axon.  Motor proteins utilize this 
stereotypical organization to transport vesicles, organelles, and other cellular cargos throughout 
the neuron.  Kinesins, the plus-end directed motor, transport cargo away from the soma in the 
anterograde direction.  Dyneins, the minus-end directed motor, carry cargo from the synapse 
towards the cell body.  Disruption of axonal trafficking can lead to mislocalization of proteins, 
lipids, and organelles, impaired clearance of cellular debris or protein aggregates, axonal 
swelling, and overall declines in neuronal function and neurotransmission.   
 Impaired axonal transport has been linked to a variety of NDDs, including AD, PD, and 
ALS.  The two pathological hallmarks of AD, tau and Aβ aggregations, are both capable of 
impairing axonal transport.  Aggregation of tau into filaments reveals an N-terminal amino acid 
sequence that is otherwise hidden; this sequence can activate protein phosphatase 1 (PP1), which 
leads to the subsequent activation of GSK3 and the eventual detachment of kinesin from its 
cargo, selectively inhibiting anterograde transport while not affecting retrograde transport 
(LaPointe, Morfini et al. 2009).  Physiological concentrations of Aβ are sufficient to inhibit both 
anterograde and retrograde transport in squid axoplasm (Pigino, Morfini et al. 2009), and to 
attenuate synaptic transmission (Moreno, Yu et al. 2009).  Further, multiple mouse models of 
AD have directly shown impaired transport of membrane bound organelles such as 
mitochondria, endosomes, and multivesicular bodies (Pigino, Morfini et al. 2003, Lazarov, 
Morfini et al. 2007), and mitochondria were redistributed and accumulate in the soma of AD 
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pyramidal neurons (Wang, Su et al. 2009).  α-syn, associated with PD and numerous other 
NDDs, binds to synaptic vesicles and is thought to be involved in vesicular transport; mutant 
versions of α-syn associated with onset of PD are unable to bind vesicles (Jensen, Nielsen et al. 
1998).  Furthermore, injection of mutant α-syn into rats perturbs axonal transport by decreasing 
kinesin and dynein levels (Chung, Koprich et al. 2009).  Lastly, a transgenic mouse model of 
ALS expressing G93A SOD1 exhibited impaired transport of radiolabeled cytoskeletal 
components (Zhang, Tu et al. 1997). 
Another pathological hallmark common to many NDDs, axonal swelling, can result from 
and contribute to defects in axonal transport.  Indeed, impairment of axonal transport can lead to 
accumulations of organelles and other cargos, forming a traffic jam that can cause swellings.  
These varicosities then further inhibit axonal trafficking in turn (Chevalier-Larsen and Holzbaur 
2006).  AD patients expressing amyloid precursor protein (APP) mutations, as well as animal 
models overexpressing APP, exhibit axonal aggregates and swellings (Gunawardena and 
Goldstein 2001, Stokin, Lillo et al. 2005).  Further, Aβ accumulates in these swellings, and 
extracellular Aβ deposits are found in close proximity, suggesting the swellings may be a site of 
release (Christensen, Huettenrauch et al. 2014).  In an experimental model of PD, expression of 
mutant α-syn impaired axonal transport and lead to axonal varicosities (Chung, Koprich et al. 
2009, Chu, Morfini et al. 2012).  Further, motor neurons from patients with ALS were found to 
have an elevated number of neurofibrillary swellings in the proximal axon which contained 
multiple types of cellular organelles (Delisle and Carpenter 1984, Sasaki, Maruyama et al. 1990).   
Synaptic loss 
 The neuronal synapse permits interneuronal communication and communication between 
neurons and non-neural tissue.  Briefly, this involves the regulated release of neurotransmitters 
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into the synaptic cleft.  Interruption of this communication can lead to cognitive decline and 
other behavioral phenotypes.  Each of the previously discussed mechanisms can lead to synaptic 
dysfunction and impaired signaling from the presynaptic neuron.  Alternatively, neurons can also 
lose synapses in their dendritic arbor.   
Synaptic loss often precedes neurodegeneration, and is considered the strongest correlate 
for cognitive decline (Koffie, Hyman et al. 2011).  AD is associated with decreased expression of 
multiple synaptic proteins (Masliah, Mallory et al. 2001) and an overall decline in synaptic 
number.  Notably, synaptic size appeared to increase as a compensatory mechanism to maintain 
the total synaptic contact area per volume (DeKosky and Scheff 1990).  Dendritic regions in 
close proximity to amyloid plaques exhibited loss of dendritic spines and more robust loss of 
synapses than regions farther away (Tsai, Grutzendler et al. 2004).  α-syn is capable of altering 
synaptic function at both the pre- and post-synaptic level.  Aggregates of α-syn are commonly 
found in the presynaptic terminal, leading to a decrease in presynaptic markers (Kramer and 
Schulz-Schaeffer 2007).  In parallel, postsynaptic markers were also decreased, and were 
accompanied by the loss of dendritic spines.   
 
Mechanisms of cell-death 
The terminal phenotype of neurodegeneration, neuronal death, is multi-faceted and 
complex.  Cell-death may occur via programmed cell-death (PCD), which comprises apoptosis 
and autophagy, through necrosis, or through a handful of rarer modalities (Kroemer, Galluzzi et 
al. 2009).  Apoptosis is primarily caspase-mediated, and can arise through cell-cycle reactivation, 
p53 activation, JNK signaling, or bcl-2 signaling, among other pathways; cell-cycle re-entry 
appears to be the most prominent apoptotic inducer in ND (Greene, Liu et al. 2007, Levy, 
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Malagelada et al. 2009).  Autophagic cell death is characterized by cell death in the absence of 
the chromatin condensation that is typically observed with apoptosis; further, there is widespread 
vacuolization of the cytoplasm (Kroemer, Galluzzi et al. 2009).  Morphologically, necrosis 
involves swelling of organelles and of the cell itself, plasma membrane rupture, and subsequent 
loss of intracellular contents.   
For many NDDs, it is still unclear what the direct mechanism utilized is, and in many 
cases, it is highly likely that multiple pathways occur even within a single patient, sample, or 
cell.  During AD, PD, and ALS, some post-mitotic neurons show evidence of re-entering the cell 
cycle, such as upregulation of mitotic markers and DNA replication (Ranganathan and Bowser 
2003, Lee, Casadesus et al. 2009, Levy, Malagelada et al. 2009).  Neurons cannot complete 
mitosis upon leaving G0, so initiation of the cell cycle leads to their death, usually via apoptosis.  
Indeed, there is evidence of transcriptional upregulation of caspases, as well as caspase 
activation, in AD samples (Spires-Jones, Stoothoff et al. 2009), and overexpressing the anti-
apoptotic protein bcl-2 prevented degenerative phenotypes in a transgenic mouse model of AD 
(Rohn, Vyas et al. 2008).  However, a separate study failed to find increases in activated 
caspases and other pro-apoptotic proteins, casting doubt on whether AD-related 
neurodegeneration occurs through apoptosis (Woodhouse, Dickson et al. 2006).  Aβ has been 
shown to induce excitotoxicity, which can cause neuronal death with morphological changes 
observed with both apoptosis and necrosis, so multiple pathways are likely involved (Gorman 
2008, Kroemer, Galluzzi et al. 2009).  Similarly, there have been conflicting results regarding 
apoptosis in PD.  Some studies have been able to show activation of caspases and an increase in 
apoptotic cells using TUNEL staining (Tompkins, Basgall et al. 1997, Tatton 2000), while others 
found no evidence of apoptosis (Kosel, Egensperger et al. 1997, Wullner, Kornhuber et al. 1999).  
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Drug models of PD have revealed that Parkinson mimetics can induce both apoptosis and 
necrosis (Levy, Malagelada et al. 2009).  Of note, many of the cellular processes underlying 
apoptosis require ATP; thus, in cases of mitochondrial dysfunction where energy output is 
impaired, a neuron may be driven towards necrosis instead of apoptosis (Gorman 2008). 
  
1.2 Investigating the relationship between aging and neurodegeneration 
Hypotheses of aging 
 The scientific literature has detailed multiple molecular and cellular mechanisms that are 
associated with both aging and NDDs.  In order to investigate aging, though, one must first 
define aging and gain a better understanding of its underlying causes.  At its most basic, aging is 
merely the daily increase in chronological age; however, this view fails to account for the variety 
of physiological changes that occur with aging.   
To date, there are more than 300 different hypotheses of aging that try to encapsulate the 
overwhelming abundance of experimental data regarding aging (Diaconeasa, Rachita et al. 
2015).  Earlier hypotheses viewed aging as a random, progressive decline in organismal fitness.  
Damage-accumulation theories posit that increased accumulation of toxic cellular byproducts, 
buildup of environmentally induced mutations, and/or decreased efficiencies of defense and 
repair mechanisms lead to physiological system failure and eventually death (Jin 2010).  More 
prominent damage theories include the rate of living theory, the free radicals theory, and the 
somatic DNA damage theory (Jin 2010).  The rate of living theory generally prescribes that 
organisms have a genetically predetermined metabolic capacity, and that lifespan is determined 
by the rate in which that energy is used; namely, the amount of metabolic energy expanded per 
gram of body weight (Sohal, Toy et al. 1986).  The free radicals theory argues that aging is the 
 17 
result of ROS and the resultant oxidative stress (Sohal and Weindruch 1996).  The somatic DNA 
damage theory suggests that decline in fitness stems from the accumulation of DNA mutations in 
somatic cells, leading to gain or loss of function paradigms that impair cellular function 
(Kennedy, Loeb et al. 2012).  Many aspects of these theories, however, fail to account for the 
wide range of lifespans among similar species, and furthermore, fail to explain more modern 
experimental observations (Goldsmith 2014).   
Conversely, more recent theories point to the presence of an aging program, per se.  
Programmed aging hypotheses argue that aging is the result of a mechanism that intentionally 
permits organismal decline and death in order to achieve an evolutionary benefit by restricting 
lifespan beyond an optimum threshold (Goldsmith 2014).  Theories of programmed aging 
include, among others, programmed longevity, the endocrine theory, and the immunological 
theory.  Programmed longevity simply states that aging results from coordinated gene expression 
changes over time.  The endocrine theory attributes these expression changes to altered hormonal 
levels.  Alternatively, the immunological theory argues that the immune system is programmed 
to decline with aging in order to restrict lifespan by leaving organisms more susceptible to 
disease (Jin 2010).   
Theories of programmed aging are supported by studies revealing that the rate of aging is 
malleable.  Indeed, multiple studies have found that, even in humans, lifespan can be extended, 
suggesting a flexible rate of aging (Fontana, Kennedy et al. 2014).  Furthermore, there is 
reproducible evidence of aging signatures on gene expression, as genome-wide profiling has 
identified hundreds of genes that exhibit consistent changes in expression with age.  Studies have 
also detected an array of “longevity genes” that appear to regulate the lifespan, further 
supporting a programmed, genetic component of aging. 
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No current theory is sufficient to completely explain each of the facets of aging, so the 
reality is likely a complex combination of multiple theories.  Indeed, a comprehensive theory of 
aging must encapsulate all known aging mechanisms and be applicable to every species.  López-
Otín et al recently summarized the cellular and molecular changes that arise with age (López-
Otín, Blasco et al. 2013).  These putative hallmarks include, among others, genomic instability, 
epigenetic changes, proteostatic dysfunction, defective mitochondria, and aberrant intercellular 
communication; each will be discussed in more detail in the subsequent section. 
 
1.3 Mechanisms of Aging 
Genomic instability 
Cells are continuously exposed to a host of both endogenous and exogenous challenges to 
DNA integrity.  Normal cellular processes, such as DNA replication, chemical reactions, and 
generation of reactive oxygen species, can compromise DNA.  Exogenous factors, like radiation 
or biological or chemical agents, also put DNA at risk (Hoeijmakers 2009).  The detrimental 
effects of such exposures can manifest as point mutations, insertions, translocations, and 
chromosomal duplication or deletion.  To combat such events, cells typically employ multiple 
DNA repair mechanisms, although these too have been found to decline with age (Gorbunova, 
Seluanov et al. 2007, Lord and Ashworth 2012). 
Telomere attrition is a unique form of genetic instability.  Located at the distal end of 
chromosomes, telomeres are composed of repetitive nucleotide sequences and serve to protect 
genes from degradation stemming from end replication issues.  It is well documented that 
telomeres of replicating cells deteriorate with age in both mice and humans (Blasco 2007).  After 
a sufficient number of replicative cycles, telomere exhaustion occurs as cells reach the Hayflick 
 19 
limit (Hayflick and Moorhead 1961), and cells enter replicative senescence.  Notably, DNA 
repair is repressed at the telomere to prevent accidental fusion of chromosome ends; as such, 
telomeres are particularly susceptible to DNA damage (Fumagalli, Rossiello et al. 2012, Hewitt, 
Jurk et al. 2012).   
 
Epigenetic changes 
Epigenetic alterations include a vast array of modifications capable of adjusting gene 
expression without altering the DNA code itself.  In order to maintain the proper epigenetic 
patterns, cells utilize multiple enzymes to add specific marks, including methyltransferases and 
acetylases, as well as the corresponding enzymes for removal.  The function of these proteins, 
however, deteriorates with age.  Global DNA methylation was found to decrease overall yet 
become more variable with age, with some loci actually showing hypermethylation (Maegawa, 
Hinkal et al. 2010, Talens, Christensen et al. 2012).  Histone methylation is also implicated in 
aging, as H4K20 and H3K4 trimethylation increases with age, while H3K9 methylation and 
H3K27 trimethylation decrease.  Further, blocking activity of histone demethylases actually 
extends lifespan in C. elegans (Jin, Li et al. 2011).  Another epigenetic mark that changes with 
age is acetylation of H4K16.  The accumulation of epigenetic changes can also drive chromatin 
remodeling by regulating heterochromatin assembly.  Heterochromatin protein 1 α (HP1α) 
recognizes and binds methylated H3K9 (Grewal and Moazed 2003), serves as a link between 
chromatin and the nuclear lamina (Ye, Callebaut et al. 1997), and is associated with nucleating 
and maintaining heterochromatin (Nielsen, Oulad-Abdelghani et al. 2001, Yamada, Fischle et al. 
2005).  Other chromatin remodelers involved with heterochromatin maintenance include the 
Polycomb PRC2 complex and the nucleosome remodeling and deacetylase (NuRD) complex 
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(Pegoraro, Kubben et al. 2009).  Markedly, there is downregulation of each of these 
heterochromatin regulators with age.  Stemming from altered epigenetic modifications and 
chromatin remodeling, there are robust changes in gene expression with age.  Indeed, multiple 
studies have characterized age-related transcriptional alterations (Lee, Klopp et al. 1999, Lee, 
Weindruch et al. 2000, Zou, Meadows et al. 2000, Pletcher, Macdonald et al. 2002, Golden and 
Melov 2004, McCarroll, Murphy et al. 2004, Lai, Parnell et al. 2007, de Magalhaes, Curado et al. 
2009).  Consistent among these analyses are perturbations to essential physiological pathways, 
including proteostasis and mitochondrial function.    
 
Proteostatic dysfunction 
Proteostasis has been strongly correlated with aging, as misfolded proteins accumulate 
and enzyme populations become less catalytically active (Taylor and Dillin 2011).  Misfolded 
proteins can interact with other proteins, forming aggregates which are often cytotoxic (Chiti, 
Stefani et al. 2003, Stefani and Dobson 2003).  Inappropriate interactions can also result in toxic 
gain or loss of function phenotypes.  Aging is associated with decreased chaperone levels, 
leading to impaired ER stress-response and accumulation of protein aggregates.  One mechanism 
underlying these declines is the downregulation of Hsp70, stemming from blockage of heat 
shock factor binding the heat shock element gene promoter (Heydari, Wu et al. 1993).  Aging is 
also associated with a decreased ability to activate the unfolded protein response (Taylor 2016).  
Further, aging results in declines of both autophagy and the ubiquitin-proteasome system 
(Rubinsztein, Mariño et al. 2011, Tomaru, Takahashi et al. 2012).  Modulation of proteostasis 
has been shown to directly regulate aging.  Decreasing chaperone-mediated folding accelerates 
aging phenotypes (Min, Whaley et al. 2008) while upregulation increases longevity (Walker and 
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Lithgow 2003, Morrow, Samson et al. 2004).  Proteostasis is also proposed to be downstream of 
multiple genetically distinguishable pathways involved with enhanced longevity, providing 
additional support for the role of proteome maintenance in aging (Taylor and Dillin 2011).   
 
Defective mitochondria 
Over time, mitochondrial function declines significantly, and is associated with 
morphological changes, decreased ATP production, and oxidative stress (Shigenaga, Hagen et al. 
1994).  Complexes I and IV of the electron transport chain (ETC) are robustly affected by aging 
and exhibit decreased enzymatic activity (Muller, Eckert et al. 2010); this is potentially due to 
lower protein levels, as older mice have diminished mRNA expression of all ETC complex genes 
(Manczak, Jung et al. 2005).  Other enzymes involved in mitochondrial function, such as adenine 
nucleotide translocase and acyl carnitine transferase, also exhibited declining activity with age 
(Yan and Sohal 1998, Liu, Killilea et al. 2002).  
Perturbations in normal mitochondrial function are associated with an increase in ROS 
production.  Elevated ROS can cause additional mitochondrial dysfunction, leading to a cyclical 
increase in ROS generation.  Aging is strongly correlated with an increase in ROS generation 
and oxidative stress (Leutner, Eckert et al. 2001, Balaban, Nemoto et al. 2005).  However, the 
detrimental effects of elevated ROS and oxidative stress have been challenged in recent years.  
Chronic reduction in SOD activity led to increased ROS and oxidative damage, but did not alter 
longevity, although a higher incidence of cancer was observed (Zhang, Ikeno et al. 2009).  
Further, increasing antioxidant defense can increase longevity in some cases, but is not sufficient 
to extend lifespan (Leuner, Hauptmann et al. 2007, Perez, Van Remmen et al. 2009).  
Interestingly, mtDNA mutator mice exhibit severe ETC deficiencies without an accompanying 
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increase in ROS production; these mice also exhibit premature aging phenotypes (Trifunovic, 
Hansson et al. 2005, Edgar, Shabalina et al. 2009).  It has been proposed that ROS therefore 
initially acts as a stress-induced survival signal, although its chronic accumulation can eventually 
exacerbate age-related changes (López-Otín, Blasco et al. 2013).  Surprisingly, there is also 
evidence that increasing ROS can actually extend the lifespan in yeast, worms, naked mole rates, 
and mice (Mesquita, Weinberger et al. 2010, Yang and Hekimi 2010, Ristow and Schmeisser 
2011). Regardless, aging is associated with mitochondrial dysfunction that causes defective 
bioenergetics. 
 
Aberrant intercellular communication 
 Aging results in defects in multiple communication paradigms, and there is accumulating 
evidence of non-cell autonomous effects.  The immune system becomes less effective with 
advanced age, losing its ability to effectively remove pathogens and dysfunctional host cells (Jin 
2010, López-Otín, Blasco et al. 2013).  Activated microglia, which are normally neuroprotective, 
become neurotoxic with age (Sawada, Sawada et al. 2008).  The persistence of pro-inflammatory 
signals leads to chronic inflammation with age, termed “inflammaging” (Salminen, Kaarniranta 
et al. 2012).  Inflammaging is accompanied by upregulation of the NFkB pathway, which is a 
key regulator of inflammation (Tak and Firestein 2001).  Overactivation of the NFkB pathway is 
consistently observed in genome-wide studies of aging (de Magalhaes, Curado et al. 2009), and 
has been linked with altered hypothalamic production of gonadotropin-releasing hormone 
(GnRH) (Zhang, Li et al. 2013).  Notably, inhibiting NFkB signaling, either genetically or 
pharmacologically, or treating with exogenous GnRH can prevent aging phenotypes (Osorio, 
Barcena et al. 2012, Zhang, Li et al. 2013).   
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 A separate modality of neuroendocrine signaling that is also affected in aging is the 
insulin/IGF-1 signaling (IIS) pathway.  Insulin sensitivity can decline with age, leading to 
hyperinsulinemia (Muller, Elahi et al. 1996).  Modulation of the IIS pathway has been found to 
control longevity and alter lifespan.  In multiple invertebrate models, as well as some mouse 
models, genetic perturbations that reduce IIS signaling result in significant increases in longevity 
(van Heemst 2010).  Caloric restriction, the most reproducible method of extending lifespan, is 
strongly linked to decreased IIS signaling, although additional mechanisms are also involved 
(Heilbronn and Ravussin 2003, Sinclair 2005).  The FOXO family of transcription factors act 
downstream of IIS, and have been linked to multiple aspects of cellular homeostasis, including 
autophagy and resistance to oxidative stress (Martins, Lithgow et al. 2016).  Modulation of IIS is 
not without controversy, however, as mammalian IIS signaling is more complex, and defects in 
this pathway have been associated with an increased risk of age-related disease, such as 
cardiovascular disease (van Heemst 2010).   
 
How are neurodegeneration and aging related? 
 A side by side comparison of the described mechanisms for neurodegeneration and aging 
reveals tremendous overlap.  Common characteristics of ND and aging include perturbation of 
proteostasis, mitochondrial dysfunction, enhanced oxidative stress, and aberrant immune 
function.  Many neurodegenerative diseases are adult-onset, indicating that incidence of these 
diseases is age-related.  Additional research is needed, however, to tease apart the relationship 
between ND and aging in order to completely reveal the causative mechanisms. 
 To investigate the relationship between degeneration and aging, we employed a 
Drosophila model of adult-onset neurodegeneration.  Cyclin dependent kinase 5 (Cdk5) has been 
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implicated in a number of NDDs, including AD, PD, and ALS; in flies, Cdk5 loss of function 
results in ND with degenerative phenotypes that resemble human pathologies.  The physiological 
role of Cdk5, and its role in ND, will be discussed in more detail in the upcoming sections. 
 
1.4 Cdk5 is essential to nervous system development and function 
Regulation of Cdk5  
Since its discovery nearly 30 years ago, cyclin-dependent kinase 5 has been recognized as 
a strong regulator of neuronal development and function, and as such, is of extreme interest for 
its role in a wide variety of neuronal disorders.  Cdk5 is ubiquitously expressed in mice, though 
it exhibits higher expression throughout the nervous system (Hellmich, Pant et al. 1992, Tsai, 
Takahashi et al. 1993, Ino, Ishizuka et al. 1994).  Despite the systemic expression pattern, Cdk5 
activity is largely restricted to postmitotic neurons due to the spatial expression of activator 
subunits.  Similar to other cdks, Cdk5 requires a direct interaction with a separate protein in 
order to adopt a permissive conformation for activity. For cdks, the subunits are cyclins; for 
Cdk5, the main activator subunits are p35 and p39. Indeed, deletion of p35 and p39 in mice 
ablates Cdk5 activity and fully mimics loss of Cdk5 (Ko, Humbert et al. 2001).  Both p35 and 
p39 are expressed highest in neurons (Tsai, Delalle et al. 1994, Humbert, Dhavan et al. 2000), 
although transient expression has also been detected in mouse testis, pancreatic b cells, 
monocytes, and myoblasts (Sahlgren, Mikhailov et al. 2003, Chen, Wang et al. 2004, Rosales 
and Lee 2006).  p35 and p39 are partially redundant, as deletion of p39 has no apparent 
phenotype and deletion of p35 results in lamination defects but does not affect viability and 
fertility (Kwon and Tsai 1998, Ko, Humbert et al. 2001).  Consistent with this redundancy, p35 
and p39 share similar subcellular localization, although there are distinct microdomains where 
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only a single activator is present, such as growth cones and synapses (Humbert, Dhavan et al. 
2000, Niethammer, Smith et al. 2000, Fu, Fu et al. 2001).  Further, p35 and p39 are specific to 
Cdk5, as they do not bind or activate other cdks (Poon, Lew et al. 1997).  While Cdk5 can bind 
other cyclins, most of these interactions do not result in Cdk5 activation.  Cdk5 interacts with 
cyclins D1, D2, D3, and E, but does not show increased kinase activity (Xiong, Zhang et al. 
1992, Miyajima, Nornes et al. 1995); rather, these interactions can serve to titrate cyclin 
availability or to modulate Cdk5 activity (Guidato, McLoughlin et al. 1998, Odajima, Wills et al. 
2011).  Conversely, cyclin I has been found to directly activate Cdk5 (Brinkkoetter, Olivier et al. 
2009), although cyclin I is more prevalent in renal podocytes and expressed at a lower level in 
neurons.  Drosophila melanogaster lack orthologs of p39 and Cyclin I, so the only known 
activator of Cdk5 in flies is p35.  As with mice, p35 expression is largely restricted to the 
nervous system, although some expression is observed in testis, limiting Cdk5 activity mostly to 
neurons (Tsai, Delalle et al. 1994, Connell-Crowley, Le Gall et al. 2000, Chintapalli, Wang et al. 
2007, Smith-Trunova, Prithviraj et al. 2015); deletion of p35 in flies abolishes Cdk5 activity and 
is indistinguishable from loss of Cdk5 (Connell-Crowley, Vo et al. 2007).  Supporting the 
pronounced importance of the complex, Cdk5 and p35/p39 are evolutionarily conserved across 
multiple vertebrate and invertebrate species, including humans, mice, and flies, among others 
(Dhavan and Tsai 2001). 
Structurally speaking, p35 adopts a three-dimensional topology similar to the 
characteristic cyclin-box fold of cyclins, but shares little sequence similarity (Tarricone, Dhavan 
et al. 2001).  Upon binding between Cdk5 and p35, the activation loop (T-loop) of Cdk5 is 
stretched into an extended conformation, permitting Cdk5 kinase activity.  Unlike other cdks, 
which require further phosphorylation to stabilize the T-loop, binding of Cdk5 to either p35 or 
 26 
p39 is sufficient for normal activity (Tarricone, Dhavan et al. 2001).  The list of Cdk5 substrates 
includes the activator subunits themselves.  While bound to Cdk5, both p35 and p39 are 
phosphorylated.  This phosphorylation leads to multi-ubiquitination of the subunits, targeting 
them for degradation via the ubiquitin-proteasome system (UPS) (Figure 1.1).  Ultimately, p35 
has a short half-life of only 20-30 minutes, allowing for rigorous regulation of Cdk5 activity 
(Patrick, Zhou et al. 1998).  Further, p35 and p39 both contain an amino-terminal myristoylation 
motif; this domain tethers the proteins to the plasma membrane, and serves to restrict the 
subcellular localization of Cdk5 to the periphery of the cell.  In mammals, the myristoylation 
motif can be removed via calpain-mediated cleavage, generating p25 and p29 from p35 and p39, 
respectively. Without a tether, the activated Cdk5 complex can then diffuse throughout the 
cytoplasm and even enter the nucleus (Patrick, Zukerberg et al. 1999, Asada, Yamamoto et al. 
2008).  Along with the myristoylation motif, cleavage also removes the residue that targets 
p35/p39 for degradation; thus, the truncated forms have a longer half-life and result in 




Figure 1.1.  Cdk5 regulation by p35/p39. 
Unbound Cdk5 is in an inactive confirmation.  Upon binding to the myristoylated p35 or p39, 
Cdk5 undergoes a confirmation change, revealing its catalytic domain.  The myristoylation 
domain (purple tail) tethers the complex to the plasma membrane, limiting Cdk5’s access to local 
substrates only.  One such substrate is the activator subunit itself.  Phosphorylation of p35 or p39 
by Cdk5 targets it for degradation via the ubiquitin-proteasome system (UPS).  In mammals, 
certain contexts of increased cytosolic Ca2+ induce calpain-mediated cleavage, removing the 
myristoylation domain and allowing the complex to diffuse freely through the cytoplasm and 
interact with a different set of substrates.  (Adapted from McLinden 2012). 
 
Cdk5 is a member of the family of proline-directed protein kinases, and typically 
phosphorylates either serine or threonine in the consensus sequence (S/T)PX(K/H/R), although 
slight variations in the recognized sequence have been identified (Beaudette, Lew et al. 1993, 
Contreras-Vallejos, Utreras et al. 2012).  Other members of the family include glycogen synthase 
kinase-3 beta (GSK3β) and mitogen activated protein kinases (MAPK).  These kinases all 
interact with one another in various contexts, and are capable of cross-regulating one another.  
Cdk5 phosphorylates GSK3β at ser-9, inhibiting GSK3β activity (Morfini, Szebenyi et al. 2004).  
When Cdk5 activity is decreased, this inhibitory phosphorylation is reduced and GSK3β activity 
increases. Within the family of proline-directed kinases, there is also overlap in target-site 
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specificity, potentially indicating a compensatory mechanism and highlighting the importance of 
maintaining proper protein phosphorylation.  Cdk5 can also be phosphorylated by a number of 
other kinases, including c-Abelson, Fyn, EphA4, and TrkB (Sasaki, Cheng et al. 2002, Lalioti, 
Pulido et al. 2010).  Phosphorylation of Cdk5 at tyr-15 has been linked to enhanced Cdk5 
activity while phosphorylation at thr-14 is actually inhibitory (Matsuura and Wang 1996, 
Zukerberg, Patrick et al. 2000).  Furthermore, phosphorylation of the T-loop at ser-159 is thought 
to block Cdk5’s interaction with p35 or p39, preventing activation (Tarricone, Dhavan et al. 
2001).  Alternative post-translation modifications, such as S-nitrosylation, have also been found 
to alter Cdk5 activity (Zhang, Yu et al. 2010).   
 
Cdk5 is required for proper nervous system function 
Given the increased expression of Cdk5 in nervous tissue, and the fact that its primary 
activators, p35 and p39, are expressed primarily in neurons, it follows that Cdk5’s most 
important roles will be in the nervous system.  Indeed, mice null for Cdk5 are perinatal lethal, 
but this lethality is completely rescued by selectively expressing Cdk5 in the nervous system 
(Ohshima, Ward et al. 1996, Tanaka, Veeranna et al. 2001), suggesting that non-neuronal Cdk5 
is dispensable for survival.  Consistent with this, Cdk5 plays no discernible role in cell cycle 
progression, unlike other cdks (Meyerson, Enders et al. 1992, van den Heuvel and Harlow 1993).  
Furthermore, podocytes from p35-null mice have a normal morphology and function, although 
they are more susceptible to stressors (Brinkkoetter, Wu et al. 2010).  Transient p35-dependent 
Cdk5 activity has also been linked to monocyte differentiation (Chen, Wang et al. 2004) and the 
development of myogenic tissue (Sahlgren, Mikhailov et al. 2003).  However, the most 
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significant roles of Cdk5 are its involvement in various aspects of neuronal development and 
homeostasis.   
 
Role of Cdk5 in axonogenesis and neuronal migration 
The first hints of Cdk5’s role in neuronal development were gleaned from its expression 
pattern in developing mouse embryos.  During early gestational stages, Cdk5 expression was 
relatively low; however, as development progressed, Cdk5 levels gradually increased until they 
reached their maximum in adult brains (Tsai, Takahashi et al. 1993).  These trends correlated 
with an increase of post-mitotic neurons and a decreasing percentage of actively proliferating 
cells, suggesting that Cdk5 plays a role in neuronal differentiation and migration.  Indeed, Cdk5-
null mice exhibited disrupted stratification of neocortical and pyramidal neurons (Ohshima, 
Ward et al. 1996).  The cortex is established by the “inside-out” generation of layers (Angevine 
and Sidman 1961, Luskin and Shatz 1985): migrating postmitotic neurons follow radial glial 
fibers, with later-born neurons moving superficially past earlier born neurons, generating 
discernible layers in a laminated structure (Chae, Kwon et al. 1997).  Loss of Cdk5 activity 
results in a complete disorganization of the cortex, although cell density is initially the same 
(Gilmore, Ohshima et al. 1998).  Cdk5-null mice also displayed layering defects in the 
cerebellum and other morphological defects throughout the central nervous system, although the 
peripheral nervous system appeared normal, as the dorsal root ganglia were not affected.  
Highlighting potential mechanisms for the observed defects, cultured embryonic cortical neurons 
showed colocalization of Cdk5 and p35 in neurites and axonal growth cones, and treatment with 
dominant negative Cdk5 mutants resulted in significant shortening of dendrites and axons 
(Nikolic, Dudek et al. 1996).  Cdk5 activity is required for both nerve growth factor (NGF)-
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induced neurite outgrowth (Harada, Morooka et al. 2001) and brain-derived neurotrophic factor 
(BDNF)-induced dendritic growth (Cheung, Chin et al. 2007).  
Additional functions of Cdk5 in axonogenesis were elucidated in Drosophila, which are 
not susceptible to the neuronal migration defects observed in mice.  When Cdk5 activity was 
either increased or decreased, guidance defects were observed in the transverse nerve, segmental 
nerve A, and the intersegmental nerve (Connell-Crowley, Le Gall et al. 2000); the observed 
phenotypes included overextension, stalling, and aberrant pathfinding, and suggest that Cdk5 
activity, while not essential for axon guidance in Drosophila, could serve to coordinate multiple 
signaling paradigms.  Cdk5 was also found to regulate Drosophila neuronal remodeling.  Cdk5 
controls the timing and rate of developmental mushroom body remodeling, specifically 
modulating neurite disassembly (Smith-Trunova, Prithviraj et al. 2015).  Neurite remodeling, 
along with activity-dependent pruning, are observed in both vertebrates and invertebrates, and 
are required for establishing and refining neuronal circuitry (Chen and Regehr 2000, Kuo, Jan et 
al. 2005, Tessier and Broadie 2009, Schuldiner and Yaron 2015).   
A plethora of studies have begun to elucidate the molecular mechanisms through which 
Cdk5 regulates axonogenesis and neuronal migration.  Multiple Cdk5 substrates are involved in 
controlling the various levels of the cytoskeleton, including actin, microtubules, and 
neurofilaments.  Rho GTPases are a family of signaling G proteins vital to intracellular actin 
dynamics and heavily regulated by Cdk5.  Cdk5 co-localizes with Rac, Pak1, and F-actin, and 
Cdk5 phosphorylates Pak1 at multiple sites through a Rac-dependent mechanism (Nikolic, Chou 
et al. 1998).  Cdk5-mediated phosphorylation of Pak1 inhibits its kinase activity, thereby 
temporarily regulating activity of Pak1’s downstream effector proteins and their role in actin 
cytoskeleton reorganization.  Further, Cdk5 can modulate Rac activity by targeting upstream 
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activators.  Phosphorylation of ser-737 of Ras guanine nucleotide releasing factor 2 (RasGRF2) 
decreases its guanine exchange factor activity towards Rac, effectively inhibiting the Rac 
signaling cascade.  Cdk5 also phosphorylates and inactivates WAVE1, which is responsible for 
activation of the actin polymerization complex Arp2/3 (Kim, Sung et al. 2006).  During 
Semaphorin3A (Sema3A)-induced growth cone collapse, Sema3a induces phosphorylation of 
Cdk5 at tyr-15 via the Fyn/Plex-A2 receptor complex, hyperactivating Cdk5 to drive 
reorganization of the actin cytoskeleton (Sasaki, Cheng et al. 2002).   
 Cdk5 specifically targets multiple microtubule-associated proteins (MAPs), including tau 
and MAP1B.  Cdk5-mediated hyperphosphorylation of tau causes dissociation of tau from 
microtubules, leading to tubulin depolymerization (Evans, Rank et al. 2000).  In cerebellar 
neurons, Cdk5 phosphorylates MAP1B, increasing its affinity for and binding to microtubules 
(Pigino, Paglini et al. 1997).  Cdk5-mediated phosphorylation of MAP1B is essential for netrin-1 
dependent migration (Del Rio, Gonzalez-Billault et al. 2004).  Another Cdk5 substrate capable of 
interacting with microtubules is doublecortin (DCX).  DCX binds to microtubules and promotes 
stabilization and polymerization.  Phosphorylation of DCX at ser-297 results in its displacement 
from microtubules (Tanaka, Serneo et al. 2004).  In mouse cerebral cortex, Cdk5 contributes to 
axon outgrowth by phosphorylating Axin.  This phosphorylation facilitates Axin’s interaction 
with GSK-3β, inhibiting GSK-3β activity (Fang et al,  2011).  With decreased GSK-3β activity, 
collapsin response mediator protein-2 (CRMP2) gets dephosphorylated and binds microtubules, 
stabilizing them and promoting axon outgrowth.  Conversely, Uchida et al demonstrated that 
Cdk5 directly phosphorylates CRMP2, leading to secondary phosphorylation by GSK-3β 
(Uchida et al, 2005).  The dual-phosphorylated CRMP2 dissociates from microtubules, leading 
to MT destabilization, and contributing to Sema3A-induced growth cone collapse.  Furthermore, 
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the Cdk5-p35 complex can itself bind to tubulin, contributing to the stability and polymerization 
of microtubules.  This interaction can be outcompeted by Calmodulin (CaM) in the presence of 
calcium, suggesting there is an intrinsic balance required to maintain the proper microtubule 
cytoskeleton (He et al, 2008).  
Lastly, Cdk5 directly targets neurofilament proteins.  Neurofilaments comprise three 
subunits of varying molecular mass: NF-high (NF-H), NF-medium (NF-M), and NF-low (NF-L).  
These subunits combine to form 10 nanometer filaments that stabilize axons and control axon 
caliber (Shea, Zheng et al. 2004).  Cdk5 phosphorylates both NF-H and NF-M (Lew, Qi et al. 
1995) to effectively regulate spacing between filaments; hyperphosphorylation of NF-H led to 
perikaryal bundling of NFs (Shea, Zheng et al. 2004).  Furthermore, phosphorylated NF-H has a 
decreased affinity for microtubules, indicating that phosphorylation status also regulates 
interactions between different aspects of the cytoskeleton (Hisanaga, Ishiguro et al. 1993). 
Cdk5 control of neuronal migration could also occur through cadherin-mediated 
adhesion.  Cdk5 has been shown to directly phosphorylate β-catenin, regulating the interaction 
between β-catenin and N-cadherin (Kesavapany, Lau et al. 2001).  Dissociation of β-catenin 
from N-cadherin leads to decreased adhesion; thus, loss of Cdk5 activity could decrease 
phosphorylation of β-catenin, stabilizing the β-catenin/N-cadherin complex, permitting stronger 
adhesion and preventing neuronal migration.  Cdk5 also regulates neuronal response to 
extracellular matrix proteins, as laminin induced p35 expression in cultured cerebellar neurons, 
accompanied by axonal elongation and phosphorylation of the microtubule-associated protein 




Role of Cdk5 in neuronal function and homeostasis 
Trafficking 
Aside from its role in establishing the nervous system, Cdk5 is also essential to the 
normal physiological functioning of mature neurons.  Cdk5 activity is responsible for regulating 
multiple aspects of intracellular transport essential for proper neuronal function.  At the 
molecular level, Cdk5 interacts with NUDEL and LIS1, mediating dynein-dependent neuronal 
transport (Niethammer, Smith et al. 2000, Sasaki, Shionoya et al. 2000).  Cdk5 directly 
phosphorylates NUDEL, which disrupts its binding to the dynein/dynactin complex, thus 
permitting axonal conveyance by removing a brake.  Inhibition of Cdk5 blocks axonal transport, 
resulting in axonal swelling.  Cdk5 is also involved in kinesin-mediated anterograde transport.  
Cdk5 inhibits GSK3β by phosphorylating it, preventing GSK3β-dependent phosphorylation of 
kinesin light chains and the release of cargo proteins (Morfini, Szebenyi et al. 2002, Morfini, 
Szebenyi et al. 2004).  In addition to the motor proteins, Cdk5 influences axonal transport 
through cytoskeletal regulation.   Cdk5 phosphorylation of NFs alters NF caliber and spacing, 
and Cdk5 hyperactivation was found to inhibit NF-dependent axonal transport (Shea, Zheng et 
al. 2004). 
Proper neuronal trafficking is dependent on the establishment and maintenance of 
neuronal polarity, as specific proteins are targeted to certain cellular regions, such as the 
dendrites or axon.  This polarity is achieved in part through the axon initial segment (AIS), a 
subcellular domain segregating the somatodendritic and axonal regions of the neuron.  The AIS 
is also responsible for action potential initiation.  Cdk5’s role in regulating the AIS will be 




Cdk5 has been linked to proteostasis through both protein translation and degradation.  
Cdk5 phosphorylates S6K1, blocking its autoinhibition and permitting its activation by mTOR 
(Hou, He et al. 2007).  S6K1 targets ribosomal proteins, among other substrates, mediating 
protein synthesis.  Additionally, Cdk5 mediates Sema3A-induced activation of eukaryotic 
translation initiation factor 4E (eIF-4E) in the growth cone of dorsal root ganglia neurons (Li, 
Sasaki et al. 2004).  In the absence of Cdk5 activity, Sema3A fails to activate eIF-4E, and local 
translation is impaired.  On the other hand, Cdk5 plays a role in protein degradation and has been 
linked to autophagy.  A number of Cdk5 substrates are targeted for degradation upon 
phosphorylation, including p35/ p39 (Minegishi, Asada et al. 2010) and GKAP (Roselli, Livrea 
et al. 2011), among others.   Alternatively, Cdk5 can regulate the activity of E3 ubiquitin ligase 
complexes, such as Cdh1/APC, suppressing their ubiquitination activity and subsequently 
preventing substrate targeting for degradation via the UPS (Maestre, Delgado-Esteban et al. 
2008).  Cdk5 is also significantly involved in regulation of autophagy.  Cdk5 phosphorylates 
endophilin B1 and VPS34, two proteins that interact with beclin 1 to regulate autophagosome 
formation in opposite directions (Takahashi, Coppola et al. 2007, Furuya, Kim et al. 2010, 
Wong, Lee et al. 2011).  The role of Cdk5 in autophagy is an evolutionarily conserved function.  
In Drosophila lacking Cdk5 activity, exposure to starvation, which is used to indicate impaired 
autophagy, led to significantly decreased survival times (Trunova and Giniger 2012).  This 
behavioral phenotype was accompanied by an accumulation of autophagic organelles in the 





Presynaptically, Cdk5 functions in vesicle trafficking, release and recycling.  Subcellular 
fractionation has revealed that Cdk5 and its activators are present in synaptic membranes 
(Dhavan and Tsai 2001).  Cdk5 helps regulate the reserve and recycling pools of synaptic 
vesicles (SVs) at the synapse by phosphorylating synapsin I (synI) (Matsubara, Kusubata et al. 
1996, Verstegen, Tagliatti et al. 2014).  Phosphorylated synI exhibits enhanced binding to the 
actin cytoskeleton, driving its trafficking of SVs to the recycling pool, situated proximal to the 
readily releasable pool.  Cdk5 modulates SV exocytosis indirectly by phosphorylating Munc18.  
Munc18 binds the SNARE protein syntaxin 1 (Hata, Slaughter et al. 1993), preventing 
interactions of the SNARE complex with SVs.  Upon phosphorylation, Munc18 dissociates, 
allowing syntaxin 1 to bind vesicles and promote membrane fusion and neurotransmitter release 
(Fletcher, Shuang et al. 1999, Lilja, Johansson et al. 2004).  Further, Cdk5 is involved in SNARE 
protein recycling.  Upon activation from Cdk5-mediated phosphorylation, PCTAIRE1 activates 
N-ethylmaleimide-sensitive fusion protein (NSF), which disassembles and recovers SNARE 
monomers from the presynaptic membrane (Liu, Cheng et al. 2006).   
Cdk5 contributes to clathrin-mediated endocytosis by phosphorylating amphiphysin I 
(Floyd, Porro et al. 2001), dynamin I (Tan, Valova et al. 2003), and synaptojanin I (Lee, Wenk et 
al. 2004).  In all three cases, Cdk5-mediated phosphorylation disrupts protein interaction: Cdk5 
activity induces dissociation of amphiphysin I from β-adaptin, of dynamin I from amphiphysin I 
(Tomizawa, Sunada et al. 2003), and of synaptojanin I from endophilin (Lee, Wenk et al. 2004).  
The ultimate effects of Cdk5 activity on endocytosis remain murky, and are likely context 
dependent.  In cultured hippocampal neurons, disruption of these interactions is thought to 
inhibit vesicular endocytosis, as blocking Cdk5 activity enhanced endocytosis.  Conversely, in 
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vitro experiments utilizing synaptosomes revealed that Cdk5 activity is required for endocytosis 
(Tan, Valova et al. 2003).  Endocytosis is further regulated by the phosphatase calcineurin; 
interplay regulating protein phosphorylation status likely contributes to the plasticity required for 
proper neuronal function. 
Neurotransmission is regulated by Cdk5 at both the transmitter and receptor levels.  Cdk5 
phosphorylates tyrosine hydroxylase (TH), the rate-limiting enzyme involved in dopamine (DA) 
synthesis, stabilizing the protein and increasing its activity (Kansy, Daubner et al. 2004, Moy and 
Tsai 2004).  Consistent with this function, Cdk5-null mice exhibited decreased levels of TH 
(Moy and Tsai 2004).  Dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-
32) serves as an additional link between Cdk5 and DA signaling.  DARPP-32 is a central 
modulator of a pathway receiving input from Cdk5, protein phosphatase 1, and protein kinase A 
(Bibb, Snyder et al. 1999).  Cdk5-phosphorylation of DARPP-32 leads to PKA inhibition and 
ultimately suppressed DA signaling.  Cdk5 itself is subject to DA signaling, as stimulation of the 
dopamine D1 receptor results in elevated calcium influx, calpain-mediated generation of p25, 
and hyperactivation of Cdk5 (Lebel and Cyr 2011).   
In postsynaptic neurons and muscle tissue, Cdk5 modulates the synaptic response of 
multiple neurotransmitter receptors.  In hippocampal neurons, Cdk5 phosphorylates ser-1232 of 
the NR2A subunit of NMDA receptors, leading to enhanced channel activity (Li, Sun et al. 
2001).  Conversely, NMDA activity was enhanced in striatal neurons by Cdk5 loss of function, 
although this occurred indirectly via dysregulated DA signaling (Chergui, Svenningsson et al. 
2004).  Levels of NMDA receptor are affected by Cdk5 interactions with Src.  Phosphorylation 
of Src modulates its binding to post-synaptic density protein 95 (PSD-95), which regulates 
NMDA receptor endocytosis (Zhang, Edelmann et al. 2008).  Through an alternative pathway, 
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Cdk5 activity induces ubiquitination of PSD-95, targeting the protein for proteasomal 
degradation (Colledge, Snyder et al. 2003).  Loss of PSD-95 is accompanied by loss of NMDA 
and AMPA from the synaptic terminal.  Receptor clustering is further regulated by interactions 
of PSD-95 with guanylate kinase-associated protein (GKAP).  GKAP colocalizes with PSD-95 
and NMDA receptors and potassium channels at the synapse (Kim, Naisbitt et al. 1997), and 
links them to the underlying cytoskeleton (Roselli, Livrea et al. 2011).  Phosphorylation of 
GKAP by Cdk5 targets it for ubiquitin-mediated proteasomal degradation, severing the tether to 
the actin cytoskeleton, and resulting in disassembly of the synaptic cluster.  Lastly, Cdk5 
phosphorylates the BDNF receptor TrkB, initiating a signaling cascade culminating in 
phosphorylation of S6 ribosomal protein, enhanced localized protein translation, and dendritic 
spine remodeling (Lai, Wong et al. 2012).   
Cdk5 activity also plays a postsynaptic role at the junction between neuron and muscle.  
p35 is transiently upregulated in embryonic muscle tissue, providing temporary Cdk5 activity, 
which is required for the formation of neuromuscular junctions (Fu, Fu et al. 2001).  At the NMJ, 
Cdk5 and p35 colocalize with acetylcholine (ACh) receptor (Fu, Ip et al. 2005, Lin, Dominguez 
et al. 2005).  Notably, neuregulin-1 (NRG-1) binds to and activates its receptor ErbB, inducing 
Cdk5-dependent upregulation of ACh receptor expression (Fu, Fu et al. 2001).  
 
Role of Cdk5 in memory and cognition 
Cdk5-mediated regulation of neuronal function overall, and specifically of 
neurotransmission, are an essential component of the neuronal plasticity vital to cognition and 
memory.  Plasticity largely arises from a neuron’s ability to alter synaptic strength.  Long-term 
potentiation (LTP) and depression (LTD) describe activity-dependent strengthening or reduction 
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in synaptic efficacy, respectively.  Given the wide range of Cdk5-mediated regulation of 
neuronal plasticity, the exact role of Cdk5 regarding LTP remains contradictory.  Under different 
paradigms, pharmacological inhibition of Cdk5 has been found to either block LTP (Wang, 
Walsh et al. 2004) or be permissive (Li, Sun et al. 2001, Wei, Tomizawa et al. 2005).  Similarly, 
loss of Cdk5 function has been linked to both impaired (Guan, Su et al. 2011) and enhanced 
(Hawasli, Benavides et al. 2007) memory formation and retrieval.  These contrasting results are 
further complicated by the fact that Cdk5 effects can be time dependent.  Conditional 
upregulation of Cdk5 activity in the hippocampus initially enhanced LTP, but sustained Cdk5 
hyperactivity eventually impaired LTP (Fischer, Sananbenesi et al. 2005).  Accordingly, 
transient upregulation of Cdk5 enhanced learning and memory, while prolonged expression of 
p25 severely impaired cognition.  Although the specific role of Cdk5 in learning and memory 
remains clouded, Cdk5 is without question an essential regulator of neuronal plasticity.  
Furthermore, these findings hint at a putative role for Cdk5 in the cognitive impairment that is a 
hallmark of neurodegenerative disease.  
 
Role of Cdk5 in neurodegenerative diseases 
 Given the essential role that Cdk5 plays in nervous system function, it is not surprising 
that disruption of normal Cdk5 function is detrimental.  Multiple studies have linked Cdk5 to a 
variety of NDDs in humans.  Alzheimer’s disease is a neurodegenerative disease resulting in 
progressive memory loss that culminates in dementia.  The hallmark pathologies of AD include 
neurofibrillary tangles (NFTs) and amyloid plaques, although how these relate to the causative 
mechanisms underlying AD is not completely understood.  Remarkably, Cdk5 has been linked to 
the formation of both NFTs and plaques.  As such, Cdk5 is considered one of the primary 
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candidates for therapeutic targeting in the treatment of AD, making the elucidation of Cdk5’s 
physiologically relevant contributions to AD essential. 
NFTs are formed by aggregation of the microtubule-associated protein (MAP) tau, which 
amasses more readily when the protein is hyperphosphorylated.  Under normal circumstances, 
tau regulates microtubule stability within axons.  Tau has two primary functional domains: a C-
terminal microtubule-binding domain and an N-terminal projection domain.  The C-terminal 
domain of tau binds the interface between tubulin heterodimers, stabilizing the microtubule and 
facilitating polymerization (Kadavath, Hofele et al. 2015).  Independent of its role in microtubule 
stability, tau is also capable of regulating axonal transport.  The N-terminal domain of tau 
contains a phosphatase-activating domain (PAD); this domain, spanning amino acids 2-18 of tau, 
is capable of activating protein phosphatase 1 (PP1) (Kanaan, Morfini et al. 2012).  This 
activation initiates a cascade resulting in the dephosphorylation and resultant activation of 
GSK3β (LaPointe, Morfini et al. 2009, Kanaan, Morfini et al. 2012), followed by the eventual 
dissociation of the motor protein from its cargo (Morfini, Szebenyi et al. 2002, Morfini, Szebenyi 
et al. 2004).  Ultimately, tau functions in stabilizing the microtubule cytoskeleton and regulating 
kinesin-mediated anterograde fast axonal transport.   
Hyperphosphorylated tau dissociates from microtubules.  This leads to destabilization of 
the microtubule cytoskeleton, as well as perturbation of trafficking.  Further, the dissociated tau 
aggregates into NFTs.  These aggregates can also sequester normal tau, exacerbating the 
detrimental effects of hyperphosphorylated tau.  When Cdk5 was first discovered, it was found to 
be a kinase that could phosphorylate tau at the specific sites that are hyperphosphorylated in 
NFTs (Paudel, Lew et al. 1993).  Initially referred to as ‘brain proline-directed protein kinase,’ 
Cdk5 phosphorylates multiple sites of bovine tau in vitro, including ser-202, ser-209, thr-212, 
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thr-238, ser-242, ser-403, and ser-411.  The corresponding residues of human tau are all 
phosphorylated in tau isoforms associated with NFTs (Lund, McKenna et al. 2001, Liu, Iqbal et 
al. 2002).  While these experiments were conducted in vitro, similar results have been 
demonstrated in cell-based assays (Michel, Mercken et al. 1998, Patrick, Zukerberg et al. 1999), 
and transgenic mice overexpressing the Cdk5 activator p25 exhibited tau hyperphosphorylation, 
increased tau aggregation, and an increased number of NFTs (Noble, Olm et al. 2003).  
Furthermore, Cdk5 activity was found to be elevated in tissue from patients with AD (Lee, Clark 
et al. 1999, Patrick, Zukerberg et al. 1999, Shelton and Johnson 2004).  
Cdk5 hyperactivity also led to increases in amyloid beta (Aβ) levels in the forebrains of 
mice.  Aβ is a cleavage product of amyloid precursor protein (APP) and is the main component 
of amyloid plaques that are found in the brains of AD patients.  Since Cdk5-induced elevations 
of Aβ levels are detected prior to any observable neuropathology, it is thought that multiple 
Cdk5-mediated pathways contribute to AD (Cruz et al 2006).  Cdk5 directly regulates Aβ at 
multiple steps.  Cdk5 phosphorylates both APP and presenilin-1 (PSEN-1); PSEN-1 is the 
catalytic subunit of gamma secretase, which is involved in the processing and cleavage of APP to 
generate Aβ.  Phosphorylation of PSEN-1 by Cdk5 stabilizes it, allowing the complex to persist 
longer and therefore cleave more APP, generating more Aβ peptides (Lau and Ahlijanian 2003).  
Phosphorylated APP is also associated with increased generation of Aβ fragments (Wen, Planel 
et al. 2008, Sadleir and Vassar 2012).  Elevated levels of Aβ42 lead to the formation of the 
amyloid plaques associated with AD.   
Aside from AD, Cdk5 has also been linked to Parkinson’s disease (PD), a degenerative 
disorder that primarily affects the dopaminergic system and its regulation of motor function.  The 
pathological hallmark of PD is the formation of Lewy bodies (abnormal aggregates of α-
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synuclein) that are associated with neurodegeneration of dopamine-secreting cells in the 
substantia nigra.  α-syn is primarily restricted to the nervous system, and further localizes 
specifically to the presynaptic terminal (Bendor, Logan et al. 2013).  The function of α-syn at the 
synapse is contradictory, as studies have found evidence that α-syn both promotes 
neurotransmitter release (Cabin, Shimazu et al. 2002) and is a negative regulator of 
neurotransmission (Abeliovich, Schmitz et al. 2000).  Likely, the role of α-syn is different in 
various cell types and is context-dependent.   
While the normal function of α-syn remains unclear, it is well established that α-syn 
deposits are associated with PD.  Immunohistochemical staining of post-mortem brain tissue 
from PD patients revealed that some of these deposits also contained both Cdk5 and p35 (Brion 
and Couck 1995, Nakamura, Kawamoto et al. 1997, Takahashi, Iseki et al. 2000). α-syn can 
induce a calcium influx, leading to calpain-mediated cleavage of p35 and eventual Cdk5 
hyperactivity (Czapski, Gassowska et al. 2013).  Once Cdk5 is activated, one of its targets is 
peroxiredoxin 2 (Prx2), an anti-oxidant enzyme.  Phosphorylation of Prx2 reduces its peroxidase 
activity, limiting its ability to help against oxidative stress; hyperphosphorylated Prx2 was found 
in substantia nigra neurons in tissue from Parkinson’s disease patients (Qu, Rashidian et al. 
2007).   
Cdk5 also phosphorylates parkin, an E3 ubiquitin ligase that is commonly mutated in 
inherited forms of PD (Kitada, Asakawa et al. 1998) and is also found in Lewy bodies of 
sporadic PD (Schlossmacher, Frosch et al. 2002).  Cdk5-mediated phosphorylation of parkin at 
ser-131 decreases parkin auto-ubiquitination and parkin-dependent ubiquitination of synphilin-1 
and p38 (Avraham, Rott et al. 2007).  Expression of a Cdk5-phosphorylation-deficient parkin 
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mutant lead to increased ubiquitination of both synphilin-1 and p38 and formation of toxic 
aggregates.   
Amyotrophic lateral sclerosis is an axonopathy that affects motor neurons of the central 
nervous system, leading to muscle weakness, paralysis, and ultimately death (Williamson and 
Cleveland 1999).  Further, motor neurons from patients with ALS were found to have an 
elevated number of neurofibrillary swellings in the proximal axon (Delisle and Carpenter 1984).  
Mutations in the gene for copper-zinc superoxide dismutase 1 (SOD1) account for approximately 
20% of familial ALS cases (Deng, Hentati et al. 1993, Rosen, Siddique et al. 1993).  SOD1 
catalyzes the conversion of superoxide anion into hydrogen peroxide and oxygen, protecting 
cells against damage caused by oxidative stress (Fridovich 1986).  More recently, SOD1 has also 
been found to function in regulating cellular respiration (Reddi and Culotta 2013).    
In a mouse model of ALS, mutations of SOD1 correlating with those seen in humans 
resulted in elevated Cdk5 activity (Nguyen, Larivière et al. 2001).  Mutant mice exhibited an 
increase of p25 and resultant mislocalization of Cdk5 to the cytoplasm and nucleus, and the 
degree of Cdk5 hyperactivation strongly correlated with a shortened lifespan.  The authors 
proposed that SOD1 dysfunction leads to oxidative stress and elevated intracellular calcium 
levels, inducing calpain-mediated cleavage of p35 into p25 and upregulating Cdk5.  Cdk5 
hyperactivity caused hyperphosphorylation of tau and neurofilament proteins, which are known 
to be involved in axonal transport.  Indeed, one of the earliest observed events in motor neurons 
expressing mutant SOD1 is the reduced transport of specific cargos such as tubulin (Williamson 




Using altered p35 levels as a model of Cdk5 dysfunction	  
In Drosophila, Cdk5 activity requires direct interaction with the activator subunit p35.  To 
investigate the physiological roles of Cdk5, it is possible to target Cdk5 directly or to modulate 
p35.  We have shown previously, however, that Cdk5 has an extremely long half-life (>24 hours; 
LCC and EG, unpublished data), making disruption of the Cdk5 gene an ineffective way to 
produce loss-of-function phenotypes in many experimental paradigms.  Moreover, high-level 
overexpression of Cdk5 does not reliably produce a gain-of-function phenotype (Connell-
Crowley, Le Gall et al. 2000).  In contrast, altering expression of the activator, p35, has 
predictable and nearly immediate effects on Cdk5 activity.  p35 has a half-life of 20-30 minutes 
(Patrick, Zukerberg et al. 1999), and is a limiting factor of Cdk5 activity in neurons as Cdk5 is 
present at excess levels (Takasugi, Minegishi et al. 2016). 	  
            Modulation of Cdk5 activator levels have previously been shown to regulate Cdk5 
activity.  Overexpression of p35 enhances Cdk5 activity in Drosophila (Connell-Crowley, Le 
Gall et al. 2000), and the deletion of p35 or of p35 and p39 abolishes Cdk5 activity in flies and 
mice, respectively (Ko, Humbert et al. 2001, Connell-Crowley, Vo et al. 2007).  It should be 
noted that we cannot formally rule out the existence of Cdk5-independent functions of p35; 
additional experiments are required to discern roles of p35 outside of Cdk5 activation.  However, 
it has been shown that p35 is unable to bind and activate other Cdks with similar structure to 
Cdk5 (Poon, Lew et al. 1997, Connell-Crowley, Le Gall et al. 2000).  Furthermore, deletion of 
p35 in Drosophila mimics Cdk5-null phenotypes (Connell-Crowley, Vo et al. 2007, Kissler, 
Pettersson et al. 2009), and is non-additive when combined with a dominant negative Cdk5 
(Connell-Crowley, Vo et al. 2007).  Additionally, Drosophila lack orthologs to either of the two 
known non-p35 activators of Cdk5, p39 or Cyclin I, making it unlikely that Cdk5 has non-p35 
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activators in this organism.  As such, experiments described in the following chapters will use 
perturbation of p35 levels as a proxy for altering Cdk5 activity. 
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1.5 Aims of this thesis 
To date, there has been little success with treating neurodegenerative disorders, and no 
cure exists for any of the major age-related degenerative diseases affecting humans.  Work in this 
thesis is aimed towards identifying new mechanisms of degeneration through the study of 
Drosophila models of adult-onset neurodegeneration.  Our lab has previously shown that Cdk5-
mediated phenotypes in fly overlap with pathologies associated with degeneration in humans, 
and that these phenotypes are also consistent with aging-induced phenotypes.  Thus, we 
hypothesized that Cdk5-mediated ND stems from both aging-dependent and aging-independent 
mechanisms.  The work presented here challenges the current view of the relationship between 
neurodegeneration and aging, and provides a foundation for the development of a variety of new 
therapeutic strategies.   
In chapter 2, I present work towards the improvement of assays for quantifying 
neurodegeneration.  I demonstrate a method for the fully automatic quantification of mushroom 
body neurons within adult Drosophila brains.  I also describe progress in adapting a silver-
staining technique for the selective labeling of degenerating neurons to the Drosophila model, in 
addition to techniques for assessing neuronal physiology during degeneration. 
In chapter 3, I show that altered Cdk5 activity induces multiple degenerative phenotypes 
and causes robust neurodegeneration.  I then develop a genome-wide expression-based metric for 
quantifying the physiological age of a tissue, and show that Cdk5 dysfunction accelerates the 
intrinsic rate of aging.  These results suggest that accelerated aging is actually a driving force 
underlying Cdk5-mediated ND.   
In chapter 4, I investigate the role of the axon initial segment in neurodegeneration.  
Although previous research has linked the AIS to ND, it has never been demonstrated in 
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Drosophila before.  Here, I characterize a novel mechanism for modulating the AIS that is 
independent of Cdk5.  I then show that perturbation of the AIS is sufficient to induce ND.  This 
data suggests that regulation of the AIS likely contributes to Cdk5-mediated ND, and is yet 


















Chapter 2: Development of assays for improved assessment of neurodegeneration 
 
2.1  Introduction 
The ever-increasing portion of the human population afflicted with neurodegenerative 
diseases (NDDs), combined with the fact that many of the underlying mechanisms of these 
diseases have yet to be elucidated, highlights a growing issue that needs to be solved.  In order to 
investigate these mechanisms, and to gauge efficacy of therapies designed to treat NDDs, it is 
essential that techniques continue to be developed for enhanced quantification of 
neurodegeneration (ND).  ND involves significantly more than just the terminal result of 
neuronal death; indeed, multiple physiological processes are disrupted prior to cellular demise.  
To fully understand the underlying causes of ND, it is necessary to assess neuronal dysfunction 
throughout the course of the entire degenerative process. 
Many of today’s current neurodegenerative assays are hindered by a variety of 
limitations.  Organismal level degenerative assays, such as lifespan and motor function, are good 
for approximating an overall level of fitness, but they fail to address the underlying mechanisms 
contributing to loss of fitness.  Further, ND can occur in neuronal populations whose functional 
output might not be obvious at the organismal level, leading to detrimental defects that are 
overlooked.  At the cellular level, the primary tools for analyzing ND are end-point assays that 
measure levels of cell death, such as terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) staining for apoptosis or propidium iodide staining for necrosis.  While 
useful, these tools are not ideal for detecting degeneration at earlier stages or in situations that do 
not result in cell death.  Other assays, such as histological sectioning, show ‘vacuoles’ that are 
consistent with ND, but that do not directly illustrate neuronal death.  Such tissue loss could be 
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the result of degeneration of the dendritic arborization without accompanying neuronal death, or 
even happen because tissue is merely more sensitive to processing.  Another limitation of these 
assays is the failure to assess the earliest stages of ND, and to distinguish the different 
mechanisms through which ND occurs.  These limitations underline the vast need for improved 
assays.  Further, the pitfalls of current techniques clearly demonstrate that no single assay on its 
own will suffice; rather, a panel of assays testing the entire degenerative process is necessary for 
assessing the underlying mechanisms.   
Here, we present multiple methods for directly quantifying neuronal loss, including a 
method for fully automatic counting of mushroom body neurons from a confocal z-stack.  We 
also describe techniques for examining earlier stages of ND, including one method to selectively 
label degenerating neurons and other methods measuring different aspects of neuronal 
physiology.  Ultimately, utilizing a panel of such assays, which probe the physiological state of 
the neuron throughout the course of degenerative processes, is vital to uncovering the key 
features of disease etiology. 
 
2.2 Materials and Methods 
Fly stocks 
Control flies were from either an Oregon Red wild-type background (w+) or a w1118 
white-eyed mutant background (w-), as described.  Cdk5 loss of function conditions (p3520C and 
DfC2) have been previously described (Connell-Crowley, Le Gall et al. 2000, Connell-Crowley, 
Vo et al. 2007, Trunova, Baek et al. 2011, Trunova and Giniger 2012, Smith-Trunova, Prithviraj 
et al. 2015).  The p35-null alleles were crossed into the wild-type background (w+; p3520C).  
Overexpression of p35 was achieved by adding four copies of a transgene encoding the p35 
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genomic locus (Connell-Crowley, Le Gall et al. 2000) in the same background (w+; P[w+,Tn 
p35] R244/P[w+,Tn p35] R244; P[w+,Tn p35]R157/P[w+,Tn p35] R157).  For MB cell counting, the 
UAS-nls-GFP and UAS-nls-mCherry fly stocks were obtained from the Bloomington Drosophila 
Stock Center (BDSC).  The gamma-neuron specific Gal4 driver 201Y-Gal4 was used to express 
UAS-nls-GFP in control (w+; 201Y-Gal4/+; UAS-nls-GFP/+), p35-null (w+; DfC2,201Y-
Gal4/p3520C; UAS-nls-GFP/+), or p35-OE (w+; 201Y-Gal4,P[w+,Tn p35] R244/P[w+,Tn p35] R244; 
UAS-nls-GFP, P[w+,Tn p35] R157/P[w+,Tn p35] R157) backgrounds.  hs-Gal4, UAS-hid was 
procured from the BDSC, and ELAV-Gal4/+; UAS-Aβ42 was provided by Dr. Koichi Iijima.  
The UAS-mito-GFP stock was a gift of Dr. Ramakrishnan Kannan. 
 
Immunohistochemistry 
Adult brains were dissected in ice-cold phosphate buffered saline (PBS) (pH 7.4) 
(Invitrogen), fixed in 4% paraformaldehyde (PFA) in PBS for 30 min, and then transferred to 4% 
PFA in PBS with 0.5% Triton X-100 (PBST) for an additional 30 min.  Brains were then rinsed 
once in PBST, followed by three five-minute washes in PBST.  Brains were incubated in 
blocking buffer (PBST, 4% bovine serum albumin (BSA), 4% goat serum, 4% donkey serum) 
for 1 h, then incubated with primary antibodies in blocking buffer for 48 hours at 4°C. Primary 
antibodies included: 1:200 mouse anti-Fasciclin 2 (Fas2) and 1:100 mouse anti-dachshund (Dac) 
from Developmental Studies Hybridoma Bank. Samples were then rinsed and washed thrice in 
PBST, before being incubated with secondary antibodies overnight at 4°C.  Secondary antibodies 
were diluted 1:500 in blocking buffer, and included goat anti-mouse conjugated with either 
A488, A568, or A633 fluorochromes (Invitrogen).  Lastly, brains were rinsed and washed thrice 
in PBST before being mounted in VectaShield antifade medium.  In order to prevent samples 
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from being squished, coverslips were set on number 1 glass chips.  Prepared samples were 
imaged under 40X-oil on a Zeiss NLO510 confocal microscope and analyzed using Imaris.   
 
Silver staining 
Whole adult brains were microdissected in ice-cold PBS, and then transferred into 
fixative (4% PFA in 0.1M cacodylate buffer, pH 7.4).  Brains were placed on a nutator for 1 hour 
at room temperature (RT), and then transferred to a nutator at 4°C for 24 hours.  After five five-
minute washes in water, the brains were transferred into a cupric-silver solution (6ml deionized 
water, 0.0525g AgNO3, 50μl 1% CuNO3, 500μl 0.1% allantoin, 300μl pyridine, 600μl absolute 
ethanol, and 300μl borate buffer) and incubated at 40°C for 1 hour.  The samples were then 
removed from heat and left at RT overnight.  Samples were washed in 100% acetone for 90 
seconds, then immediately transferred to a silver diamine incubation solution (6ml deionized 
water, 1.2g AgNO3, 3ml 0.4% NaOH, 1.5ml NH4OH, 6ml deionized water).  After a 35-minute 
incubation in the dark, the samples are transferred to a reducing agent solution (13.5ml deionized 
water, 1.5ml absolute ethanol, 18μl 37% w/w formaldehyde, 1.05mg anhydrous citric acid) for 5 
minutes.  Samples were then incubated in ferricyanide bleaching solution (0.3% K3Fe(CN)6) for 
no more than 10 minutes with gentle agitation, until the brains achieved a dark straw color.  
Once the brains were the appropriate color, they were washed thrice in distilled water, then 
transferred to 0.1% sodium thiosulfate for 1 minutes.  Following three more washes, the brains 






Thioflavin S staining 
Whole adult brains were microdissected in ice-cold PBS, then fixed in 4% PFA for 1 
hour.  After three five-minute washes, brains were permeabilized in 2% Triton X-100 for 4 
hours.  Brains were then washed twice in PBS, washed once in 50% ethanol/PBS, and then 
incubated in 0.2% thioflavin-S for 11-13 hours.  Following this overnight incubation, samples 
were washed once in 50% ethanol/PBS, washed twice in PBS, and then mounted.  Microscopy 
was performed on a Zeiss NLO510 confocal microscope using a Chameleon 750nm laser to 
excite the thioflavin S.  Images were acquired using either a 20-X dry or 40-X oil objective. 
 
Mushroom Body Neuron Counting 
Whole adult brains were microdissected in ice-cold PBS and fixed in 4% PFA for 1 hour, 
washed, and then mounted on slides with VectaShield (Vector Laboratories, Burlingame, CA).  
Microscopy was performed on a Zeiss NLO510 confocal microscope or with the Zeiss 
Yokogawa Spinning Disk (SD) system mounted on an inverted Zeiss Axio Observer Z1 
microscope; images were acquired using a 40-X oil objective.  Z-stacks were collected from 
individual brain hemispheres, and were analyzed using Bitplane’s IMARIS (version 7.5.2) and 
its ‘Add spots’ function to semi-automatically count the labeled neurons; false positives were 
manually removed, and false negative nuclei were manually added.   
 For automatic quantification of MB neurons using UAS-nls-mCherry, the spot counting 
diameter was set to “2” and the threshold value was set to “2.12.”  These values were determined 






Nuclear reporters can assay neurodegeneration by directly counting neuron number 
Prior to assessing specific stages of neurodegeneration, it is necessary to first establish 
that neurodegeneration is even occurring.  In a Drosophila model of adult-onset 
neurodegeneration, histological sectioning of p35-null brains revealed the formation of 
‘vacuoles’ in the brain; these holes in the tissue were largely localized to the mushroom bodies 
(MB), responsible for olfactory learning and memory (Trunova and Giniger 2012).  While such 
vacuole formation is consistent with neurodegeneration, it falls short of directly showing 
neuronal loss.  As such, we sought to directly count the number of MB neurons.  First, we used 
antibody staining to selectively label MB neurons.  The protein Dachshund is expressed in a 
large set of neurons, including MB neurons.  To restrict our analysis to MB neurons only, we 
analyzed flies carrying a MB-specific Gal4 driver and a fluorescent-tagged membrane marker 
(OK107-Gal4>UAS-mCD8-GFP), and focused our analysis on double positive neurons.  Co-
labeling with anti-Dac antibody staining and with UAS-mCD8-GFP revealed individual MB 
neurons (Figure 2.3.1a-c); however, quantifying neurons from the entire MB by counting each Z-
slice in a stack proved problematic due to issues with tallying the same neuron multiple times 
from adjacent slices.  To solve this, we used mCD8-GFP to outline a MB volume, and only 
counted Dac-positive neurons contained within it (Figure 2.3.1d).  However, Dac-staining could 
not sufficiently distinguish between adjacent neurons for automatic counting, as the cell bodies 







Figure 2.3.1.  Antibody staining and mCD8-GFP expression labels MB neurons for direct 
quantification. 
Flies with OK107-Gal4-driven MB-specific expression of mCD8-GFP were stained with anti-
Dac to co-label the MB neurons.  (A) anti-Dac staining labels the nuclei of a large set of neurons 
including MB neurons, while (B) expression of mCD8-GFP specifically labels MB neurons.  (C) 
Neurons that are positive for both Dac and mCD8-GFP are selected for quantification.  (D) A 3D 
volume was generated from composite confocal images of the mCD8-GFP label; only Dac 
staining that was encompassed by the volume was quantified. 
 
Given the lack of sensitivity and insufficient signal:noise ratio from antibody staining and 
the membrane marker, we next tested a nuclear-targeted fluorescent protein to quantify MB 
neurons.  We combined UAS-nls-GFP with 201Y-Gal4, which expresses in a subset of MB 
neurons.  This combination permitted quantification of most gamma neurons, as well as some 
alpha and beta neurons (Figure 2.3.2A; (Aso, Grübel et al. 2009)).  Out of multiple platforms 
tested, Imaris proved the most successful at automatically counting labeled neurons.  However, it 
was observed that the nls-GFP signal was not entirely restricted to nuclei and also labeled the 
calyx (Figure 2.3.2A – side view), which added to the background noise and ultimately 
prevented fully automatic quantification.  Nevertheless, the signal was sufficient for precise 









regardless of the microscope used to collect the images (Figure 2.3.2C-D), and regardless of the 
orientation of the brain when mounted on a slide (Figure 2.3.2E).  We also tested a separate 
construct, UAS-nls-mCherry, which revealed better restriction of the fluorescent probe to the 
nuclei (Figure 2.3.2B).  With the enhanced signal:noise ratio, fully automatic quantification 




Figure 2.3.2.  Expression of nuclear-localized fluorescent protein permits automatic 
quantification of MB neurons. 
201Y-Gal4-driven MB-specific expression of (A) UAS-nls-GFP or (B) UAS-nls-mCherry is 
used to quantify MB neurons (side and top views are presented).  (C-D) Quantification with a 
nuclear label is robust enough that samples imaged on different microscopes yield essentially 
identical counts, regardless of whether imaging was first completed on the NLO microscope (C) 
or initially done on the spinning disk (D).  Brain hemispheres are color-coded to identify which 
counts come from the same sample.  (E) MB neuron quantification is not affected by the 
orientation of the brains on the slide when imaged.  3-day old control and p35-null samples were 
dissected and mounted with either the anterior (A) side of the brain adjacent to the coverslip, or 
the posterior (P) side of the brain. Subsequent quantification revealed no significant difference 
between orientations, regardless of genotype.  (F) Labeling with nls-mCherry is precise enough 
that completely automated counting can quantify 88.03+2.21 (mean+SEM) of the labeled MB 





As this method of labeling relies on expression from a Gal4 driver, we next verified that 
that expression remains constant with age.  Specifically, we wanted to be sure that any observed 
decrease in cell numbers was due to neurodegeneration and not the result of decreased Gal4 
expression.  We addressed this by two methods: co-labeling MB neurons of young and old flies 
with both nls-GFP and anti-Dac antibody, and by co-labeling MB neurons with both ROBO2-
GFP and anti-FasII antibody.  In either case, a significant increase in the number of antibody-
positive/GFP-negative neurons in old flies would indicate that some neurons are still present but 
are not expressing Gal4.  Co-labeling MB neurons of 3- and 30-day old control flies (201Y-
Ga4/+; UAS-nls-GFP/+) with anti-Dac revealed robust GFP expression even at old age (Figure 
2.3.3A, C).  Both FasII and ROBO2-GFP are restricted to the axonal lobes of MB neurons.  In 
adult flies, FasII is expressed to varying degrees in different subsets of MB neurons; in the 
gamma neurons where 201Y-Gal4 is primarily expressed, FasII has low but still detectable 
expression (Figure 2.3.3B’).  Similar to nls-GFP, ROBO2-GFP expression does not diminish 
with age (Figure 2.3.3B,D).  These trends hold true regardless of p35 expression, as p35-null 
flies also exhibited robust 201Y-Gal4 expression at 30 days (Figure 2.3.3E-H).  Taken together, 
these data demonstrate that 201Y-Gal4-driven expression of a nuclei reporter is a viable option 







driven expression does not 
decrease with age. 
Composite confocal images of 
MB cell bodies and axonal 
lobes from control and p35-
null flies aged to 3- or 30-days 
old.  Specific loss of the 
fluorescently-labeled marker 
without concordant loss of 
antibody staining would reveal 
decreased Gal4 expression 
with age.  (A,C,E,G) Flies 
expressing UAS-nls-GFP 
driven by 201Y-Gal4 were 
stained with anti-Dac.  
(B,D,F,H) Flies expressing 
UAS-Robo2-GFP driven by 
201Y-Gal4 were stained with 
anti-FasII.  White arrows 
highlight the subset of gamma 
neurons where 201Y 
expression is the highest.
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A modified silver-strain protocol labels degenerating neurons 
As an alternative to quantifying the number of remaining MB neurons, which fails to 
distinguish between healthy and dying neurons, we sought to selectively label degenerating 
neurons.  Over the past few decades, significant progress has been made towards such a goal in 
mammalian samples.  de Olmos first developed a modified cupric-silver technique for the 
selective impregnation of degenerating neurons in 1969 (De Olmos 1969).  Since then, others 
have continued to develop techniques that can label neuronal cell bodies, axons, dendritic 
processes, and synaptic terminals of degenerating neurons, while healthy neurons are left 
unlabeled (Switzer 2000, Tenkova and Goldberg 2007).  Starting with these mammalian-specific 
protocols, we combined aspects of multiple methods to generate a new protocol for use in 
Drosophila, as no such technique has been developed for insects.  To be certain that we were 
detecting neurodegeneration, we employed several methods to induce neuronal death.  Neuronal 
apoptosis was triggered by heat-shock induced expression of the head involution defective gene 
(HS-Gal4>UAS-hid), which has been shown to cause programmed cell death (Grether, Abrams 
et al. 1995).  Second, expression of amyloid beta 42 (Aβ42) was driven pan-neuronally using 
ELAV-Gal4.  In humans, Aβ42 aggregates into plaques and is linked to Alzheimer’s disease; in 
Drosophila, expression of Aβ42 has been found to induce age-dependent memory defects, 
locomotor dysfunction, and neurodegeneration (Iijima, Chiang et al. 2008).  Lastly, we examined 
p35-null flies, which exhibited age-dependent formation of ‘vacuoles’ in the MB (Trunova and 
Giniger 2012).  In each case, there were instances of successful silver staining and evidence of 
neurodegeneration (Figure 2.3.4).  However, staining results were largely inconsistent; indeed, 
only 1/30 p35-null brains exhibited evidence of selectively-labeled degenerating neurons within 
the MB.  Furthermore, there was extreme variation in the staining of samples within genotypes, 
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even among controls; this observation pointed to the prerequisite for additional troubleshooting 
before any meaningful conclusions could be drawn.  Ultimately, this labor-intensive procedure, 
which would require even further optimization, was removed from the panel of 
neurodegenerative assays. 
 
Figure 2.3.4.  Modified silver staining can selectively label degenerating neurons. 
Silver staining of (A) heat-shock control samples reveals minimal neuronal labeling.  Staining of 
(B) hs-hid, (C) 45 day old p35-null, and (D) ELAV-Gal4>UAS-AB42 samples reveals selective 
labeling of cell bodies and neuronal processes (white arrowheads).   
 
Development of assays to evaluate defects in neuronal physiology 
Proper mitochondrial function is essential for neuronal maintenance and homeostasis.  
Certainly, damaged and non-functional mitochondria have been associated with 
neurodegeneration in many paradigms across multiple species (Leuner, Hauptmann et al. 2007).  
Here, we sought to analyze the ratio of healthy, functional mitochondria to total mitochondria, 
positing that an increase in non-functional mitochondria could be an underlying mechanism of 





tetramethylrhodamine, methyl ester (TMRM), a fluorescent dye that permeates into cells and is 
readily sequestered by healthy, active mitochondria; mitochondria with a perturbed membrane 
potential fail to take up the dye (Perry, Norman et al. 2011).  Additionally, we co-labeled 
mitochondria by staining with MitoTracker-Green, which stains all mitochondria regardless of 
membrane potential (Cottet-Rousselle, Ronot et al. 2011).  Thus, all mitochondria will be labeled 
with MitoTracker-Green, while only healthy mitochondria will also be labeled with TMRM.  As 
our previous findings identified the MB as a susceptible population in the p35-null background, 
we focused our analyses on this neuronal subpopulation.  As a positive control, we treated intact 
brains with the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone 
(FCCP) to disrupt mitochondrial membrane potential (Perry, Norman et al. 2011). The addition 
of FCCP resulted in a drastic decrease of TMRM-positive puncta, indicating loss of healthy 
mitochondrial with intact membrane potential (Figure 2.3.5E).  In the end, we failed to get 
adequate depth of penetration of the TMRM dye into the intact brain samples to stain the MB 
neurons (Figure 2.3.5B), so we could not quantify the ratio of healthy versus unhealthy 
mitochondria.  As such, TMRM staining is not a viable option for analyses in whole brain; 
however, future experiments can utilize UAS-mito-GFP constructs to visualize mitochondrial 
number and defects in fission or fusion.  
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Figure 2.3.5: Labeling of mitochondria with multiple reagents distinguishes healthy versus 
damaged mitochondria. 
Wild-type brains were dissected and stained with (A,D) MitoTracker-Green (MT) and (B,E) 
TMRM in the presence or absence of the decoupler FCCP.  (D-F) Treatment with FCCP 
significantly reduced TMRM staining, indicating effective disruption of the mitochondrial 
membrane potential.   
 
In addition to mitochondrial dysfunction, disrupted autophagy has been associated with 
multiple neurodegenerative diseases (NDDs) (Hara, Nakamura et al. 2006, Komatsu, Waguri et 
al. 2006, Spencer, Potkar et al. 2009, Inagaki, Kamikouchi et al. 2010, Winslow, Chen et al. 
2010).  Indeed, it was demonstrated that p35-null mutants are more sensitive to autophagic stress 
as they exhibit enhanced sensitivity to starvation (Trunova and Giniger 2012).  Furthermore, 
utilizing electron microscopy, it was found that p35-null mutants also exhibited enhanced 
accumulation of autophagic organelles both at young and old ages.  To assess if autophagy was 
being compromised by the aberrant formation of protein aggregates, which has been observed in 
several NDDs (Menzies, Fleming et al. 2015), whole brains were stained with thioflavin S (TS).  
TS recognizes beta-sheet rich protein aggregates and intercalates within the beta-sheet folds; this 
a c b 
d f e 
MT Merged TMRM 
MT Merged TMRM 
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interaction induces a conformational shift of the TS molecule and leads to a detectable shift in 
fluorescence (Greenfield 2008).  TS has previously been used as a diagnostic marker for some 
NDDs, and has even been used in Drosophila (Iijima, Chiang et al. 2008).  As a positive control, 
flies with pan-neuronal overexpression of Aβ42 were first stained with TS.  97.3% (36/37) of 
ELAV-Gal4/+, UAS- Aβ42/+ brains showed elevated levels of TS staining, relative to age-





Figure 2.3.6.  Thioflavin-S staining labels protein aggregates. 
Adult brains of various age and genotype are stained with Thioflavin-S to label protein 
aggregates.  20-day old w1118 (A) control flies and (B) flies overexpressing Aβ42 (ELAV-Gal4> 
UAS-Aβ42) were used to test the TS-staining protocol; Aβ42-expressing samples exhibited 
significantly higher numbers of TS-positive puncta.  (C-J) w1118 control and p35-null samples 
show age-dependent accumulation of aggregates, although the phenotype is accelerated by loss 
of Cdk5 activity.  (C-F) Control and (G-J) p35-null samples were aged to (C,G) Day 3, (D,H) 
Day 10, (E,I) Day 30, or (F,J) Day 45.  3-day old red-eyed w+ (K) control, (L) p35-null, and (M) 




After confirming that the protocol worked in our hands, we next stained control (w1118) 
and p35-null (w1118; p3520C) flies at various ages (Figure 2.3.6C-J).  Controls and p35-null 
samples both exhibited a trend of increasing TS-positive puncta with age, with this trend being 
accelerated in p35-null brains, consistent with evidence that p35 deficiency accelerates the age-
dependent disruption of autophagy seen in controls.  Additionally, p35-null mutant brains show a 
shift from a high number of small aggregates to a smaller number of larger aggregates with age.  
In some cases, p35-null brains showed TS-positive puncta localized within the MB calyx (Figure 
2.3.6J), consistent with previously described ND (Trunova and Giniger 2012).   
We next looked for protein aggregation in control, p35-null, and p35-OE flies of a wild-
type genetic background (w+).  Surprisingly, staining revealed a large number of TS-positive 
puncta regardless of genotype.  Relative to the w1118 samples, which exhibited minimal staining 
at Day 3, the w+ samples all showed an increase in TS-positive puncta, with w+ control samples 
actually displaying the greatest number of spots (Figure 2.3.6K-M).  As the young, 3-day old 
control samples, which are essentially a negative control, exhibited a significant number of 
puncta, we were forced to question the specificity of the stain.  Thus, while TS reactivity is 
modified by neurodegeneration, that effect is obscured by an effect of the wild-type white 
protein, a transporter of small molecules.  Consequently, this assay was not practical and was 
replaced with other established markers of autophagy.  Specifically, we analyzed Atg8-II and 
Ref(2)P levels, two proteins which are known to accumulate when autophagy is impaired 
(Ichimura, Kirisako et al. 2000, Li, Zhang et al. 2008, Nezis, Simonsen et al. 2008).  
Accumulation of these proteins will be described in more detail in Chapter 3.  Additionally, the 
lab has tested a fluorescent probe capable of discerning between autophagic induction and 
autophagic flux (Arvind Shukla, personal communications).  Atg8a tagged with both mCherry 
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and GFP labels all autophagosomes, thereby tracking levels of autophagic induction.  In the non-
acidic autophagosome, both mCherry and GFP express, resulting in yellow fluorescence.  Once 
the autophagosome fuses with a lysosome, the GFP fluorescence is quenched by the increased 
acidity, leaving only red fluorescence to label the autolysosome (DeVorkin and Gorski 2014).   
 
2.4 Discussion 
One pitfall of current assays for labeling degenerating neurons is that they can be 
selective to the mechanism of induced neuronal death and be excluded from neurons dying 
through separate pathways.  To counter this, we used direct neuron counting, which has the 
benefit of revealing neurodegeneration regardless of how neuronal death was induced.  In some 
cases, antibody staining is sufficient for quantification.  However, this is not a viable option 
when dealing with dense populations of neurons such as the mushroom bodies.  Further, 
antibody staining can be dependent on the functional state of the neuron: if the neuron is no 
longer producing the targeted protein, it will not be labeled.  Using Gal4 expression, which we 
demonstrated was not age- or genotype-dependent, we were able to robustly label and quantify 
neurons, thus revealing neurodegeneration.  Notably, this method can be applied to any other cell 
type by using specific Gal4 constructs to drive expression of the nuclear labels, although 
controlling for the reliability of Gal4 expression will be essential. 
In addition to directly measuring neuron loss, flies will be evaluated for various 
degenerative phenotypes.  While overall lifespan can be subject to non-biological confounding 
factors, it is generally accepted as a method for demonstrating degeneration and loss of fitness.  
Another behavioral technique for testing degeneration is to assess motor function.  To do so in 
Drosophila, flies are tested for their ability to climb up the wall of a vial in response to being 
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startled and knocked down to the bottom.  Typically, simple wall-climbing assays generate a 
binary score of either pass or fail.  Conversely, the counter-current apparatus permits a more 
quantitative assessment through the calculation of a partition coefficient.  Lifespan and motor 
function assays will be described in more detail in Chapter 3.   
Although cell counting, motor defects, and shortened lifespan can all measure 
degeneration, these phenotypes can sometimes take weeks to manifest.  To fully understand the 
underlying mechanisms leading to neurodegeneration, it is necessary to assess the degenerative 
processes at their earliest stages.  Unfortunately, technical difficulties prevented silver staining 
and mitochondrial staining from being viable options for quantifying neurodegeneration.  Using 
thioflavin-S staining to detect protein aggregation appeared to be successful in white-eyed w1118 
mutants, but not in wild-type red-eyed w+ flies.  In Drosophila, the white gene encodes a subunit 
of an ATP-binding cassette transporter (O'Hare, Murphy et al. 1984, Hazelrigg 1987).  This 
complex transports a variety of substrates, and plays a role in pigment synthesis from precursor 
granules, vesicular accumulation of cyclic guanosine monophosphate, and neurotransmission 
(Xiao and Robertson 2016).  Thus, the increased TS staining observed in w+ flies likely reflects 
physiologically relevant aggregates generated through normal neuronal activity, although 
additional studies would be necessary to confirm this.  In place of TS staining, we will measure 
Atg8-II and Ref(2)P levels to assess proteostasis and autophagy.  Atg8 (LC3 homolog) is cleaved 
and lipidated before it binds to autophagosomes and gets degraded (Ichimura, Kirisako et al. 
2000); impaired autophagy results in an accumulation of the cleaved form, assayed as an 
increase of Atg8-II levels.  Ref(2)P, a p62 homolog, accumulates on autophagosomes and then 
gets degraded upon fusion of the autophagosome with a lysosome.  However, if autophagy is 
impaired, an increase in Ref(2)P levels is observed (Li, Zhang et al. 2008, Nezis, Simonsen et al. 
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2008).  Furthermore, we will assess autophagic induction and flux using the double-tagged 
Atg8a construct (DeVorkin and Gorski 2014).   
Staining earlier stages of degeneration alone is not a sufficient marker of 
neurodegeneration, as perturbation of physiological processes does not always result in neuronal 
death.  Thus, a panel of assays that probes both the initial dysfunction and the terminal 
phenotypes is needed.  Here, we have established a method for fully automated quantification of 
mushroom body neurons in adult flies.  For experiments presented in following chapters, we will 
also utilize techniques to assess a range of organismal and cellular phenotypes.  As an overall 
measure of organismal health and fitness, we will track the lifespan of flies, while negative-
geotaxis will be used to measure motor function.  At the cellular level, autophagy will be 
assessed by measuring levels of autophagic proteins.  Assays developed here, in combination 
with previously existing assays, will allow the effective analysis of multiple points of the 
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Chapter 3: Altered activity of Cdk5/p35 kinase causes neurodegeneration in part  
by accelerating the rate of aging 
 
3.1 Introduction 
Age is the most prominent risk factor for neurodegenerative disease (NDD), but the 
relationship between neurodegeneration and aging is complex and controversial.  While each 
NDD has its own unique hallmarks, most degenerative diseases share a variety of cellular 
phenotypes with aging, including disrupted proteostasis, impaired cellular trafficking, and 
increased generation of oxidative stress.  Despite this, NDD goes beyond being merely brain 
aging; indeed, not every individual that grows old develops a NDD, so aging alone is insufficient 
to cause neurodegeneration.  Gaining a productive understanding of the pathogenesis of 
neurodegenerative disease will require that we untangle the relationship of degeneration to aging. 
Cyclin-dependent kinase 5 (Cdk5) has previously been linked to multiple NDDs, 
including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s 
disease (PD) (Patrick, Zukerberg et al. 1999, Nguyen, Larivière et al. 2001, Qu, Rashidian et al. 
2007).  Cdk5 is an atypical cdk that has no role in cell cycle progression, but rather has only been 
found to act in postmitotic cells. Cdk5 also does not depend on a canonical cyclin for activation; 
instead, its kinase activity requires binding to an activator that has a three-dimensional fold 
similar to cyclins, but little sequence similarity.  In mammals, there are two Cdk5 activators, p35 
and p39, while Drosophila has only a single activator, p35 (Tsai, Delalle et al. 1994, Connell-
Crowley, Le Gall et al. 2000).  Expression of these activators is largely restricted to neurons, 
localizing Cdk5 activity to the nervous system (Tsai, Delalle et al. 1994, Tang, Yeung et al. 
1995, Connell-Crowley, Le Gall et al. 2000).  In addition to the spatial regulation by activator 
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availability, the activity of Cdk5 is further regulated by the phosphorylation status of the kinase 
and its activator subunits.  Upon binding to p35, Cdk5 autophosphorylates its activator, targeting 
it for proteasomal degradation.  There is also cross-regulation of activity with other kinases that 
share a similar target sequence preference (“proline-directed” protein kinases) (Anderton, Betts 
et al. 2001, Morfini, Szebenyi et al. 2004, Zheng, Li et al. 2007).  Proper regulation of Cdk5 
activity is essential to maintaining normal neuronal function and homeostasis. 
Deregulation of Cdk5 activity contributes to a variety of NDDs.  Altered Cdk5 activity 
has been found to lead to hyperphosphorylation of tau, inducing formation of neurofibrillary 
tangles associated with AD (Patrick, Zukerberg et al. 1999), and of neurofilament, as in ALS 
(Nguyen, Larivière et al. 2001).  Cdk5 also hyperphosphorylates and inhibits peroxiredoxin 2 
(Prx2), an antioxidant enzyme; elevated levels of phosphorylated Prx2 were found in brain tissue 
of PD patients (Qu, Rashidian et al. 2007).  Aside from links to multiple NDDs, both gain and 
loss of Cdk5 function have been shown to cause neuronal death in culture, and to cause 
neurodegeneration in mouse models (Patrick, Zukerberg et al. 1999, Cruz, Tseng et al. 2003, 
Zheng, Li et al. 2007, Takahashi, Ohshima et al. 2010).  We have shown previously that p35 loss 
of function in the fly produces degeneration-like phenotypes that mimic cellular phenotypes 
observed in human disease (Trunova and Giniger 2012).  This is consistent with a large and 
growing literature documenting that the fly is a valid and valuable model for dissecting the 
molecular mechanisms underlying the cascade of events in human NDDs (Feany and Bender 
2000, Iijima, Liu et al. 2004, Watson, Lagow et al. 2008).  While investigating p35-associated 
neurodegeneration in the fly, we noted that many of its central phenotypes resemble early onset 
of normal aging phenotypes (Trunova and Giniger 2012).  As in human disease, this underscored 
the need to distinguish degeneration from aging, both analytically and mechanistically. 
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Here, we first demonstrate that either gain or loss of p35 causes death of neurons in the 
learning and memory center of the Drosophila brain (the mushroom body), and is associated 
with characteristic phenotypes of degeneration and aging, including impaired autophagy, 
progressive loss of motor function, and shortening of the lifespan.  We then used gene expression 
profiling to develop an unbiased and quantitative metric for physiological age.  Applying this 
metric reveals that gain or loss of p35 accelerates the intrinsic rate of aging of the fly.  Finally, 
we further test this hypothesis and show that an age-dependent phenotype identified by the 
expression profiling, sensitivity to oxidative stress, also shows aging-like changes in flies with 
altered p35 levels.  Taken together, our data suggest that neurodegeneration in response to 
altered p35 arises from a combination of the direct effects of accelerated aging, in concert with 
non-aging pathologies induced by the altered pattern of cytoplasmic protein phosphorylation. 
 
3.2 Materials and methods 
Fly stocks 
Control flies were from an Oregon Red wild-type background (w+).  Loss of p35 
conditions (p3520C and DfC2) have been previously described (Connell-Crowley, Le Gall et al. 
2000, Connell-Crowley, Vo et al. 2007, Trunova, Baek et al. 2011, Trunova and Giniger 2012, 
Smith-Trunova, Prithviraj et al. 2015).  The p35-null alleles were crossed into the control 
background (w+; p3520C).  Overexpression of p35 was achieved by adding four copies of a 
transgene encoding the p35 genomic locus (Connell-Crowley, Le Gall et al. 2000) in the same 
background (w+; P[w+,Tn p35] R244/P[w+,Tn p35] R244; P[w+,Tn p35]R157/P[w+,Tn p35] R157).  The 
‘rescue’ line was generated by putting a single copy of the transgene into the p35-null 
background (w+; p3520C/p3520C; P[w+,Tn p35] R157/+).  For MB cell counting, the original UAS-
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nls-GFP fly stock was obtained from the Bloomington Drosophila Stock Center.  The gamma-
neuron specific Gal4 driver 201Y-Gal4 was used to express UAS-nls-GFP in control (w+; 201Y-
Gal4/+; UAS-nls-GFP/+), p35-null (w+; DfC2,201Y-Gal4/p3520C; UAS-nls-GFP/+), or p35-OE 
(w+; 201Y-Gal4,P[w+,Tn p35] R244/P[w+,Tn p35] R244; UAS-nls-GFP, P[w+,Tn p35] R157/P[w+,Tn 
p35] R157) backgrounds. 
 
Mushroom Body Neuron Counting 
Control, mutant, and p35-OE male flies carrying single copies of 201Y-Gal4 and UAS-
nls-GFP were aged to 3-, 10-, 30-, or 45-days old.  MB cell counting was done as described in 
Chapter 2.  
 
Lifespan Assay 
To assay lifespan, 10-14 male and 10 female newly-eclosed flies were aliquoted into a 
vial containing standard KD food and a strip of tegocept paper.  Flies were maintained at 25°C 
with a 12 hr∶12 hr light∶dark cycle.  Flies were transferred to fresh vials every three days; dead 
male flies were counted at each transfer until all flies had died.  At least three sets of seven to 10 
vials were collected for each genotype (control = 485, p35-null = 378, rescue = 410, p35-OE = 
472 total flies).   
 
Motor Function Assay 
Motor function was assayed using a modified version of the negative geotaxis assay 
originally developed by Benzer (Benzer 1967); our version of the apparatus had six tubes on the 
lower frame and five tubes on the upper frame.  We completed five replicates for each genotype 
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at each of the four time points, and assayed each replicate twice; a single replicate contained 20 
male flies.  For the assay, the flies were slightly anesthetized under CO2, divided into replicates, 
and transferred to fresh vials.  After waiting for three hours to let the anesthesia wear off, flies 
were transferred to the first tube of the lower frame, and then given three minutes to acclimate to 
the apparatus.  Once acclimated, the apparatus was gently tapped down on the table five times to 
pool the flies at the bottom of the tube.  The top frame is then slid to the left, such that the flies 
can climb from their current tube in the bottom into the first tube on the top.  After 20 seconds, 
the upper frame is slid to the right.  The apparatus is gently tapped down on the table again, 
depositing all of the flies that climbed up into the top tube down into the second tube on the 
bottom frame.  This process is then repeated four more times, ultimately resulting in the flies 
being distributed throughout the six bottom tubes based on their climbing ability. 
 
A partition coefficient (PC) was calculated using a weighted average as described by the 
formula below (Inagaki, Kamikouchi et al. 2010): 
PC = [(#F6 X 5)+(#F5 X 4)+(#F4 X 3)+(#F3 X 2)+(#F2 X 1)]/[#FT] 
where #Fn is the number of flies in tube ‘n,’ and #FT is the total number of flies.  Percent change 
was calculated relative to the Day 3 control (100-100*(PCSample/PCD3ctrl)).  Percent rescue was 
calculated as “100*(PCRescue – PCp35-null)/(PCControl – PCp35-null)” at each time point. 
 
Western Analysis 
Twenty male flies of each genotype were collected at the defined age (3, 10, 30 and 45 
days), then flash frozen with liquid nitrogen and stored at −80°C.  Six independent biological 
samples were collected to analyze Atg8-II levels; for Ref(2)P, three independent biological 
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samples were collected.  Heads were separated from the rest of the body and homogenized in 
lysis buffer (2% SDS, 150 mM NaCl, 50 mM Tris, pH 7.5) containing protease inhibitors 
(Thermo Scientific, Pierce, Rockford, IL, USA).  Supernatant protein concentrations were 
determined using the Coomassie Protein assay reagent (Thermo Scientific).  Protein samples 
(25μg) were resolved on a 4-12% Bis-Tris plus gel (Invitrogen/Thermo Fisher Scientific, 
Carlsbad, CA, USA) and transferred onto iBlot2 NC membranes using the iBlot 2 system 
(Invitrogen/Thermo Fisher Scientific).  Membranes were cut to separate bands based on 
molecular weight, and then probed with primary antibodies overnight at 4°C.  Primary antibodies 
used included anti-Ref(2)P (1:1000; gift from Sheng Zhang, University of Texas, TX, USA) 
(Rui, Xu et al. 2015), anti-dATG8 (1:500; gift from Sara Cherry, University of Pennsylvania, 
PA, USA; (Shelly, Lukinova et al. 2009)) and anti-β-Tubulin (Catalog #E7,1:500, 
Developmental Studies Hybridoma Bank (E7 was deposited to the DSHB by Klymkowsky, 
Michael)).  Infrared fluorescence IRDye secondary antibodies, including goat anti-rabbit IgG 
(H+L) 800 CW, goat anti-rabbit (680 RD) and/or goat anti-mouse (H+L), were applied for 20 
minutes at room temperature (1∶5000, LI-COR Biosciences, USA) followed by washing with 
PBS. Visualization and quantification was carried out with the LI-COR Odyssey scanner and 
software (LI-COR), with tubulin serving as a loading control. 
 
Microarray and mRNA expression analysis 
For microarray analysis, five biological replicates for each genotype and time point were 
collected.  Each replicate consisted of 140 male flies, aged as described for the lifespan assay; 
following aging, collected totals ranged from 90-140 flies.  We did not use any formal a priori 
statistical methods to predetermine sample sizes; rather, sample sizes were selected based on 
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recommendations from the microarray literature to account for variability.  Replicates consisted 
of pooled tissue samples to provide sufficient material for microarray and qPCR analysis.  Upon 
collection, flies were transferred to a 1.5ml Eppendorf tube and flash frozen in liquid nitrogen, 
then stored at -80°C.  All time points were collected and stored prior to processing.  Eppendorf 
tubes containing frozen flies were transferred into liquid nitrogen to further chill them, then 
vortexed to separate the heads, wings, and legs from the rest of the bodies.  Keeping the samples 
cold on dry ice, the heads were manually transferred to a fresh 1.5ml Eppendorf tube.  Thoraces 
were separated from the abdomen using a surgical blade, and then transferred to their own tube.  
Total RNA was extracted for both head and thorax samples using TRIzol (Invitrogen), then 
processed and labeled according to the manufacturer’s guidelines for use with the DroGene 1.0 
ST GeneChip (Affymetrix, GeneChip Whole Transcript Sense Target Labeling).  The Scanner 
3000 (Affymetrix) was used in conjunction with GeneChip Operation Software (Affymetrix) to 
generate one .CEL file per hybridized cRNA.  Two separate batch runs were required due to 
logistical reasons, with a common technical replicate sample included in both batches.  The first 
batch run included control samples from four time points (Day 3, Day 10, Day 30, and Day 45) 
plus 10-day-old p35-null and p35-OE samples; the second batch run included Day 10 control and 
Day 10 rescue samples.  The Expression Console (Affymetrix) was used to summarize the data 
contained across all .CEL files and generate 16,322 RMA normalized gene probe expression 
values. Subsequent analysis of these values was then performed for head and separately for 
thorax. Specifically, quality of expression was challenged and assured via Tukey box plot, 
covariance-based PCA scatter plot, and correlation-based heat map using functions supported in 
“R” (www.cran.r-project.org, data not shown).  Following this initial inspection, a single Day 3 
control head sample present itself as a cohort-level outlier; this sample was removed and not 
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included in any downstream analysis.  To remove batch effects between the two runs, baseline 
subtraction was performed using expression for a common technical replicate present across 
batches followed by use of quantile normalization to correct for differences in spread.  To 
remove noise-biased expression values, we used lowess modeling to look for a relationship 
between mean gene expression and the corresponding coefficient of variation (CV).  Lowess fits 
were then over-plotted to identify the common low-end expression value where the relationship 
between mean expression (signal) and CV (noise) deviated from linearity (mean expression 
value = 7.5).  Expression values less than this value were set to equal 7.5, while gene probes not 
having at least one sample greater than 7.5 were discarded as non-informative. Annotations for 
genes observed to have differential expression and/or modeled were obtained from NetAffx 
(Affymetrix) and FlyBase (www.flybase.org).  Full probe lists are available in Supplemental 
Tables ST4.3.1-ST4.3.4.   
Polyserial correlation (library = polycor) was used to generate estimates of how 
expression observed per gene linearly relates to age in control samples.  These estimates were in 
turn compared to those obtained when true age is randomized, with estimates greater than or less 
than two standard deviations of the mean of random generated estimates considered as 
significant (p<0.05); genes passing these conditions were deemed aging-related.  To identify 
p35-related genes, ANOVA testing was applied using sample class as the factor under 
Benjamini-Hochberg false discovery rate multiple comparison condition.  Gene probes observed 
to have a corrected p-value < 0.05 by this test were further post hoc challenged via TukeyHSD 
test.  Gene probes observed to have a post hoc p-value < 0.05 and an absolute difference of 
means >1.5X for a class comparison were considered to have differential expression between the 
two classes.  Chi-square with Yates’ continuity correction was used to determine the significance 
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of the overlap between gene lists.  The linear relationship between overlapping probes was tested 
with Pearson’s correlation analysis.   
To test similarities in the expression profiles, the mean expression value of the set of 
genes affected by both aging and altered p35 was calculated.  Each individual Day 10 p35-null or 
p35-OE sample was compared to each Day 3-, Day 10-, Day 30-, and Day 45-control sample, 
generating a set of Pearson correlation coefficients.  Comparing each of five p35-null replicates 
to four Day 3 control head and five of every other control sample yielded 95 total comparisons 
for head tissue, and 100 comparisons for thorax tissue.  The same number of comparisons was 
used for p35-OE.  Significance was determined using one-way ANOVA with Tukey’s MTC. 
To identify aging classifiers, leave-one-out (LOO) testing was employed using the same 
methods described, but on gene expression not discarded for Day 3-, Day 10-, Day 30-, and Day 
45-control samples only. For each LOO round, gene probes deemed to have differential 
expression for at least one class comparison were used to construct a k-Nearest Neighbor (k-NN) 
model and predict the class of the left out sample (Dudoit, Fridlyand et al. 2002). Gene probes 
selected 100% of the time over all LOO rounds were deemed control aging classifiers. These 
genes were then used to construct a principal component seeded AIC-optimized linear model 
using expression for Day 3-, Day 10-, Day 30-, and Day 45-control samples only.  This model 
was used to predict the physiological age of each biological replicate (four Day 3 control head 
samples, and five of every other sample and time point).  Statistical differences in the predictions 
produced by the linear model were determined by performing one-way ANOVA with Tukey’s 
MTC on the predictions themselves. 
To test whether expression changes observed in the p35-null samples were specific to 
p35, a transgene carrying the p35 genomic locus was added to the p35-null background.  Genes 
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were considered fully rescued if they showed >1.5-fold change (based on microarray data) 
relative to D10 controls in the p35-null samples, but not the rescue samples.  Partially rescued 
genes were those with expression values that trended towards the control values but still 
exhibited >1.5-fold change relative to D10 controls.   
 
Gene Ontology Analysis  
Gene ontology analysis was performed using annotated probes identified as aging-related 
or p35-related (see Statistical Analysis section below), using version 6.7 of Database for 
Annotation, Visualization, and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov; 
Huang, Sherman et al. 2009a, Huang, Sherman et al. 2009b).  The background was set to 
“Drosophila_2 Array,” and then “Functional Annotation Clustering” with medium classification 
stringency was used to identify groups that were significantly enriched.  An Enrichment Score 
greater than 1.3, correlating to a non-log scale p-value less than 0.05, was considered statistically 
significant.  The resulting annotated clusters were grouped together based on similarity of 
biological modules; only the highest enrichment score for each ontology group is presented here.  
Full DAVID results are available in Supplemental Tables 4.3.5-4.3.6 and 4.3.9-4.3.12.   
 
qPCR validation 
Excess RNA from the microarray samples was converted into cDNA using the Applied 
Biosystems High Capacity cDNA Reverse Transcription kit; three biological replicates were run 
in triplicate for every gene probe.  qPCR reactions were prepared using the Affymetrix 
VeriQuest Probe qPCR Master Mix with specific TaqMan gene primers (Supplemental Table 
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4.3.7); reactions were carried out on the BioRad iQ5 Multicolor Real-time PCR Detection 
System.  Threshold cycle numbers were determined automatically by the BioRad software.   
The set of probes included four reference genes (eIF-1a, Rap2L, Rpl32, and Sdha), which 
were used to compute a geometric mean for normalization.  Fold changes were determined using 
ΔΔCt (Livak and Schmittgen 2001), relative to Day 3 controls (for aging-specific changes) or 
Day 10 controls (for mutant-specific changes).  qPCR probe information is provided in 
Supplemental Table 4.3.7. 
 
Oxidative stress sensitivity assay 
Sensitivity to oxidative stress was assayed by survival following challenge with paraquat 
(PQ; 15mM), which catalyzes the production of superoxide and induces oxidative stress 
(Farrington, Ebert et al. 1973), or hydrogen peroxide (H2O2; 5%), which induces oxidative stress 
through the generation of reactive hydroxyl radicals (Halliwell and Gutteridge 1984).  Male flies 
were mated for three days, and then females were removed.  Males were then aged to 3-, 10-,  
30-, or 45-days old, starved for four hours on filter paper damp with water, and then transferred 
to vials containing filter paper moistened with 5% sucrose solution and PQ or H2O2.  A separate 
set of flies received only 5% sucrose as control (data not shown).  Survival was scored every 12 
hours, and median survival time calculated.  Three biological replicates were analyzed for each 
genotype and time point.  Each replicate consisted of 2-5 vials of 7-20 males each (Day 3 control 
= 189, Day 10 control = 175, Day 30 control = 196, Day 45 control = 256, Day 3 p35-null = 190, 
Day 10 p35-null = 150, Day 30 p35-null = 199, Day 45 p35-null = 259, Day 3 rescue = 199, Day 
10 rescue = 147, Day 30 rescue = 209, Day 45 rescue = 240, Day 3 p35-OE = 200, Day 10 p35-
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OE = 179, Day 30 p35-OE = 223, Day 45 p35-OE = 239 total flies); individual replicate sizes are 
presented in Supplemental Table 4.3.14. 
 
Statistical Analysis 
All data were analyzed with GraphPad Prism 7.0b and R.  Differences between groups 
were assessed by either one-way or two-way ANOVA with post-hoc Tukey multiple comparison 
testing, as described. Statistical differences in survival curves (lifespan and oxidative stress 
response) were measured by log rank (Mantel-Cox).  All statistical tests were two-tailed, and 
statistical significance was considered at p < 0.05.  Experimental groups were determined based 
on genotype, so no randomization was used; data collect and analysis was not performed blind to 
the conditions of the experiments.  Sample sizes were not predetermined using statistical 




Microarray data are available from NCBI GEO under accession number GSE7483. 
 
Code Availability 
R sessions, R code, and R input files used in the analysis of the microarray data will be 





Loss or gain of p35 causes accelerated neuron loss with age 
Histology of p35-null flies has previously demonstrated age-dependent formation of 
‘vacuoles’ in the brain, particularly in the mushroom bodies (MB) (Trunova and Giniger 2012).  
While these vacuoles are suggestive of neurodegeneration, this assay was not definitive as it did 
not directly demonstrate neuron loss, as opposed to alternative explanations, such as expansion 
of inter-neuronal spaces or reduced dendritic arborization.  We therefore counted a specific class 
of MB neurons directly.  Flies expressing a nuclear-localized GFP (UAS-nls-GFP) under the 
control of a MB-specific Gal4 driver (201Y-Gal4, which labels gamma neurons and a small 
subset of alpha and beta neurons (Aso, Grübel et al. 2009)) were grown to various ages and then 
dissected.  Control flies showed steady numbers of 201Y-positive neurons through early and 
middle age, before showing a decline at Day 45 (mean+SEM: D3 control = 763.2±50.3, D30 
control = 731.3±37.0, D45 control = 532.4±72.3 neurons/MB; Figure 3.3.1B).  At Day 3 and 
Day 10, p35-null flies exhibited a similar number of MB neurons as controls.  At Day 30, 
however, p35-null flies showed a sharp decline in neuron number (D30 p35-null 515.0±35.2 
neurons/MB, p=0.0012 (two-way ANOVA with Tukey’s multiple comparison test (MTC)); 




Figure 3.3.1.  Gain and loss of p35 induces overt neurodegeneration and degenerative 
phenotypes.   
(A) Projected confocal image of MB neuron nuclei labeled with nls-GFP.  (B) Altered p35 levels 
lead to progressive loss of MB neurons.  The number of 201Y>nls-GFP positive MB neurons per 
hemisphere is presented as mean+SEM, along with individual counts.  For each genotype and 
time point, the number of hemispheres analyzed is presented at the bottom of the bar.  Significant 
differences are determined using two-way ANOVA with Tukey’s MTC; presented p-values are 
from MTC, and are relative to the Day 3 control.  (C) Altered p35 leads to a shortened lifespan.  
Sample size for control, p35-null, p35-OE, and rescue samples were as follows: 485 male flies, 
518, 472, and 410, respectively.  Significant differences in lifespan were determined using the 
Mantel-Cox log-rank test.  (D) Loss or overexpression of p35 leads to progressive loss of motor 
function.  A partition coefficient (PC) was calculated from the flies’ ability to complete a series 
of negative geotactic tasks (see Materials and methods).  PC is presented as mean+SEM; 
individual replicate PCs are also shown.  Five replicates of 20 flies were analyzed twice for each 
genotype and time point.  Significant differences are determined using two-way ANOVA with 
Tukey’s MTC; presented p-values are from MTC, and are relative to the Day 3 control.  In all 
panels, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.  For the rescue samples, significant 




We noted that the average number of MB neurons at Day 45 was actually higher in p35-
null flies than at Day 30 (D45 p35-null = 668.3±33.9 neurons/MB), though still less than the 
number measured at Day 3.  Based on staining for phosphorylated histone H3, which stains 
mitotic cells, and EdU, which labels newly synthesized DNA, we found no evidence of 
neurogenesis (data not shown).  Since no new neurons are being born, the simplest hypothesis is 
that the small fraction of p35-null flies still surviving at Day 45 (8.3%) are those that had 
sustained the least amount of neuron loss with age.  Consistent with this, MB neuron number in 
individual brain hemispheres of the mutant shows large variance at middle age, including a 
population with relatively little cell loss, and experiments suggest that the flies retaining the most 
motor function at middle age (15 days), as assayed by counter-current, tend to have more 
remaining MB neurons than the feeblest flies (data not shown).   
In mammals, increased activity of Cdk5 causes neuronal death, as does the loss of 
function (Patrick, Zukerberg et al. 1999).  We therefore modestly overexpressed p35 and assayed 
MB neuron survival.  We introduced four copies of a transgene bearing the p35 genomic locus 
(Connell-Crowley, Le Gall et al. 2000), which results in an increase of p35 levels by 3.5-fold in 
head tissue, and 2.2-fold in thorax tissue, as measured by qPCR (Supplemental Table 4.3.8C).  
Overexpression of p35 is sufficient to increase Cdk5 activity (Connell-Crowley et al, 2000).  At 
three- and 10-days-old, the number of 201Y-positive MB neurons in flies overexpressing p35 
was lower than controls, albeit not significantly so (D3 p35-OE = 626.8±39.8, D10 p35-OE = 
576.9±40.2 neurons/MB).  By Day 30, however, p35-OE flies exhibited a significant decrease in 
MB neuron number, with a further reduction by Day 45 (D30 p35-OE = 510.8±27.7, p=0.0271; 
D45 p35-OE = 433.9±37.6 neurons/MB, p=0.0002).  Thus, in the fly, as in mammals, both p35 
 84 
deletion and overexpression lead to progressive age-dependent neurodegeneration, demonstrated 
by loss of MB neurons. 
 
Altered p35 expression induces degeneration-associated phenotypes 
We have shown previously that a p35 mutation causes a variety of degeneration-
associated phenotypes, consistent with the cell loss we observed here in the brain (Connell-
Crowley, Vo et al. 2007, Trunova and Giniger 2012).  We now show organismal- and cellular-
level degenerative phenotypes in animals with increased p35 similar to what was observed in 
flies lacking p35.  In a wild-type (w+) genetic background, deletion of p35 results in a 31.9% 
reduction in lifespan relative to control flies (control median survival = 47 days; p35-null = 32 
days, p<1.0E-15 (Mantel-Cox log rank test); Figure 3.3.1C).  To confirm that the shortened 
lifespan was a result of p35 levels, we expressed a single copy of the p35 genomic transgene in 
the p35-null flies, and found that one copy of the transgene substantially rescues lifespan, 
resulting in a median survival nearly equivalent to the control (rescue median survival = -6.4% 
change relative to control, p=0.19; rescue vs. null: p<1.0E-15 (Mantel-Cox log rank test)).  
Therefore, the observed decrease in lifespan is caused by a reduction of p35 and thus Cdk5 
activity.  Overexpression of p35 had a more severe effect on lifespan than loss of function, as 
p35-OE flies had a median survival of only 28 days (-40.4% change relative to control, p<1.0E-
15).  Thus, altered Cdk5/p35 activity in either direction drastically shortens lifespan. 
Overexpression of p35 also caused strong, age-dependent, progressive loss of motor 
function, as previously reported for p35 loss of function (Connell-Crowley, Vo et al. 2007).  
Here, motor function was assayed using an apparatus that gives each fly five sequential 
opportunities to perform a negative geotaxis task, and reports performance as a partition 
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coefficient (see Methods; (Benzer 1967, Inagaki, Kamikouchi et al. 2010)).  In both gain and loss 
of p35, and in controls, flies showed progressive worsening of motor function with age; 
however, flies lacking or overexpressing p35 exhibited behavioral decline with a substantially 
accelerated time course.  Control flies showed slight, insignificant decreases in calculated 
partition coefficient from Day 3 through Day 30, and then showed a significant decrease at Day 
45 (D10 control = -5.8% change in mean relative to D3 control, D30 control = -7.8%, p=0.83; 
D45 control = -54.6%, p<1.0E-15 (two-way ANOVA with Tukey’s MTC); Figure 3.3.1D).  p35-
null flies were nearly identical to controls at Day 3, but showed significant decreases at each 
subsequent timepoint (D3 p35-null = -5.7% change in mean relative to D3 control, p=0.98; D10 
p35-null = -44.9%, p=6.9E-14; D30 p35-null = -72.4%, p<1.0E-15; D45 p35-null = -98.5%, 
p<1.0E-15).  The presence of the p35 genomic transgene in the null background rescued 
locomotive ability at each timepoint (D10 = 68.9% rescue, p=6.9E-14; D30 = 48.7% rescue, 
p=1.0E-9; D45 rescue = 95.2% rescue, p=1.0E-13).  Flies overexpressing p35 actually started out 
with severely impaired ability, as their partition coefficient was already significantly lower at 
Day 3 (D3 p35-OE = -55.2% change in mean relative to D3 control, p<1.0E-15); their motor 
function remained well below that of controls at all time points, further worsening significantly 
at Day 45 (D45 p35-OE = -67.9% change in mean relative to D45 control, p=3.9E-9).  As such, 
both gain and loss of p35 result in accelerated loss of motor function relative to controls. 
Disrupted autophagy is strongly associated with many forms of degeneration (Hara, 
Nakamura et al. 2006, Komatsu, Waguri et al. 2006, Li, Zhang et al. 2008, Spencer, Potkar et al. 
2009, Winslow, Chen et al. 2010).  Consistent with this, Cdk5 loss of function was previously 
found to result in an increase of autophagic organelles, as well as an increased sensitivity to 
starvation, consistent with impaired autophagy (Trunova and Giniger 2012).  As more direct 
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measures, here we assayed Atg8 cleavage and Ref(2)P levels as markers for disrupted 
autophagy. Atg8 (LC3 homolog) is cleaved and lipidated before it binds to autophagosomes and 
gets degraded (Ichimura, Kirisako et al. 2000); impaired autophagy results in an accumulation of 
the cleaved form, assayed as an increase of Atg8-II levels.  Both loss and overexpression of p35 
resulted in enhanced accumulation of Atg8-II, relative to control samples.  Brain homogenate 
from control flies revealed a gradual, modest increase in Atg8-II from Day 3 through Day 45, 
reaching a maximum 2.5-fold increase at the latest time point (Figure 3.3.2A).  p35-null samples 
showed a 4.9-fold increase in Atg8-II by Day 45; the increased Atg8-II levels were partially 
blocked by the presence of the p35 transgene, as the rescue samples only exhibited a 3.5-fold 
increase at Day 45.  Samples overexpressing p35 showed further exacerbation, as they surpassed 
the maximum levels observed in controls by Day 10, and ultimately reached an 11.1-fold 
increase in Atg8-II by the last time point (p=2.7E-5 relative to Day 3 control (two-way ANOVA 
with Tukey’s MTC)).  Both p35-null and p35-OE samples showed trends towards Atg8-II 




Figure 3.3.2.  Accumulation of autophagic markers indicates inhibition of autophagic flux.   
Representative western blot of (A) Atg8-II and (C) Ref(2)P levels in brain homogenate of 
control, p35-null, p35-OE, and rescue flies;  tubulin was used as a loading control.  In all cases, 
the loading control was probed from the same membrane as the target protein.  In (A), bands 
marked with ‘<’ refer to the uncleaved Atg8-I.  Quantification of (B) Atg8-II and (D) Ref(2)P 
accumulation based on WB levels as seen in A and C, respectively; at least three replicate 
experiments were analyzed for both.  Values presented are mean+SEM.  In (B) and (D), 
significance relative to the Day 3 control was determined using two-way ANOVA with Tukey’s 
MTC; *=p<0.05; ***=p<0.001; ****p<0.0001.  For the rescue samples, significant differences 
between rescue and age-matched p35-null samples are indicated as follows: ##p<0.008. 
 
p35-null and p35-OE flies also exhibited elevated Ref(2)P levels.  Ref(2)P, a p62 
homolog, accumulates on autophagosomes and then gets degraded upon fusion of the 
autophagosome with a lysosome.  However, if autophagy is impaired, an increase in Ref(2)P 
levels is observed (Nezis, Simonsen et al. 2008).  While control samples showed age-dependent 
increases in levels of Ref(2)P in brain homogenate, both p35-null and p35-OE brains showed 
enhanced accumulation at each of the later time points (Figure 3.3.2B).  At Day 45, the control 
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samples showed a 3.2-fold increase in Ref(2)P.  In contrast, p35-null samples showed a 5.6-fold 
increase at Day 45 (p=1.8E-4 relative to Day 3 control (two-way ANOVA with Tukey’s MTC)), 
whereas p35-OE exhibited a 7.5-fold increase in Ref(2)P levels (p=2.4E-7).  The p35 genomic 
transgene blocked the accumulation of Ref(2)P in the p35-null background, as the rescued 
samples had only a 2.1-fold increase by Day 45, which is comparable to the age-matched control, 
and significantly different from the age-matched p35-null sample (p=0.008).  Deletion and 
overexpression of p35 both result in significantly elevated levels of Ref(2)P at Day 45; this is 
consistent with the Atg8-II accumulation, and supports that autophagy is impaired. 
Collectively, these data demonstrate that, as in mammals, either increase or decrease of 
Cdk5 activity results in degeneration of susceptible neurons, and induces a variety of 
characteristic degeneration-associated phenotypes.  Further, many of these phenotypes occur 
chronologically earlier in the mutant and p35-OE flies than in control flies.   
 
Identification of genes whose expression is altered by p35 levels and aging 
The phenotypes we observed from altered p35 levels resembled effects that are also seen 
in natural aging, but only at advanced ages.  This led us to wonder whether altered p35 might be 
accelerating the absolute rate of aging.  To test this hypothesis, we used genome-wide expression 
profiling to develop a comprehensive, quantitative and unbiased metric for physiological age.  In 
many systems, it has been found that expression levels of ~2-30% of genes change in 
reproducible ways with age (Pletcher, Macdonald et al. 2002, Girardot, Lasbleiz et al. 2006, de 
Magalhaes, Curado et al. 2009).  We hypothesized that we could characterize the evolution of the 
gene expression profile with aging in control flies, genome-wide, and use it as a ‘standard curve,’ 
comparing the profile of a mutant to that of the reference set to infer physiological age (Figure 
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3.3.3A).  We separately isolated RNA from head and thorax of control flies grown to various 
ages and measured the RNA expression profile using microarrays, with the primarily neural 
tissue of the head serving as an indicator of neuron-specific changes, and the thorax, which is 
dominated by non-neural tissue such as muscle, serving as a proxy for systemic changes.  We 
then selected aging-related genes by using polyserial correlation to calculate the association of 
each gene with aging.  Random permutation of expression values with each age class was used to 
establish significance cutoffs, ultimately identifying 3,235 and 3,809 probes from control head 
and thorax tissue, respectively, that show consistent directional changes in expression with age 
(see Methods; Figure 3.3.3B-C).  These probes correspond to 2,789 unique genes in the head, 






Figure 3.3.3.  Identification of aging-related genes and affected biological processes. 
(A) Experimental outline schematic.  RNA samples were extracted from heads and thoraces of 3-
, 10-, 30-, and 45-day-old control samples, and from 10-day-old p35-null and p35-OE samples.  
Five replicates of each sample were collected for microarray analysis.  (B) An example of a gene 
(Arc1) showing increased expression with age.  Our analysis identified genes with this pattern, or 
the reverse pattern, as aging-related.  (C) Identification of genes positively- or negatively-
correlated with age in head tissue.  The green line represents the observed correlation values; the 
red line represents the correlation estimates when true age is randomized.  The randomized set 
was used to establish significance cutoffs.  The vertical red lines indicate correlation values with 
a corrected p-value <0.05 (see Materials and methods).  The same procedure was used to define 
aging-related genes in the thorax (not shown).  The full list of aging-related probes is available in 
Supplemental Table 4.3.1.  (D)  Gene ontology (GO) analysis of aging-related genes from head 
and thorax tissue samples. GO analysis was performed on each set of affected probes using 
DAVID.  The resulting annotated clusters were grouped together based on similarity of 
biological modules; only the highest enrichment score for each ontology group is presented here.  
Full DAVID results are available in Supplemental Tables 4.3.5-4.3.6.  By DAVID’s statistical 
analysis, an enrichment score >1.3 has a p-value <0.05. 
 
To validate our set of identified ‘aging-related’ genes, we first used gene ontology 
analysis (Database for Annotation, Visualization and Integrated Discovery (DAVID)) to identify 
biological processes that were over-represented in the set of putative age-correlated genes 
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(Huang, Sherman et al. 2009a, Huang, Sherman et al. 2009b).  The set of processes identified as 
enriched in our dataset using DAVID enrichment scores (EASE > 1.3) was largely consistent 
with previous analyses of aging in Drosophila (Zou, Meadows et al. 2000, Pletcher, Macdonald 
et al. 2002, Lai, Parnell et al. 2007) and in other organisms (Lee, Klopp et al. 1999, Lee, 
Weindruch et al. 2000, Golden and Melov 2004, de Magalhaes, Curado et al. 2009) and included 
mitochondrial function, immunity, proteostasis, and particular aspects of metabolism, among 
others (Figure 3.3.3D, Supplemental Tables 4.3.5-4.3.6).  Similar results were obtained using 
other gene ontology databases, including Gene Ontology Consortium and Gene Set Enrichment 
Analysis, for this and all other gene ontology analyses presented below (data not shown). 
We next profiled RNA from head and thorax of 10-day-old flies either lacking or 
overexpressing p35.  As above, overexpression was achieved by introducing four copies of a 
transgene containing the wild-type p35 genomic locus, while the loss of function was the null 
mutant.  Genes with significantly altered expression were identified by ANOVA under multiple 
comparison correction condition followed by Tukey-HSD post hoc testing.  Significance was 
defined as corrected p<0.05 and >1.5-fold change in expression level when compared to 10-day-
old controls.  Loss of p35 significantly altered expression of 198 probes in the head and 193 
probes in the thorax, while p35 overexpression affected 328 probes in the head and 405 probes in 
the thorax (Supplemental Tables 4.3.2-4.3.3). 
Three lines of evidence validate the dataset and the identification of affected genes.  In a 
supplemental microarray experiment, we profiled p35-null flies carrying a single copy of the p35 
genomic transgene to test whether the transcriptomic effects observed in p35-null flies are indeed 
p35-specific.  The presence of the rescue transgene either fully or partially rescued the 
expression levels of 81.9% of the p35-null affected probes in head tissue, and 74.1% of probes in 
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thorax (see Methods, Figure 3.3.4A, Supplemental Table 4.3.4).  We used qPCR to validate a 
subset of twenty genes showing age-dependent or p35-specific changes, in addition to four 
reference genes, and found that nearly 70% (164/240) of conditions tested were concordant with 
the array results (Supplemental Table 4.3.8).  Lastly, we observed significant overlap of affected 
genes between gain and loss of p35, which is consistent with the striking similarity of the 
observed degeneration phenotypes.  Not only was the size of the intersecting set of probes 
significant (80 probes in head, p<2.2E-16; 76 probes in thorax, p<2.2E-16 (Chi-square with 
Yates’ continuity correction)), but the probes affected in both p35-null and p35-OE flies were 
highly concordant (head: R2=0.60, p<2.2E-16; thorax: R2=0.56, p=6.7E-15 (Pearson’s product-
moment correlation); Figure 3.3.4B).  Within these overlapping probes, the magnitude of 
expression changes was generally larger in the p35-OE flies, relative to the p35-null samples.  
This is also consistent with the physiological assays, where overexpression of p35 typically had 
more severe phenotypes than did the mutant.   
 
Altering p35 levels mimics aging: 1. Gene ontology analysis of p35-affected genes strongly 
overlaps that of aging-related genes 
As a first test of the relationship between the effects of p35 and aging, we examined 
biological processes identified by gene ontology and found a strong overlap between categories 
enriched by aging or by altered p35.  We first compared the list of p35-affected genes and 
noticed a strong overlap with the aging-related genes (Figure 3.3.4C).  In the p35-OE samples, 
153 probes in head and 221 in thorax intersected with the aging set (head: p=0.01, thorax: 
p=0.002 (Chi-square with Yates’ continuity correction)).  In the mutant samples, 92 probes in 
head and 112 in thorax overlapped with the aging set (head: p=0.056, thorax: p=0.002).  We then 
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performed gene ontology analysis, which revealed that nine of the top 17 categories enriched in 
aging-related genes are also among the top categories affected by altered p35, including 
mitochondria, oxidoreductases, metabolism, proteostasis, and immunity (Figure 3.3.4D, 5A, 
Supplemental Tables 4.3.6-4.3.9).  Some categories that were significantly enriched by the set of 
aging-related probes were also enriched by the set of p35-related probes, but at levels further 
down the enrichment scale: examples include protein translation in the p35-OE samples, and 
proteostatic processes in the p35-null samples.  We also found instances of categories 
significantly enriched by p35-related probes but not by aging, as well as categories that differed 





Figure 3.3.4.  Identification of genes impacted by altered p35 and affected biological 
processes. 
p35-null, p35-OE, and rescue samples were analyzed for genes with altered expression relative 
to age-matched controls.  The full list of probes with altered expression is available in 
Supplemental Tables 2-4.   (A) The presence of the p35 transgene rescues expression changes 
resulting from loss of p35.  Fully-rescued probes are those that are significantly altered in the 
p35-null samples, but are not altered in the rescue samples.  Partially-rescued probes had their 
expression levels shifted towards control expression values, but still exhibited >1.5 fold change 
relative to controls. (B) Concordance of p35-null and p35-OE intersecting genes in head or 
thorax tissue.  For probes affected by both gain and loss of p35, 91.3% are concordant in head 
samples, and 96.1% are concordant in thorax samples.  Significance of the linear relationship 
between expression fold change in p35-null versus p35-OE samples was assessed by Pearson’s 
product moment correlation.  (C) Overlap of aging-related probes and probes affected by either 
loss (upper row) or overexpression (lower row) of p35 in head (left column) and thorax (right 
column) samples.  The significance of the size of the overlap between sets was determined using 
a chi-square test with Yates’ continuity correction.  (D)  GO analysis of genes affected by gain or 
loss of p35 in head and thorax tissue samples.  Enrichment scores are presented as described in 
Figure 3.3.3; full DAVID results are available in Supplemental Tables 4.3.9-4.3.12. 
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Altering p35 levels mimics aging: 2. Expression profile of affected genes in young mutant and 
p35-OE flies resembles the profile in the oldest controls 
Comparing the mean expression values of genes affected by both aging and by p35 
revealed that young flies with altered p35 had expression profiles that correlated better with the 
oldest control profiles than with age-matched profiles.  We compared the Day 10 mutant or p35-
OE profiles of intersected probes to the control profile at each of the four time points.  In the case 
of p35 overexpression, comparing the head profiles from Day 10 p35-OE flies with each of the 
controls yielded average Pearson correlation coefficients of: D3 = 0.34±0.02, D10 = 0.38±0.02, 
D30 = 0.51±0.02, D45 = 0.63±0.01 (mean+SEM; Figure 3.3.5B).  Similar trends were observed 
in the thorax, and in both the head and thorax of p35-null mutants (Figure 3.3.5B-C): in each 
case, the correlation value of ‘D10 mutant vs. D45 control’ was significantly greater than that of 
‘D10 mutant vs. D3 control’ (p35-OE_Head: p=4.6E-10; p35-OE_Thorax: p=4.3E-10; p35-
null_Head: p=4.7E-10; p35-null_Thorax: p=0.008 (one-way ANOVA with Tukey’s MTC)).  
These correlations support the hypothesis that young flies with altered p35 have expression 
profiles more similar to those of older flies, and suggest that aberrant Cdk5/p35 activity does 
indeed result in an acceleration of at least a portion of aging processes. Given the neuronal 
specificity of Cdk5/p35 activity, it was unexpected to see such strong effects in thorax tissue: 
while the thorax includes the thoracic and abdominal ganglia, its cell mass is dominated by 
muscle, where p35 is not expressed.  We note, however, that there is precedent for neuron-
specific alterations driving systemic changes, and even shifting lifespan of the entire organism 





Figure 3.3.5.  p35 mutant and p35-OE expression profiles are most similar to older control 
profiles. 
(A)  Comparison of significantly enriched GO groups for aging-affected and p35-affected genes.  
Heatmap is based on DAVID Enrichment scores; cells marked with “---” were not enriched.  
Annotation clusters with an Enrichment Score >1.3 were significantly enriched; those <1.3 were 
enriched, but not significantly so.  For (B) p35-OE and (C) p35-null samples, the mean 
expression value of Day 10 p35-modified samples was compared to the mean expression value 
for each of the four control samples, using the intersecting set of p35-affected and aging-affected 
probes.  Box and whisker plots show minimum and maximum values. Significant differences 
between samples were determined by one-way ANOVA with Tukey’s MTC; presented p-values 
are from MTC, and are relative to the Day 3 correlation values (*p<0.05, **p<0.01, 
****p<0.0001).  (D-F) Tissue-specific linear models were developed to measure the 
physiological age of each sample.  In (D) and (E), the physiological age is graphed against the 
chronological age for (D) head and (E) thorax tissue of each sample.  The mean physiological 
age is presented in (F) as mean+SEM.  Significant differences between samples were determined 
by one-way ANOVA with Tukey’s MTC; presented p-values are from MTC, and are relative to 




Altering p35 levels mimics aging: 3. p35 mutant and p35-OE flies are physiologically older 
than age-matched controls 
Experiments above show a strong correlation between the gene expression effects of 
altering p35 and increasing age for a subset of genes; however, it remained unclear whether 
altered Cdk5/p35 activity mimics specific components of aging, or accelerates aging more 
globally.  To develop a true gene expression metric for aging, we used machine learning to 
ascertain ‘aging classifiers.’  Using k-nearest-neighbor (kNN) modeling with leave-one-out 
(LOO) cross validation, we identified individual probes from the control profiles that can be used 
to estimate the age of an unknown sample based on gene expression levels (see Methods).  We 
then identified the most robust classifiers that were present in every iteration of the kNN 
modeling (381 and 882 classifiers in the head and thorax, respectively, Supplemental Table 
4.3.13), and used them to derive tissue-specific linear models for physiological age based on 
principle component analysis of the expression data (Figure 3.3.5D-E).  In the head samples, the 
linear model measured the physiological age of the 10-day-old p35-OE samples as 17.6±1.3 days 
(mean+SEM; p=7.9E-8, Figure 3.3.5F (one-way ANOVA with Tukey’s MTC)), nearly twice the 
chronological age.  The p35-null head samples were measured to be 12.7±0.4 days (p=0.049), 
corresponding to nearly 30% acceleration of aging.  Similar results were obtained for the thorax 
samples (D10 p35-OE: 25.5±0.7 days, p=1.8E-14; D10 p35-null: 15.8±0.5 days old, p=1.8E-8).  
These data demonstrate that flies overexpressing p35 exhibit a physiological age that is 
dramatically older than its chronological age, both in neural and non-neural tissue, while loss of 




Flies with altered p35 show defects in array-identified biological processes 
Gene expression data above suggest that there is acceleration of aging with gain-and loss-
of-function of Cdk5/p35.  Thus, we performed further physiological tests to challenge this 
interpretation, drawing on processes highlighted by the expression profiling.  The gene ontology 
analysis revealed that genes affected both by aging and by altered p35 included a variety of 
oxidoreductases.  We therefore assayed the abilities of flies lacking or overexpressing p35 to 
withstand oxidative stress.  Control, p35-null, and p35-OE flies were aged to 3-, 10-, 30-, or 45-
days old, and then exposed to hydrogen peroxide (H2O2) or paraquat (PQ).  p35-null and p35-OE 
flies of each age show enhanced sensitivity to H2O2-induced oxidative stress, relative to controls.  
For example, 3-day-old mutant and p35-OE flies show significantly altered survival curves 
following exposure (p35-null: p<1.0E-15; p35-OE: p=6.1E-12 (Mantel-Cox log rank test)) and 
reduced median survival times (control median survival time = 100 hours, p35-null = 60 hours 
(p=1.4E-5), p35-OE = 76 hours (p=0.023) (two-way ANOVA)).  The detrimental effect in p35-
null samples was rescued by the presence of the p35 genomic transgene (rescue vs control: 
p=0.39; rescue vs p35-null: p=<1.0E-10 (Mantel-cox long rank test), Figure 3.3.6A; rescue 
median survival time = 100 hours, rescue vs control: p>0.99, rescue vs p35-null: p=1.4E-5 (two-
way ANOVA), Figure 3.3.6A inset).  Similar trends were observed with multiple ages, as the 
median survival time was always lower in p35-null and p35-OE samples than control samples 
(Figure 3.3.6A inset).  Paraquat treatment also significantly shortened survival time of all 
genotypes following exposure, with the p35-null and p35-OE flies being more susceptible than 
controls at every time point (Figure 3.3.6B, inset). Together, these data indicate that both 
increase and decrease of p35 lead to increased susceptibility to various oxidative stresses.   
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Figure 3.3.6.  Altered p35 increases sensitivity to oxidative stress. 
(A,B) Survival curves of 3-day-old samples exposed to (A) hydrogen peroxide or (B) paraquat; 
error bars represent mean+SEM.  Significant differences in survival curves were determined 
using the Mantel-Cox log-rank test; *p<0.05, **p<0.01, ****p<0.0001.  For the rescue samples, 
significant differences between rescue and p35-null curves are indicated as follows: 
####p<0.0001.  Insets demonstrate the median survival time (in hours) following exposure of 3-, 
10-, 30-, and 45-day-old flies; error bars represent mean+SEM.  Sample sizes are outlined in 





We have shown here that aberrant gain or loss of Cdk5/p35 activity accelerates the 
effective rate of aging in Drosophila, and induces multiple age-dependent neurodegenerative 
phenotypes.  We exploit the natural modulation of gene expression across lifespan to define an 
unbiased, comprehensive, and quantitative metric for physiological age.  Applying this metric to 
flies with altered levels of the Cdk5 activator p35 shows that absence of p35 increases the rate of 
aging by >25%, while a modest, threefold increase in p35 expression causes the aging rate to 
double.  Change of Cdk5/p35 activity in either direction, and the attendant acceleration of aging, 
is associated with adult-onset neurodegeneration, marked by a variety of well-characterized 
degeneration-associated changes in neuronal physiology, including inhibition of autophagy and 
sensitivity to oxidative stress, as well as loss of neurons from the central brain, progressive 
decline in motor function, and early death.  
It is clearly understood that aging is the greatest risk factor for neurodegeneration, but the 
mechanistic basis for the relationship between degeneration and aging has remained frustratingly 
enigmatic.  One central challenge to clarifying this relationship is the absence of a metric for the 
physiological age of a subject.  Typically, age is defined chronologically, but chronological age 
is an imprecise, and sometimes misleading, measurement.  The rate of aging can be altered by 
nearly 30% through a combination of genes, environment, and happenstance in C. elegans 
(Stroustrup, Anthony et al. 2016), for example, and lifespan is equally variable in other 
organisms.  Consequently, we sought a more robust quantification of age.  Numerous studies 
document that the expression levels of a significant portion of genes show reproducible 
directional change with age.  Consistent with this, we assayed multiple points throughout the life 
of control flies and identified aging-related genes that showed consistent changes in expression 
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with time.  We hypothesized that by comparing a young mutant expression profile to the control 
profile, we could accurately infer physiological age.  This comparison had three potential 
outcomes: Day 10 mutant profiles could have most closely resembled age-matched control 
profiles; been too disrupted to resemble any particular control profile; or they might have 
resembled older control profiles. 
Our results here display the last of these options: young, essentially presymptomatic Day 
10 p35 mutant and p35-OE samples have an RNA expression profile that strongly resembles that 
of older control samples.  Three separate analyses demonstrate that altered p35 mimics aging.  
First, there is significant overlap in the gene ontology categories enriched by aging genes and 
those enriched by p35-affected genes.  Second, a correlation analysis of the mean expression of 
the set of intersecting aging-related genes and p35-related genes revealed that the samples with 
altered p35 were more strongly correlated with older controls than with the age-matched control; 
this increased correlation was true in both the head and thorax tissue of both mutant and 
overexpression samples.  Third, using a quantitative metric, we showed that both tissue types of 
the p35 mutants and p35-overexpressing flies were physiologically ‘older’ than their 
chronological age.  Whether accelerated aging is a universal mechanism of neurodegeneration 
remains to be seen. A previous study of Drosophila neurodegeneration failed to detect 
expression changes indicative of accelerated aging; in that case, however, mortality was 
accelerated profoundly by the experimental manipulations, and the compressed timescale may 
have obscured the ability to detect any age-related effects (Favrin, Bean et al. 2013).  In contrast, 
other Drosophila models of degeneration show a variety of aging phenotypes, as well as 
demonstrating aging-related effects on the transcriptome (Kumimoto, Fore et al. 2013).  
Similarly, it has been shown that post-mortem tissue from human AD patients displays a gene 
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expression profile comparable to the profile predicted for non-demented samples at extreme old 
age, though in that study it was not possible to distinguish whether this reflects an early, causal 
step in disease pathogenesis or a late consequence of terminal disease processes (Podtelezhnikov, 
Tanis et al. 2011).   
Our data show that in flies, as in mice and in cultured neurons, gain and loss of Cdk5/p35 
activity cause similar degenerative phenotypes and neuron loss.  Consistent with this, change of 
p35 in either direction accelerates the rate of aging. The expression profiles revealed that a 
significant number of genes were affected by both loss and overexpression of p35, and these 
overlapping genes showed very high concordance in directionality.  Evidence from mammalian 
systems suggests that cross-regulatory interactions among proline-directed kinases may be 
responsible for the similar effects of Cdk5 activation and inactivation.  Cdk5 is one member of a 
group of interacting kinases that have related target-site specificity, including glycogen synthase 
kinase-3 beta (GSK3β) and mitogen activated protein kinases (MAPK) (Anderton, Betts et al. 
2001, Hashiguchi, Saito et al. 2002, Liu, Iqbal et al. 2002).  Consequently, certain key residues 
of tau, for example, have the same phosphorylation status in both gain and loss of Cdk5 activity, 
potentially due to deregulation of GSK3β upon modulation of Cdk5 (Hashiguchi, Saito et al. 
2002, Hallows, Chen et al. 2003, Morfini, Szebenyi et al. 2004).  If relevant proteins are 
hyperphosphorylated in similar ways in the context of both increased and decreased Cdk5 
activity, it could explain how both conditions modify the same pathways to produce similar 
degenerative phenotypes.  Alternatively, we cannot formally rule out the possibility that gain and 
loss of p35 lead to degeneration by parallel but distinct mechanisms, much as gain and loss of 
Rac activity both cause axon stalling during development, but through opposite molecular effects 
(Luo, Liao et al. 1994). 
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Although gain and loss of p35 both give rise to similar phenotypes, hyperactivation 
consistently produces stronger effects than loss of function, and modulates more gene expression 
categories in a statistically significant way.  It may be that compensation by related kinases is 
less effective at buffering the effects of kinase hyperactivation than kinase insufficiency.  It is 
also worth noting that we focused our analysis on young, essentially pre-symptomatic flies that 
had yet to show neurodegeneration, and presumably had yet to exhibit the full effects of altered 
p35 on their transcriptome.  Moreover, we set relatively restrictive criteria for significance when 
identifying p35-affected probes, so the set of genes that are affected by altered p35 is likely to be 
rather larger than what we identify.  Indeed, when we focus on the 17 gene ontology groups that 
were significantly enriched for our aging probes, all but three (neurotransmitter transporter 
activity, amino acid transport, and phototransduction) show some level of enrichment among the 
set of probes altered by aberrant p35 levels.  These findings suggest that gain and loss of p35 
likely affect a larger percentage of aging-related genes than formally demonstrated in our 
analysis. 
Among the most prominent phenotypes revealed by our expression profiling of altered 
p35 are a number that are typically considered early events in the mechanism of 
neurodegeneration.  These include impaired autophagy, which we verified by assaying 
accumulation of autophagosome-related proteins, and oxidative stress, established by measuring 
sensitivity to oxidative challenge with paraquat or hydrogen peroxide. However, in our 
paradigm, much of the disruption of these processes can be accounted for by the observed 
change in aging rate.  We must now consider whether oxidative stress and impaired autophagy, 
which are usually thought of as degeneration phenotypes, might more accurately be 
characterized as secondary consequences of altered aging.  By extension, we must further 
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consider whether other p35-associated pathological processes should really be considered as 
downstream consequences of the acceleration of aging rather than as causative, early steps in the 
degeneration cascade per se.   
It has been argued that neurodegeneration is not simply ‘brain aging’ inasmuch as one 
can have aging without overt degeneration. Our data do not contradict this view, but rather 
suggest that aging can promote degeneration, in part, by synergistically enhancing the effects of 
underlying non-aging insults to neuronal integrity.  The p35-null head samples exhibited a 27% 
increase in aging rate, but showed a severe, localized reduction of MB neurons well before any 
neurodegeneration was observed in controls.  We hypothesize that the increase in physiological 
age either sensitizes neurons to, or synergizes with, cell-intrinsic defects we have documented 
previously as resulting from the absence of Cdk5/p35 activity, such as modulation of the axon 
initial segment, aberrant organization of actin and ankyrin, or defects in microtubule stability 
(Trunova, Baek et al. 2011, Smith-Trunova, Prithviraj et al. 2015).  Our findings are consistent 
with the age-dependent hypothesis of Alzheimer’s disease, which proposes that aging aggravates 
an initial injury that alters the cellular physiology of neurons and primes them for 
neurodegeneration (Herrup 2010). In the case of p35 overexpression, the aging effect was more 
pronounced, and appeared sufficient to largely account for the accelerated MB neuron loss and 
reduction in median survival.  It is possible that, in Drosophila, a strong enough intervention at 
key signaling molecules can induce acceleration of aging that alone can drive neurodegeneration, 
although cell-intrinsic defects likely contribute here as well.  Recent experiments with tissue 
from human AD and PD patients hint that processes similar to those we observe in Drosophila 
may be occurring in human disease, as epigenetic characterization of patient tissue reveals both 
apparent acceleration of aging (Podtelezhnikov, Tanis et al. 2011, Horvath and Ritz 2015, 
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Levine, Lu et al. 2015) and alterations in regulatory marks associated with ankyrin genes that are 
key to neuronal cytoarchitecture (De Jager, Srivastava et al. 2014, Lunnon, Smith et al. 2014).  
More directed studies of human patient samples will be essential to test this hypothesis. 
Using our quantitative metric for physiological age, we observe acceleration of the aging 
rate upon alteration of proline-directed protein phosphorylation, and crucially, we observe this 
phenotype prior to evidence of neurodegeneration.  This discovery seemingly inverts our picture 
of the causal relationship of aging and neurodegenerative disease, and raises profound questions 
for our view of neurodegenerative disease.  Is it meaningful to use the consequences of age-
dependent processes as biomarkers of disease if aging itself is variably affected by the disease 
mechanism?  If tau pathology and associated kinase dysregulation enhance oxidative stress 
essentially as a downstream consequence of accelerated aging, does it imply that treatments 
directed at the consequences of oxidative stress would only protect against disease if they 
reversed aging itself?  It will be essential to fully dissect the relationship of protein 
phosphorylation to aging, and to neurodegenerative disease, if we are to have a rational basis for 
advances in treatment of aging-associated disorders, such as Amyotrophic Lateral Sclerosis, 
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Chapter 4: Investigation of the role of the axon initial segment in neurodegeneration 
 
4.1  Introduction 
The axon initial segment (AIS) is a key neuronal domain which lies between the 
somatodendritic and axonal compartments.  The central functions of the AIS include initiating 
action potentials (APs) and maintaining neuronal polarity, two actions which are essential for 
optimal neuronal function and excitability.  Indeed, the AIS serves as the intersection between 
neuronal input and output, providing the basis for neuronal circuits.  Unsurprisingly, perturbation 
of the AIS can have significant impacts on the operation of the nervous system, and has been 
found to play a role in multiple disease and injury paradigms.  AIS function in the nervous 
system, how the AIS is involved in ND, and how the AIS relates to p35-mediated ND in 
particular will be reviewed below.   
 
Action potential initiation 
Communication within the nervous system arises from the release of neurotransmitters 
from a neuron into a synaptic cleft with another neuron or muscle tissue.  A long cascade of 
events lies upstream of neurotransmission, most notably the initiation of an AP.  Nobel-prize 
winners Hodgkin and Huxley characterized the electrical properties of the squid giant axon over 
the course of multiple publications; their seminal work resulted in a mathematical model 
outlining the fundamentals of AP initiation and propagation (Hodgkin and Huxley 1952).  At 
rest, most neurons have a resting membrane potential of approximately -70 millivolts.  Upon 
stimulation, an influx of sodium (Na+) or calcium (Ca2+) ions from the extracellular space into 
the neuron raises the membrane potential.  Once the membrane potential passes a threshold, an 
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AP is initiated; if the stimulus fails to depolarize the neuron past this threshold potential, the 
neuron will not fire.  After reaching the threshold, the depolarization causes voltage-gated ion 
channels to temporarily open, allowing more positively-charged ions to enter the neuron, further 
raising the membrane potential in the immediate vicinity and inducing neighboring channels to 
also open.  Thus, the depolarization is propagated along the length of the axon.  At the synaptic 
terminal, depolarization causes voltage-gated calcium channels to open; the resultant influx of 
Ca2+ triggers synaptic vesicles holding neurotransmitter to fuse with the presynaptic membrane 
and release their contents into the synaptic cleft.  The released neurotransmitters can then diffuse 
across the synapse, bind receptors, and stimulate the postsynaptic neuron or muscle cell, or be 
actively transported back into the presynaptic neuron.  This entire process is extremely rapid, as 
an AP only lasts approximately one millisecond.  After depolarization, the sodium and/or 
calcium channels close, preventing additional ions from entering.  Potassium (K+) channels then 
open, transporting K+ ions from the neuron into the extracellular space, repolarizing the neuron.  
The neuron will actually hyperpolarize, temporarily preventing additional firing.  After this 
refractory period of about two milliseconds, sodium-potassium ATPases transport K+ and Na+ 
ions to re-establish the resting membrane potential so that the neuron can fire again upon fresh 
stimulation.     
An essential property of neuronal function is adaptability in response to various stimuli.  
This plasticity arises in large part from the M-current, a non-inactivating potassium current 
(Wang, Pan et al. 1998, Rasmussen, Frokjaer-Jensen et al. 2007).  The M-current has been found 
in neurons of both the central and peripheral nervous system (Brown and Adams 1980, Wang, 
Pan et al. 1998), highlighting its importance to the overall function of the nervous system.  In 
neurons, the conductance of potassium channels is regulated prior to and during depolarization.  
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The result is a highly-regulated membrane potential that shifts the threshold potential for AP 
firing and ultimately determines neuronal excitability. 
Following elucidation of the electrical properties of neurons, significant strides were 
made in investigating the underlying mechanisms of AP initiation.  To do so, it was necessary to 
establish the site of AP initiation.  Initial work measuring responses of spinal motoneurons to 
different stimuli demonstrated that AP initiation occurs within the axon, and specifically starts at 
the initial segment.  Subsequent experiments further localized the start of AP initiation to the 
distal part of the AIS.  Using voltage-sensitive dyes, Palmer and Stuart found that APs initiate 
~35 microns from the axon hillock, coinciding with the distal AIS (Palmer and Stuart 2006).  By 
having a primary site for starting AP firing, it is simpler to either enhance or suppress neuronal 
excitability, and it is easier to synchronize signaling among multiple neurons.   
 
Electrophysiological properties of the AIS 
As the site of AP initiation, the AIS serves as gatekeeper of the nervous system.  This 
function is achieved by a specialized set of ion channels, which are responsible for the 
electrophysiological properties of the AIS that permit APs.  Generally, the AIS is characterized 
by a high density of sodium channels and a lower number of potassium channels (Figure 4.1.1) 
(Khaliq 2006, Shah, Migliore et al. 2008).  Kole et al found that the AIS of cortical pyramidal 
neurons had a sodium channel density approximately 50 times that of the proximal dendrites 
(Kole, Ilschner et al. 2008).  This enrichment results from interactions between channels and the 
underlying cytoskeleton, anchoring the channels in place.  The cytoplasmic loop linking domains 
II and III of Nav1.1 channels associates with AnkyrinG (AnkG) and is responsible for targeting 
the channel to the AIS (Garrido, Giraud et al. 2003); once there, voltage-gated sodium channels 
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interact with both AnkG and βIV-spectrin (Kole, Ilschner et al. 2008).  While different types of 
neurons have varying compositions of channel subtypes, the channels at the AIS usually 
comprise a combination of Nav1.1, Nav1.2, and/or Nav1.6 (Ogawa and Rasband 2008).  
Notably, the AIS exhibits a further level of polarity as domains within the AIS can have different 
compositions and thus, different properties.  The low-threshold subunit Nav1.6 locates distally 
within the AIS, while Nav1.2, which has a higher threshold, accumulates proximally (Van Wart, 
Trimmer et al. 2007, Hu, Tian et al. 2009).  This specialized segregation regulates AP initiation, 
as the AP initiates from the distal AIS as opposed to the proximal region (Palmer and Stuart 






Figure 4.1.1.  Molecular composition of the axon initial segment. 
The AIS is characterized by a specific composition of ion channels and membrane proteins, its 
unique cytoskeleton, and accumulation of ankyrin proteins.  The AIS is enriched with sodium 
(Nav) and potassium (KCNQ, Kv) channels, as well as a select group of transmembrane proteins.  
The underlying cytoskeleton comprises microtubules and actin.  AIS interactions with the 
cytoskeleton are mediated through Ankyrin G and βIV-spectrin.  (Reproduced from Rasband, 
2010).   
 
The AIS is also home to a specialized collection of potassium channels that modify the 
properties of APs.  These potassium channels function in generating the M-current, which 
controls membrane excitability.  The set of voltage-gated potassium channels found within the 
AIS includes Kv1.1, Kv1.2, Kv1.4, Kv2.2, Kv7.2 (KCNQ2), and Kv7.3 (KCNQ3) (Ogawa and 
Rasband 2008).  Enrichment of potassium channels at the AIS was more modest than that of 
sodium channels, as the density of potassium channels within the axon was three to five times 
the somatic density (Shah, Migliore et al. 2008).  Like sodium channels, some potassium 
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channels show segregation within microdomains of the AIS.  Kv1.2 channels accumulate in the 
distal AIS, but are excluded from the proximal region (Van Wart, Trimmer et al. 2007).  Of the 
potassium channels, Kv7.2 (KCNQ2) and Kv7.3 (KCNQ3) have been identified as essential 
components for generating the M-current (Wang, Pan et al. 1998, Rasmussen, Frokjaer-Jensen et 
al. 2007).  Kv7.2 (KCNQ2) forms a heterotetramer with Kv7.3 (KCNQ3), and both concentrate 
at the AIS (Pan, Kao et al. 2006, Rasmussen, Frokjaer-Jensen et al. 2007); this localization is 
dependent on AnkG, as the AIS accumulation of Kv7.2 (KCNQ2) and Kv7.3 (KCNQ3) in 
cerebellar neurons from ankG-null mice was completely abolished (Pan, Kao et al. 2006).  While 
both channels can directly bind AnkG, localization at the AIS is only dependent on interactions 
between AnkG and Kv7.3 (KCNQ3) (Rasmussen, Frokjaer-Jensen et al. 2007).  Functionally, 
these channels help control resting membrane potential and the threshold for AP initiation, thus 
serving to suppress spontaneous AP firing (Shah, Migliore et al. 2008).  Further, these channels 
also regulate the resting membrane potential by regulating subthreshold currents, preventing 
repetitive AP firing (Ogawa and Rasband 2008).  Taken together, it is clear that changes in 
potassium channel levels, location, and activity, in conjunction with similar regulation of sodium 
channels, permits the necessary plasticity necessary for nervous system function. 
 
Establishment of neuronal polarity 
The second primary function of the AIS is to establish and uphold neuronal polarity.  To 
maintain polarity and proper neuronal function, the distribution of specific proteins must be 
restricted to certain domains; specifically, somatodendritic proteins must be constrained 
proximal to the AIS, while axonal proteins must be contained within axonal projections.  Cells 
can accomplish this segregation by selectively targeting proteins to their final destination 
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(Nakata and Hirokawa 2003, Sampo, Kaech et al. 2003), distributing proteins non-discriminately 
and then selectively retaining them in the proper location (Garrido, Fernandes et al. 2001, 
Sampo, Kaech et al. 2003), or by utilizing localized translation (Jimenez-Diaz, Geranton et al. 
2008, Yoon, Jung et al. 2012).  Of these possibilities, the AIS has been most associated with 
selective axonal targeting as it serves as a cytosolic diffusion barrier, effectively separating the 
cell body and axonal compartments while permitting transport of select cargoes between the two 
regions.  This polarity stems in part from a unique cytoskeletal architecture maintained within 
the AIS.  It has been known for decades that the AIS has a characteristic local microtubule 
cytoskeleton that distinguishes it from other neuronal domains (Palay, Sotelo et al. 1968) (Figure 
4.1.1) .  Within the AIS, microtubules are organized into fascicles of usually three to five 
microtubules, with multiple bundles running parallel to one another through the length of the 
AIS.  These microtubules are oriented such that their plus end is away from the soma and 
towards the neurite tips (Baas, Deitch et al. 1988).  More recently, it has been found that the 
microtubule skeleton within the AIS also has different post-translational modifications, which 
alters interactions with motor proteins responsible for trafficking.  The microtubules within the 
somatodendritic domain are heavily tyrosinated, preventing interactions with kinesin-1 (Konishi 
and Setou 2009).  Conversely, axonal microtubules have significantly higher levels of acetylated 
microtubules, compared to dendrites (Hammond, Huang et al. 2010).  The preference of certain 
motor proteins for specific subpopulations of MT tracks is likely related to the recruitment of the 
plus-end directed kinesin motor KIF5 to the AIS and its selective buildup in axons (Nakata and 
Hirokawa 2003).  Furthermore, Tapia et al demonstrated that acetylated microtubules localized 
within the AIS are resistant to detergent treatment (Tapia, Wandosell et al. 2010).  As 
development progresses, F-actin also concentrates locally within the AIS (Nakada, Ritchie et al. 
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2003, Song, Wang et al. 2009), and this F-actin cytoskeleton remains intact following detergent 
treatment (Winckler, Forscher et al. 1999).  Directly disrupting the actin cytoskeleton with 
depolymerizing agents results in loss of the diffusion barrier, indicating the significance of the 
underlying cytoskeleton (Winckler, Forscher et al. 1999, Nakada, Ritchie et al. 2003, Song, 
Wang et al. 2009).   
In addition to F-actin and microtubules, the submembranous cytoskeleton that 
characterizes the AIS is composed of specific ankyrin and spectrin isoforms (Figure 4.1.1).  
Ankryin and spectrin proteins are known to link various membrane proteins to the underlying 
cytoskeleton in a variety of contexts, and are largely associated with establishing and stabilizing 
specialized membrane domains (Kizhatil and Bennett 2004, Mohler, Davis et al. 2005, Pielage, 
Fetter et al. 2005).  In mammals, there are three separate Ankyrin genes (Ank1, 2, and 3 encoding 
AnkR, AnkB, and AnkG, respectively), each of which is expressed to some degree in the 
nervous system.  Of the three, AnkG is deemed the master organizer of the AIS.  While the distal 
axonal cytoskeleton contains AnkB, αII-spectrin, and βII-spectrin, AnkG and βIV-spectrin are 
found in the AIS (Yoshimura and Rasband 2014).  AnkG is essential for the clustering and 
localization of βIV-spectrin, as well as other proteins, to this subcellular domain (Sobotzik, Sie 
et al. 2009).  AnkG directly binds spectrin repeat 15 of βIV-spectrin, and this binding is required 
for the proper targeting of βIV-spectrin to the AIS, as βIV-spectrin fails to localize to the AIS in 
AnkG-null mice (Yang, Ogawa et al. 2007).  While AnkG can recruit βIV-spectrin to the AIS, 
the reverse is not true.  However, βIV-spectrin does play a role in maintaining the AIS, as its 
absence leads to loss of stabilization and dispersion of AnkG from the AIS (Komada and Soriano 
2002).  Without AnkG and βIV-spectrin, the diffusion barrier is lost, and axons exhibit dendritic 
characteristics, including accumulation of proteins normally restricted to dendrites and the 
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formation of spines with post-synaptic receptors (Hedstrom, Ogawa et al. 2008, Sobotzik, Sie et 
al. 2009).  Thus, the AIS is characterized by a stable cytoskeleton comprising actin, 
microtubules, ankyrin G, and βIV-spectrin, and is favored by motor proteins moving towards the 
axon and away from the soma. 
Along with the specialized cytoskeleton, a unique composition of transmembrane 
proteins also contributes to the diffusion barrier separating the somatodendritic region from the 
axonal compartment (Figure 4.1.1).  Indeed, cell adhesion molecules (CAMs) such as 
neurofascin (NF)-186 and neuron-glia related CAM (NrCAM) are enriched within the AIS 
(Nakada, Ritchie et al. 2003).  Again, AnkG is responsible for the correct recruitment and 
localization of proteins to the AIS, as NF-186 and NrCAM fail to be retained when their binding 
with AnkG is disrupted (Zhang, Davis et al. 1998, Lemaillet, Walker et al. 2003) or AnkG 
expression is silenced (Hedstrom, Ogawa et al. 2008).  The high concentration of these 
transmembrane proteins, in combination with the dense cytoskeleton, prevents diffusion via 
steric hindrance and hydrodynamic friction-like effects (Nakada, Ritchie et al. 2003).  CAMs 
may also contribute to AIS stability and/or plasticity through interactions with the extracellular 
matrix (ECM).  The C-terminal of CAMs binds with AnkG intracellularly (Dzhashiashvili, 
Zhang et al. 2007); CAMs also span the plasma membrane and extend into the extracellular 
space.  NF-186 directly interacts with a host of ECM proteins, including brevican, gliomedin, 
syndecans, laminins, neural/glial antigen 2 (NG2), and versican (Hedstrom, Xu et al. 2007, 
Nelson and Jenkins 2017).  Brevican accumulates around the AIS of cultured hippocampal 
neurons via an NF-186-dependent mechanism.  This specialized brevican-rich milieu is part of a 
larger ‘perineuronal net’ surrounding the majority of CNS neurons, and may provide a 
specialized microenvironment for optimal ion channel function or serve to stabilize axo-axonic 
 116 
contacts (Hedstrom, Xu et al. 2007).  Alternatively, connections to the ECM may function as a 
stabilizing force for NF-186 and its interacting partners.  Altogether, the unique structure and 
composition of the AIS allow it to effectively segregate different regions of the neuron and to 
maintain axonal identity.   
 
The role of the AIS in neuronal injury and neurodegeneration 
Provided the essential role of the AIS in neuronal function, it is no surprise that recent 
literature has implicated the AIS as a target of neuronal injury and contributor to 
neurodegeneration.  Exposing mice to ischemic injury, as is seen in strokes, results in the loss of 
AnkG, βIV-spectrin, and sodium channels from the AIS of cerebral cortex neurons (Schafer, Jha 
et al. 2009).  Loss of these proteins from the AIS was the result of calpain-mediated proteolysis, 
and occurred independently of axon degeneration or cell death.  Expanding on these results, del 
Puerto et al found that activation of the purinergic P2X7 receptor channel leads to a calcium 
influx, activation of calpain, and the eventual loss of AnkG from the AIS (del Puerto, Fronzaroli-
Molinieres et al. 2015).  This disruption of the AIS was accompanied by decreased current 
amplitudes and excitability.  Disruption of the AIS also leads to loss of neuronal polarity.  Under 
normal conditions, tau is primarily restricted to the axons of neurons.  In AD, however, the 
primary constituents of the AIS are downregulated, and tau localization is disrupted, as tau is 
found in the somatodendritic region as well (Sohn, Tracy et al. 2016).  Li et al demonstrated that 
the microtubule cytoskeleton supporting the AIS is specifically responsible for restricting tau to 
the axons as it permits anterograde flow of tau, but not retrograde (Li, Kumar et al. 2011).  One 
mechanism through which the AIS is compromised in AD is due to post-translational 
modifications of tau.  Tau acetylated at lys-274 and lys-281 accumulates in post-mortem AD 
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brain samples, and expression of tau mutants that mimic acetylation at these residues was found 
to decrease AIS-associated proteins and shorten the overall length of the AIS (Sohn, Tracy et al. 
2016).  Acetylation reduces the affinity of tau for microtubules, leading to destabilization of the 
microtubule cytoskeleton, disruption of the AIS diffusion barrier, and the eventual redistribution 
of tau into the somatodendritic region.  Once in the dendrites, tau induces decreased expression 
of AMPA and NMDA receptors, leading to synaptic dysfunction and functional impairments 
(Hoover, Reed et al. 2010).   
 
The AIS is conserved in Drosophila 
The plasticity and polarity provided by the AIS serve as the cornerstones of the intricate 
vertebrate nervous system; recent literature, however, has also identified AIS-containing neurons 
in Drosophila (Trunova, Baek et al. 2011).  Indeed, the AIS domain identified in mushroom 
body (MB) gamma neurons exhibits the characteristic hallmarks of the mammalian AIS.  First, 
there is selective accumulation of an anchoring protein within this subcellular domain.  In 
mammals, AnkG is the primary organizer of the AIS.  In contrast, Drosophila only have two 
Ankyrin genes, the ubiquitous Ank1 and the neuron-specific Ank2 (Bouley, Tian et al. 2000, 
Hortsch 2002), neither of which is exclusively expressed at the AIS.  However, while Ank1 did 
show ubiquitous expression, it also exhibited elevated levels concentrated within the AIS.  
Second, the Drosophila AIS has a localized enrichment of a unique set of voltage-gated 
potassium channels.  Specifically, Elk, Shaw (Kv3), and Shal (Kv4) channels were enriched in 
the AIS, while dORK-C2 (Ork1), Shaker (Kv1.3), and EKO (Kv1.3) were selectively excluded.  
In mammals, Elk channels mediate neuronal excitability by raising the threshold for AP firing 
(Zhang, Bertaso et al. 2010), while Shaw channels regulate neuronal resting membrane potential 
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(Hodge and Stanewsky 2008).  Shal channels play a role in establishing the A-type current, a 
transient inactivating current, as well as regulating action potential waveform (Shibata, Nakahira 
et al. 2000).  Lastly, there is a specialized F-actin cytoskeleton within the AIS.  In the 
somatodendritic and axonal regions, actin is highly expressed and ubiquitous; within the AIS, 
actin levels are reduced significantly and appear as parallel fibrils (Trunova, Baek et al. 2011).  
Similar to mammals, the actin cytoskeleton within the Drosophila AIS is more stable than in 
surrounding areas, as blocking actin polymerization reduced actin levels within dendrites and 
axonal lobes while not visibly affecting the AIS actin cytoskeleton.  Taken together, the defined 
~20-30 micron domain within Drosophila MB neurons satisfies the characteristic hallmarks of 
its mammalian counterpart.  A similar domain was also observed in multipolar dendritic 
arborization neurons.  Jegla et al identified a diffusion barrier localized to the proximal axon of 
ddaE neurons that coincided with a localized accumulation of Shal and Elk potassium channels 
(Jegla, Nguyen et al. 2016).  That multiple neuronal subtypes exhibit an AIS in Drosophila 
supports flies as a valid model, and suggests that more types of neuron will be found to also have 
an AIS.   
 
The Drosophila AIS is regulated by Cdk5/p35 kinase activity 
The AIS of Drosophila mushroom body neurons is regulated by Cdk5 activity.  Cdk5 
activity modulates the AIS size in a dose-dependent manner: loss of p35 or overexpression of a 
dominant-negative Cdk5 results in a shorted or absent AIS, whereas increased p35 levels 
significantly elongated the AIS (Trunova, Baek et al. 2011).  AIS size was assessed using a 
number of somatodendritic markers (Drl, dORK2-C2) and axon-specific labels (Robo2, FasII), 
as well as with proteins showing selective accumulation within the AIS (Ank1, Elk).  Notably, 
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p35 perturbation did not alter neuronal polarity or disrupt its function as a diffusion barrier.  
When the AIS was either shortened or elongated, somatodendritic markers remained localized to 
the soma and calyx, as the proximal boundary of the AIS remained intact.  Conversely, the 
proximal boundary of axonal markers shifted towards or away from the somatodendritic border, 
depending on the genetic manipulation.  Thus, the proximal border of the axonal compartment 
shifts in accordance with the distal boundary of the AIS (Trunova, Baek et al. 2011).   
Cdk5 also contributes to regulation of the AIS in mammals.  Cdk5 phosphorylates the 
Kvβ2 subunit of the potassium channel Kv1, which is enriched at the AIS (Vacher, Yang et al. 
2011).   The unphosphorylated subunit interacts more strongly with the microtubule plus-end 
tracking protein EB1.  Cdk5-mediated phosphorylation disrupts this interaction, releasing the 
channel from its tether and permitting its trafficking to the cell surface.  Phosphorylation of 
serine residues has also been shown to alter AnkG binding.  Casein kinase 2 (CSNK2)-mediated 
phosphorylation of serine residues of sodium channels regulates interaction with AnkG and thus 
accumulation at the AIS; indeed, blocking CSNK2 activity lead to decreased levels of Nav1.2 at 
the AIS (Brechet, Fache et al. 2008).  Cdk5-mediated phosphorylation of voltage-gated channels 
could potentially act through similar mechanisms to regulate channel localization.  Furthermore, 
Cdk5 also phosphorylates the voltage-gated potassium channel Kv7.2 at multiple serine residues 
within its phosphatidylinositol-4,5-bisphosphate (PIP2)-binding domain by Cdk5 (Salzer, Erdem 
et al. 2017).  The phosphorylation status of the channel alters its sensitivity towards PIP2, which 
is required for channel opening.  Consequently, Cdk5 helps control potassium channel 
localization and activity at the AIS, regulating the action potential threshold.   
Despite an abundance of research, the underlying molecular mechanisms responsible for 
establishing the AIS, and those involved in its dysregulation, have yet to be fully untangled.  
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Exploiting the simpler nervous system of Drosophila will allow tremendous gains in parsing 
apart AIS regulation.  To this end, we completed a brief candidate screen for additional 
modulators of AIS size.  We show here that overexpression of a construct encoding the C-
terminal tail of an Ank2-L isoform is sufficient to induce shortening of the AIS, and that this 
shortening mimics the effects of Cdk5/p35 loss of function.  Furthermore, we show that Ank2-L-
induced effects on the AIS may be sufficient to cause neurodegeneration.  Taken together, our 
data suggest that cell-intrinsic insult, such as shortening of the AIS, stemming from loss of Cdk5 
activity likely contributes to p35-mediated neurodegeneration.   
 
4.2 Materials and Methods 
Fly stocks 
All stocks were generated in an Oregon Red wild-type background (w+).  p35 loss of 
function conditions (p3520C) have been previously described (Connell-Crowley, Le Gall et al. 
2000, Connell-Crowley, Vo et al. 2007, Trunova, Baek et al. 2011, Trunova and Giniger 2012, 
Smith-Trunova, Prithviraj et al. 2015).  Overexpression of p35 was accomplished using UAS-
p35 (Connell-Crowley, Le Gall et al. 2000).  Ank2 constructs (UAS-VENUS-Ank2-S, UAS-
VENUS-Ank2-L4, UAS-VENUS-Ank2-L4) were graciously provided by Jan Pielage 
(University of Kaiserslautern, Kaiserslautern, Germany).  Ank2-RNAi lines were procured from 
Dr. Graem Davis (University of California – San Francisco, San Francisco, CA), the 
Bloomington Drosophila Stock Center (BDSC), and from the Harvard Transgenic RNAi Project 
(TRiP) (Harvard Medical School, Boston, MA).  Ank2518 stocks were a gift of Dr. Melissa Rolls 
(Pennsylvania State University, University Park, PA); Ank22001 was provided by the BDSC.  
Stocks for assessing the AIS included UAS-Act-RFP (BDSC) and UAS-Syt-HA (provided by 
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Dr. Prokop, University of Manchester, Manchester, UK).  In all experiments, MB-specific 
expression was accomplished with the gamma-neuron specific Gal4 driver 201Y-Gal4. 
To enhance efficacy, RNAi constructs were also co-expressed with UAS-Dcr2.  Some 
experiments were carried out at 29°C to enhance Gal4 expression and raise the level of Ank2-
RNAi.  For select RNAi experiments, ELAV-Gal4 was used to achieve pan-neuronal expression 
of constructs (BDSC).   
 MB cell counting utilized the UAS-nls-mCherry fly stock, which was obtained from the 
BDSC.  201Y-Gal4 was used to express UAS-nls-mCherry in control flies (w+; 201Y-Gal4/+; 
UAS-nls-mCherry/+ and w+; 201Y-Gal4/+; UAS-nls-mCherry/UAS-GFP) and flies 
overexpressing Ank2-L4 (w+; 201Y-Gal4/+; UAS-nls-mCherry/UAS-VENUS-Ank2-L4). 
 
Immunohistochemistry 
Third-stage larval brains were dissected in ice-cold PBS (pH 7.4) (Invitrogen), fixed in 
4% PFA in PBS for 25 min, and then transferred to 4% PFA in PBS with 0.5% Triton X-100 for 
an additional 25 min. Brains were then rinsed once in PBS buffer with 0.5% Triton X-100 
(PBST), followed by three five-minute washes in PBST.  Brains were incubated in blocking 
buffer (PBST, 4% BSA, 4% goat serum, 4% donkey serum) for 1 h, then incubated with primary 
antibodies in blocking buffer for 48 hours at 4°C. Primary antibodies included: 1:200 mouse 
anti-Fasciclin 2 (Fas2) from Developmental Studies Hybridoma Bank, 1:1000 rabbit anti-myc 
(Sigma-Aldrich), and 1:1000 rat anti-HA (Roche). Samples were then rinsed and washed thrice 
in PBST, before being incubated with secondary antibodies overnight at 4°C.  Secondary 
antibodies were diluted 1:500 in blocking buffer, and included goat anti-mouse, anti-rabbit, and 
anti-rat conjugated with either A488, A568, or A633 fluorochromes (Invitrogen).  Lastly, brains 
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were rinsed and washed thrice in PBST before being mounted in VectaShield antifade medium.  
In order to prevent samples from being squished, coverslips were set on number 1 glass chips.  
Prepared samples were imaged under 40X-oil on a Zeiss NLO510 confocal microscope and 
analyzed using Imaris.   
 
Mushroom Body Neuron Counting 
Control flies and flies overexpressing Ank2-L4 were aged to 3-, 10-, 30-, or 45-days old.  
Sample preparation and image acquisition were completed as described in the Materials and 
Methods section of Chapter 2.  Following image acquisition, MB cell nuclei were automatically 
counted using the “Add spots” function in Imaris.  For automatic quantification of MB neurons 
using UAS-nls-mCherry, spot counting diameter was set to “2” and threshold value was set to 
“2.12.”  These values were determined through manual testing to yield the most accurate results. 
 
Statistical Analysis 
The effects of pan-neuronal expression of constructs were tested genetically; significant 
differences in ratios of offspring were assessed by chi-square analysis.  Mushroom body cell 
counts were analyzed with GraphPad Prism 7.0b.  Differences between groups were assessed by 
either one-way or two-way ANOVA with post-hoc Tukey multiple comparison testing, as 
described.  All statistical tests were two-tailed, and statistical significance was considered at p < 
0.05.  Experimental groups were determined based on genotype, so no randomization was used; 
data collect and analysis was not performed blind to the conditions of the experiments.  Sample 
sizes were not predetermined using statistical methods.  Data distribution was assumed to be 
normal with equal variance, although this was not formally tested.    
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4.3 Results 
p35 regulates the size of the axon initial segment in central brain neurons 
p35 has previously been shown to regulate the size of the axon initial segment in a dose-
dependent manner (Trunova, Baek et al. 2011); we now confirm this regulation in a wild-type 
(w+) genetic background.  The cell adhesion protein fasciclin II (FasII) shows specific patterns 
of sub-cellular localization in a number of neuronal types.  For example, it labels the axonal 
lobes of mushroom body neurons, but is noticeably absent from the somatodendritic region and 
the AIS.  Here, we see that loss of loss of p35 results in a shift of the distal boundary of the AIS 
towards the calyx (Figure 4.3.1b).  Conversely, overexpressing UAS-p35 with a MB-specific 
Gal4 driver (201Y-Gal4) results in a shift of the distal boundary away from the calyx (Figure 
4.3.1c).  Thus, Cdk5/p35 kinase activity regulates the AIS similarly in multiple control genetic 
backgrounds. 
 
Figure 4.3.1.  p35 regulates the size of the AIS in MB neurons. 
Third-instar larva brains are stained with anti-FasII.  In each panel, the boundaries of the FasII 
staining in the MB peduncle are outlined by the red-dashed line.  The pink arrow indicates a 
stereotypical nerve that crosses over in front of the MB peduncle.  This nerve is used as a 
landmark to gauge changes in the AIS size.  (A) FasII staining in control flies stops below the 
crossover nerve, leaving a small gap.  In (B) p35-null flies, the FasII boundary is shifted 
proximally towards the calyx and extends beyond the crossover nerve.  In (C) flies 
overexpressing p35, the FasII boundary is shifted distally down the peduncle. 
 
control p35-­‐null OE	  p35 
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Overexpression of the C-terminal tail of Ank2-L robustly shortens the AIS 
A small screen for alternative modifiers of the AIS revealed that constructs encoding the 
C-terminal tail of the Ank2-L isoform can alter the size of the AIS.  AnkG, the master organizer 
of the AIS in mammals, has a giant exon that is essential for assembly of the AIS (Jenkins et al, 
2015).  In Drosophila, Ank2 has specific isoforms that also have giant exons (Ank2-L and Ank2-
XL) and that share structural similarities with AnkG.  Ank2-L was found to contribute to axon 
caliber and synaptic structure (Stephan et al, 2015), but its relationship to the AIS has yet to be 
fully elucidated.  Here, we found that expression of Ank2-L4 (UAS-VENUS-Ank2-L4; amino 
acids 1530-3005) in the MB results in a shortening of the AIS.  Ank2-L4 expression leads to a 
proximal shift in FasII staining towards the somatodendritic region of MB neurons (Figure 
4.3.2B).  Ank2-L8 (UAS-VENUS-Ank2-L8; amino acids 1530-4083) overexpression resulted in 
a more severe shortening of the AIS, as FasII staining, which stops at the boundary between the 
peduncle and calyx in Ank2-L4 samples, was observed in the calyx of Ank2-L8 samples (Figure 
4.3.2C).  Notably, Ank2-mediated modulation of the AIS was specific to the distal end of Ank2-
L, as expressing Ank2-S (UAS-VENUS-Ank2-S; amino acids 1-1159), the N-terminal domain of 
Ank2, had no effect on the AIS (Figure 4.3.2A).  Thus, the C-terminal tail of Ank2-L is both 
sufficient and necessary to induce shortening of the AIS. 
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Figure 4.3.2.  The C-terminal tail of Ank2-L is necessary and sufficient for modulation of 
the AIS. 
Third-instar larva brains are stained with anti-FasII.  Expression of (A) UAS-VENUS-Ank2-S, 
(B) UAS-VENUS-Ank2-L4, and (C) UAS-VENUS-Ank2-L8 was driven by the MB-specific 
driver 201Y-Gal4.  Ank2-S had no observable effect on the AIS, while both Ank2-L4 and Ank2-
L8 shortened the AIS.  In each panel, the boundaries of the FasII staining in the MB peduncle are 
outlined by the green-dashed line.  The pink arrow indicates a stereotypical nerve that crosses 
over in front of the MB peduncle.  This nerve is used as a landmark to gauge changes in the AIS 
size. 
 
Because Ank2-L4-induced shortening of the AIS more closely mimicked the p35-null 
phenotype, all further experiments utilize this construct.  In addition to FasII, we also assessed 
the AIS with markers labeling different sub-cellular domains within the MB neurons.  Actin 
tagged with RFP (Act-RFP) is expressed throughout control neurons, but shows an altered 
cytoskeletal architecture within the AIS; the AIS contains stabilized actin organized into parallel 
fibrils (Figure 4.3.3B; (Trunova, Baek et al. 2011)).  Synaptotagmin linked with hemagglutinin 
(syt-HA) localizes to the axonal lobes and calyx of control neurons while being selectively 
excluded from the AIS (Figure 4.3.3D).  With every marker, the proximal boundary of the 
axonal label was consistently shifted towards the calyx, indicating robust shortening of the AIS 
(Figure 4.3.3E-H).  Antibody staining of the somatodendritic-specific protein Futsch/MAP1B did 
UAS-VENUS-Ank2-L8 UAS-VENUS-Ank2-L4 UAS-VENUS-Ank2-S 
FasII FasII FasII 
a c b 
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not reveal any alterations (data not shown), indicating that neuronal polarity is maintained even 
















Figure 4.3.3.  Ank2-L4 overexpression robustly shortens the AIS. 
Labeling of the AIS of MB gamma neurons from (A-D) control or (E-H) Ank2-L4 
overexpressing third instar larva.   Panels (A) and (E) show staining with anti-FasII, panels (B) 
and (F) show Actin-RFP expression, and panels (C) and (G) show the resulting merged image.  
Panels (D) and (H) outline the AIS using Synaptotagmin-HA.  In each panel, the proximal 
border of the axonal signal is indicated by the light blue arrow.  In (B-D), the somatodendritic 
boundary is marked by the green arrow.  The pink arrow indicates a stereotypical nerve that 
crosses over in front of the MB peduncle.  This nerve is used as a landmark to gauge changes in 
the AIS size. 
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Ank2-L4-mediated modulation of the AIS is a neomorphic function 
We next sought to discern the underlying mechanism of Ank2-L4-mediated shortening of 
the AIS.  As expression of Ank2-L4 mimicked the effect of p35 deletion on the AIS, we 
hypothesized that the inverse would be true, and that decreasing Ank2 levels would affect the 
AIS in a similar manner as increased p35 levels.  To address this, we expressed Ank2-RNAi in 
the MB, as well as observing the AIS in various Ank2 mutant backgrounds.  Multiple Ank2-
RNAi constructs showed some evidence of a partially shortened AIS, but the AIS was never 
affected as severely as was seen with loss of p35 or overexpression of Ank2-L4 (Figure 4.3.4A).   
 
Figure 4.3.4.  Reduction of Ank2 levels has modest effects on the AIS. 
Brains from third-instar larva (A) expressing UAS-Ank2-RNAi, (B) heterozygous for Ank22001, 
or (C) homozygous for Ank22001 are stained with anti-FasII.  In each panel, the pink arrow 
indicates a stereotypical nerve that crosses over in front of the MB peduncle.  The proximal 
boundary of FasII staining in the peduncle is shifted towards the somatodendritic region of the 
MB neurons. 
 
The lack of a strong phenotype resulting from knockdown of Ank2 is likely not the result 
of ineffective knockdown, as pan-neuronal expression of the RNAi construct mimics larval/pupal 
lethality observed in Ank2-null mutants (Pielage, Cheng et al. 2008).  Flies carrying UAS-Ank2-
RNAi were crossed to ELAV-Gal4/CyO, and the ratio of CyO to non-CyO offspring was 
UAS-Ank2-RNAi                 Ank2
2001
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quantified.  Compiled results from multiple experiments revealed that the majority of offspring 
were CyO, and therefore not expressing Ank2-RNAi throughout the nervous system (Table 
4.3.1; p<0.0001).  These results support that pan-neuronal expression of Ank2-RNAi is lethal, 
and that the RNAi is being expressed and is functional, at least to a certain degree.  Neither the 
presence of Dicer2 nor enhancing RNAi levels by raising flies at elevated temperatures to 
increase Gal4 activity was sufficient to generate an aberrant AIS phenotype (data not shown).  
Alternatively, we also utilized a genetic mutant to decrease Ank2 levels.  Ank22001 is selectively 
null for the Ank2-L isoform (Pielage, Cheng et al. 2008).  Mutants heterozygous for Ank22001 
exhibited a slightly shortened AIS phenotype, while Ank22001 homozygous mutants did not show 
an exacerbated phenotype (Figure 4.3.4B-C).  Together with the RNAi results, these results 
demonstrate that decreased Ank2 levels do not significantly alter the AIS to the extent that 
overexpression of Ank2-L4 does.  
 
 CyO offspring Non-CyO offspring 
ELAV-Gal4/CyO ♀ X UAS-Ank2-RNAi 
♂ 
140 62 
ELAV-Gal4/CyO ♀ X UAS-VENUS-
Ank2-L4 ♂ 
122 130 
Table 4.3.1.  Reduction of Ank2 levels in all neurons results in lethality. 
Genetic tests were completed to assess viability upon expression of Ank2-RNAi or Ank2-L4.  
ELAV/CyO virgins were crossed with males expressing either UAS-Ank2-RNAi or UAS-
VENUS-Ank2-L4.  The resultant offspring were collected, and the ratio of CyO to non-CyO 
offspring was tallied.   The ratios suggest that pan-neuronal knockdown of Ank2 leads to 
lethality, whereas pan-neuronal overexpression of Ank2-L4 does not. 
 
Next, we tested if decreasing Ank2 levels could alter the AIS phenotype resulting from 
Ank2-L4 overexpression.  We combined Ank2-L4 with Ank2-RNAi or with various Ank2 
mutants and then assessed the size of the AIS.  The shortened AIS observed in MB neurons 
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expressing Ank2-L4 was not affected by either context of Ank2 reduction (Figure 4.3.5A-B).  
The failure of Ank2 reduction to induce an AIS phenotype or to alter the shortened AIS resulting 
from Ank2-L4 suggests that Ank2-L4 is neither acting as a gain of function or a loss of function.  
Indeed, if Ank2-L4 was acting as a dominant negative, one would expect it to cause lethality 
when expressed in all neurons, as was seen in Ank2-null mutants and with pan-neuronal 
expression of UAS-Ank2-RNAi.  An equal number of CyO and non-CyO offspring were 
observed after crossing ELAV-Gal4/CyO with UAS-VENUS-Ank2-L4, indicating that pan-
neuronal Ank2-L4 expression does not induce larval or pupal lethality (Table 4.3.1; p=0.722).  
Taken together, these data suggest that Ank2 does not strongly regulate the size of the MB AIS, 
at least during development, and that the observed effects resulting from Ank2-L4 
overexpression are likely a neomorphic effect.   
Figure 4.3.5.  Reduction of Ank2 levels fail to modify Ank2-L4-induced shortening of the 
AIS. 
Brains from third-instar larva with MB-specific overexpression of UAS-VENUS-Ank2-L4 in 
combination with (A) UAS-Ank2-RNAi or (B) the Ank22001 allele are stained with anti-FasII.  In 
each panel, the pink arrow indicates a stereotypical nerve that crosses over in front of the MB 
peduncle.  The robust shortening of the AIS resulting from Ank2-L4 overexpression is not 










Ank2-L4 and p35 regulate the AIS through independent pathways 
Ank2-L4 and p35 both alter the size of the AIS, so we investigated whether they do so 
through common or parallel pathways.  We have demonstrated that expression of UAS-p35 in 
MB neurons extends the AIS, while UAS-Ank2-L4 shortens the AIS.  If Ank2-L4 and p35 are 
epistatic, with one acting downstream of the other, then expressing both constructs would result 
in an AIS phenotype that mimicked either of the constructs alone.  However, Fas2 staining 
revealed that co-expressing UAS-p35 and UAS-VENUS-Ank2-L4 yields an intermediate 
phenotype, as these flies exhibit a normal-sized AIS (Figure 4.3.6B).  The lack of suppression of 
phenotypes demonstrates that Ank2-L4 and p35 are not epistatic, and indicates that Ank2-L4 and 
p35 act independently through parallel pathways to modulate the AIS.  
 
 
Figure 4.3.6.  p35 and Ank2-L4 modify the AIS through independent pathways. 
Third-instar larva brains are stained with anti-FasII. The pink arrow indicates a stereotypical 
nerve that crosses over in front of the MB peduncle.  This nerve is used as a landmark to gauge 
changes in the AIS size.  The blue arrows indicate the proximal boundary of the FasII staining.  
(A) FasII staining in flies overexpressing p35 stops below the crossover nerve.  In (B), flies 
overexpressing both UAS-p35 and UAS-VENUS-Ank2-L4 exhibit FasII staining that is 
indistinguishable from wild-type controls.  In (C), flies overexpressing UAS-VENUS-Ank2-L4 
alone show FasII staining that extends above the landmark crossover nerve. 
UAS-p35 UAS-VENUS-Ank2-L4 UAS-p35 +  UAS-VENUS-Ank2-L4 
a b c 
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Reduction of Ank2 fails to restore the shortened AIS phenotype in p35-null flies  
Next, we sought to test if reducing Ank2 levels could restore or modify the AIS in p35-
null flies, even if Ank2 was dispensable for AIS regulation under normal conditions.  Using the 
same MB-specific Gal4 driver (201Y-Gal4), we expressed Ank2-RNAi in p35-null animals.  
Labeling the AIS with FasII revealed a shortened AIS similar to loss of p35 alone, indicating that 
the knockdown of Ank2 had no effect on the p35 phenotype.  (Figure 4.3.7).   
 
Figure 4.3.7.  Ank2-RNAi does not alter the shortened AIS resulting from loss of p35. 
Third-instar larva brains are stained with anti-FasII.  The boundaries of the FasII staining in the 
MB peduncle are outlined by the red-dashed line.  The pink arrow indicates a stereotypical nerve 
that crosses over in front of the MB peduncle.  This nerve is used as a landmark to gauge 
changes in the AIS size.  Expressing UAS-Ank2-RNAi in a p35-null background does not result 
in any noticeable alterations to the AIS, relative to deletion of p35 alone. 
 
Shortening of the AIS is sufficient for neurodegeneration 
Perturbation of the AIS has been linked to neurodegeneration under a variety of contexts 
(Li, Kumar et al. 2011, Sun, Wu et al. 2014, Chand, Galliano et al. 2015, del Puerto, Fronzaroli-
Molinieres et al. 2015, Sohn, Tracy et al. 2016).  We have shown that deletion of p35 leads to a 
shortening of the AIS in MB neurons and accumulation of axonal swellings in the vicinity of the 
absent AIS, as well as enhanced loss of MB neurons (Figure 4.3.1B; Figure 3.3.1B).  As such, 
DfC2, 201Y/p3520C; UAS-Ank2-RNAi 
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we hypothesized that aberrant modulation of the AIS could directly lead to neurodegeneration in 
Drosophila.  We aged flies co-expressing UAS-VENUS-Ank2-L4 (Ank2-L4) and UAS-nls-
mCherry in MB neurons.  Additionally, we analyzed flies expressing a cytosolic GFP (UAS-
GFP) in place of Ank2-L4.  Control flies expressing UAS-nls-mCherry alone showed relatively 
consistent levels of 201Y-positive MB neurons from Day 3 to Day 30 before declining at Day 45 
(Figure 4.3.8).  Flies co-expressing UAS-nls-mCherry with UAS-GFP exhibited lower numbers 
of MB neurons at all time points, although these decreases were not significantly different from 
the three-day old controls until Day 45.  Expression of Ank2-L4 resulted in significant loss of 
MB neurons by Day 30, and an even further reduction at Day 45.  Thus, shortening of the axon 
initial segment results in accelerated neurodegeneration.   
 
Figure 4.3.8.  Ank2-L4 overexpression results in accelerated loss of MB neurons. 
Overexpression of Ank2-L4 lead to progressive loss of MB neurons.  The number of 201Y>nls-
mCherry positive MB neurons per hemisphere is presented as mean+SEM.  Flies overexpressing 
Ank2-L4 show a significant reduction in MB cell number at Day 30, with a further reduction at 
Day 45.  Flies expressing cytosolic GFP in place of Ank2-L4 show a significant decrease only at 
Day 45.  Significant differences were assessed by two-way ANOVA; differences labeled with 
asterisks (*) are relative to the Day 3 UAS-nls-mCherry alone control; differences marked with 
“#” are relative to the Day 3 sample co-expressing UAS-GFP and UAS-nls-mCherry.  *p<0.05; 




 Here we have identified a novel regulator of the axon initial segment in Drosophila 
central brain neurons.  We show that overexpression of the C-terminal portion of the Ank2-L 
isoform drastically shortens the AIS in MB neurons, and that this modulation of the AIS occurs 
through a pathway that is parallel to p35-mediated regulation of the AIS.  We also provide 
evidence that disruption of the AIS is sufficient to induce neurodegeneration.   
 Based on structural similarities and the presence of a giant exon, Drosophila Ank2 was 
proposed to be the ortholog of the mammalian AnkG.  Our results here suggest that Drosophila 
Ank2 is not the master organizer of the AIS; however, we do see evidence that Ank2 at least 
plays a role.  In mammals, deletion of AnkG results in the complete loss of the AIS; consistent 
with this, we observe a partial shortening of the AIS when we reduce Ank2 levels, either through 
RNAi or genetically with mutants.  However, we fail to see the complete absence of the AIS by 
reduced Ank2 levels, even when those levels are decreased enough to cause lethality.  This 
discrepancy could stem from the differing sets of ankyrin genes between flies and mammals.  
Drosophila only have two identified ankyrins while mammals carry three ankyrin genes.  As 
mammals have an expanded ankyrin repertoire with more specialized functions for each gene, 
the loss of one completely ablates the associated function.  In Drosophila, the neuron-specific 
Ank2 is accompanied by Ank1, which is enriched at the AIS.  It is possible that deletion of Ank2 
disrupts the AIS to a certain degree, but there is compensation by Ank1, preventing the complete 
dissolution of the AIS.  Interplay between multiple ankyrins at the AIS has been shown in 
mammals, as overexpression of AnkB in cultured hippocampal neurons resulted in a more 
restricted distribution of AnkG at the AIS (Galiano, Jha et al. 2012).  Another possibility is that 
Ank1 plays a significant role in the organization of the Drosophila AIS.  However, Ank1 lacks 
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the giant exons common to mammalian AnkG, so if it were to be the sole organizer of the AIS, it 
would likely do so through novel mechanisms.  Experiments utilizing MB-specific RNAi to 
decrease Ank1 levels will reveal the specific contributions of Ank1 in establishment and 
maintenance of the AIS.  Furthermore, it will be interesting to see if Ank1 is altered in MB 
neurons when Ank2-L levels are perturbed or Ank2-L4 is overexpressed. 
Unlike reduction of Ank2 levels, overexpression of Ank2-L4 in MB neurons drastically 
shortened the axon initial segment, as measured with various AIS markers.  This was 
unexpected, as overexpression of AnkG in cultured hippocampal neurons nearly tripled the 
length of the AIS (Galiano, Jha et al. 2012).  Independent experiments reducing levels of 
endogenous Ank2 failed to match the severity of Ank2-L4 overexpression despite being 
sufficient to induce lethality, suggesting that Ank2-L4 likely does not shorten the AIS by acting 
as a dominant negative.  Conversely, expressing Ank2-RNAi with Ank2-L4 fails to rescue the 
AIS phenotype observed when Ank2-L4 is expressed alone, suggesting that Ank2-L4 also does 
not act as a gain-of-function.  Therefore, we have concluded that Ank2-L4-mediated shortening 
of the axon initial segment is a neomorphic effect.  It has been previously demonstrated that the 
C-terminal domain of Ank2 also exhibits neomorphic activity during neuromuscular junction 
(NMJ) development, as expression of Ank2-L8 in presynaptic neurons at the NMJ results in the 
formation of small, highly ramified satellite boutons at the synapse (Pielage, Cheng et al. 2008).    
In motoneurons at the Drosophila neuromuscular junction, Ank2-L was localized to the 
axon and pre-synaptic terminal at the NMJ (Pielage, Cheng et al. 2008).  Both Ank2-L4 and 
Ank2-L8 also trafficked to the presynaptic nerve terminal in motoneurons, indicating that the C-
terminal domain of Ank2 is sufficient for this localization.  As the Ank2-S domain remained 
restricted to the cell body, it was concluded that the C-terminal region is also necessary for nerve 
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terminal targeting.  However, Ank2-L4 exhibited different expression patterns in multiple 
neuronal subtypes.  In ddaE neurons, Ank2-L4 was accumulated in the proximal axon and 
regulated the diffusion barrier, while Ank2-S appeared ubiquitously throughout the entire neuron 
(Jegla, Nguyen et al. 2016).  In our hands, neither Ank2-S, Ank2-L4, or Ank2-L8 showed any 
specific localization within MB gamma neurons, as expression was observed in the cell bodies, 
dendrites, and axonal lobes.  Thus, it is apparent that different neuronal subtypes utilize different 
targeting paradigms.  Interactions with specific sets of proteins or specific isoforms could result 
in altered localizations between neurons.  The N-terminal domain of Ank2 contains 24 ankyrin 
repeats, a membrane-binding domain, and a spectrin-binding domain, while the C-terminal 
region can interact with microtubules (Bennett and Baines 2001, Pielage, Cheng et al. 2008).  As 
Ank2-L4 lacks the membrane- and spectrin-binding domains, its localization is likely driven by 
interactions with microtubules.  Indeed, expressing Ank2-L4 in Drosophila S2 cells severely 
perturbed the microtubule cytoskeleton, generating spike-like processes innervated by bundles of 
microtubules (Pielage, Cheng et al. 2008).  Similar perturbation of the underlying microtubule 
cytoskeleton could be the mechanism through which Ank2-L4 shortens the AIS.  Alternatively, 
Ank2-L4 could also interface with microtubule-binding proteins.  End-binding (EB) protein EB3 
accumulates at the AIS of cultured rat hippocampal neurons, and directly binds to AnkG 
(Leterrier, Vacher et al. 2011).  shRNA-mediated reduction of EB3, and of EB1, resulted in 
decreased AnkG levels at the AIS.   
Perturbation of the AIS has been implicated in neurodegenerative diseases; we show here 
that direct shortening of the AIS may be sufficient to induce neurodegeneration.  Overexpression 
of Ank2-L4 induces accelerated loss of MB neurons, as flies carrying the construct showed 
significant reductions in MB cell number at 30 days, well before control samples.  While 
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expression of cytosolic GFP in place of Ank2-L4 did result in enhanced neurodegeneration 
relative to controls only expressing a nuclear label, the effects were not as severe as those 
observed with Ank2-L4.  One possibility is that expression of fluorescent proteins causes 
photocytotoxicity; indeed, multiple studies have demonstrated GFP toxicity (Liu, Jan et al. 1999, 
Ansari, Ahmed et al. 2016).  Ongoing experiments will address this by aging control flies and 
flies overexpressing Ank2-L4 in total darkness to prevent excitation of the fluorescent proteins.  
Alternatively, the increased protein levels from Gal4-driven expression could induce 
proteotoxicity and contribute to degeneration.  Regardless, Ank2-L4 caused greater cell loss than 
was seen in either control, suggesting that at least some of the observed neurodegeneration stems 
from shortening of the AIS.  This neurodegeneration is also likely a direct result of the AIS 
modulation, and not due to any non-specific detrimental effects on neuronal morphology or 
physiology.  Expression of neither Ank2-L4 nor Ank2-L8, which had a more severe effect on the 
AIS, significantly altered the gross morphological structure of the MB neurons, indicating that 
any phenotypes are largely restricted to subcellular domains.  Furthermore, using the same AIS 
markers, we were unable to identify an AIS in dopaminergic (DA) neurons, and expressing the 
same Ank2-L4 construct in DA neurons did not result in accelerated neuronal loss (Arvind 
Shukla, personal communication).  Potentially, only neurons with an AIS are susceptible to 
Ank2-L4-induced ND.  It is worth noting that even with the apparent loss of the AIS, Futsch 
remained restricted to the somatodendritic region when Ank2-L4 was overexpressed.  Thus, it is 
likely that the observed ND stems from alterations in neuronal excitability or axon structural 
integrity rather than disruption of polarity.   
Cdk5 activity has been extensively linked to the AIS in both mammals and Drosophila.  
Further, a common link among many neurodegenerative diseases is the aberrant activation of 
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Cdk5.  In flies, upregulation of Cdk5/p35 activity has been found to elongate the AIS (Figure 
4.3.1; (Trunova, Baek et al. 2011)).  It is possible that perturbation of AIS size and/or function 
contributes to disease progression.  Therefore, any mechanism that could restore the AIS could 
potentially alleviate detrimental aspects of these diseases.  Because Ank2-L4 modulates the AIS 
independently of Cdk5/p35, it may be capable of restoring the AIS to its normal size in contexts 
of Cdk5 hyperactivity.  Furthermore, the fact that Ank2-L4 seems to target the AIS specifically, 
without obvious non-specific effects, make it a plausible therapeutic agent.   
Using a novel reagent, we have unlocked a new method for modulating the AIS 
independent of the only known AIS regulator in Drosophila MB neurons, and shown that this 
modulation is sufficient to induce neurodegeneration.  By expanding the toolbox, we have made 
it easier to investigate the underlying mechanisms establishing and maintaining the AIS.  In the 
MB neurons, Ank2-L does not appear to be functionally homologous to the mammalian master 
organizer AnkG; thus, researching AIS regulation in Drosophila could reveal mechanisms that 
have previously been overlooked.  Future investigations of these mechanisms, and of interactions 
between the involved proteins, will likely lead to the development of new therapeutic strategies 
for diseases stemming from AIS dysfunction, including Angelman syndrome and epilepsy, 
diseases related to altered Cdk5 activity, neuronal injuries caused by ischemic stroke, or even 
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Chapter 5.  Concluding Remarks and Future Directions 
Cdk5 plays significant roles in neurodevelopment, neuronal homeostasis, and 
neurotransmission.  Given the importance of Cdk5, it is not surprising that its dysfunction has 
been linked to multiple neurodegenerative diseases.  Despite, or perhaps because of, the wide 
range of established and putative functions of Cdk5, however, the mechanisms underlying Cdk5-
mediated neurodegeneration remain opaque.  Through the study of Cdk5 in a simpler biological 
model, we can gain an appreciation of physiologically relevant functions that contribute to 
neurodegeneration.   
 Work in this thesis characterized the effects of Cdk5 gain and loss of function at the 
organismal, cellular, and molecular levels.  In both cases, we have observed severe declines in 
motor function and lifespan, accompanied by robust loss of central brain neurons, impairment of 
autophagy, and increased susceptibility to oxidative stress.  At the gene expression level, young 
presymptomatic animals with deletion or hyperactivation of Cdk5 activity both exhibited 
transcriptional changes consistent with chronologically older control flies.  Indeed, construction 
of a linear model based on the expression data revealed significantly elevated physiological ages 
of the p35-null and p35-OE samples.  Provided the precocious effects on the transcriptome, we 
propose that Cdk5 dysfunction accelerates the intrinsic rate of aging, and that this serves as one 
mechanism for the observed neurodegeneration.   
 Separately, we demonstrate that loss of Cdk5 function results in shortening of the axon 
initial segment, and that this phenotype is mimicked by overexpression of Ank2-L4 through a 
Cdk5-independent mechanism.  Subsequently, we show that shortening of the AIS is sufficient to 
induce neurodegeneration, as Ank2-L4 overexpression caused enhanced MB cell loss relative to 
controls.  Combining multiple experiments discussed throughout this thesis, we see that aging 
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alone results in a low level of neurodegeneration within the MBs, and that Ank2-L4 
overexpression causes degeneration, but absence of Cdk5 activity causes more robust 
neurodegeneration.  Put simply, aging and cell-intrinsic insult alone can result in 
neurodegeneration, but neither is sufficient to reach the severity of ND observed in p35-null 
mutants.  Further, our lab previously demonstrated that p35-null flies only exhibited localized 
vacuolization, rather than degeneration throughout the entire brain (Trunova and Giniger 2012), 
suggesting that some neurons are more susceptible than others.  Collectively, these findings 
support the hypothesis that synergy between aging and neuronal insults exacerbates 
neurodegeneration in flies lacking Cdk5 activity.  
 It is notable that transcriptomic changes and elevated physiological age were evidenced 
in both head and thorax tissue.  As Cdk5 activity has only been demonstrated in neuronal tissue 
of Drosophila, this suggests that the systemic effects are secondary to neuronal dysfunction; 
systemic effects resulting from neuron-specific perturbations has been demonstrated previously 
(Bahadorani, Cho et al. 2010, Kumimoto, Fore et al. 2013).  Our data are consistent with several 
mechanisms by which this may occur.  Cdk5-mediated neuronal dysfunction could disrupt 
neuroendocrine secretion, either directly or through defects in relevant neural circuits.  It is well 
established that the aging program is regulated by insulin-like peptides in Drosophila, as well as 
other systems.  Drosophila Insulin-like Protein 2 (DILP-2), DILP-3, and DILP-5 showed altered 
expression in the p35-OE head samples.  In p35-null head samples, DILPs 3 and 5 were 
significantly altered, while DILP2 exhibited changes just below our 1.5 magnitude fold change 
cutoff.  Alternatively, dysregulation of Cdk5 could induce an inflammation-like response, which 
could then spread systemically.  Our gene ontology results revealed that affected genes from 
both mutant contexts showed significant enrichment of immunity-related processes, in both head 
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and thorax tissue.  To discern if specific neuronal subpopulations are driving the effect, or if it is 
the result of general neuronal dysfunction, it will be necessary to alter Cdk5 in individual 
populations.  Conditional deletion or overexpression of p35 will reveal if there are any regions 
where expression of p35 is sufficient to recapitulate the observed systemic effects or any of the 
other degenerative phenotypes.  Further, conditional mutants will permit us to rule out the 
hypothesis that adult-onset neurodegeneration is a delayed manifestation of developmental 
defects.   
Now that we have demonstrated that Cdk5 dysfunction accelerates the intrinsic rate of 
aging, the next step is to delineate the mechanisms responsible.  Future experiments will focus 
on determining if the observed gene expression changes stem directly from Cdk5 activity on 
transcription factors, are secondary effects of altered neuronal physiology, or more likely, a 
combination of both.  To date, only a handful of studies have identified physiologically relevant 
modification of transcription factor activity by Cdk5.  In mice, Cdk5 phosphorylates FOXO3a, 
leading to elevated FOXO3a levels and nuclear translocation (Shi, Viccaro et al. 2016).  
FOXO3a initially upregulates MnSOD, protecting neurons from oxidative stress.  However, 
prolonged FOXO3a activation eventually led to increased expression of Bim and FasL, and 
ultimately neuronal death.  Cdk5 has also been linked to STAT3 (Fu, Fu et al. 2004) and MEF2 
(Gong, Tang et al. 2003), each of which could also contribute to Cdk5-mediated transcriptomic 
effects.  A subset of the observed expression changes is consistent with studies characterizing 
physiological perturbations, such as oxidative stress and impaired autophagy (Zou, Meadows et 
al. 2000) (Landis, Abdueva et al. 2004, Érdi, Nagy et al. 2012), suggesting that a portion of the 
altered transcriptome arises from secondary effects of Cdk5 dysfunction. Analyzing gene 
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expression at earlier time points will highlight the progression of changes in the profile and could 
pinpoint targets involved in the initiation of the degenerative processes.   
A separate method for elucidating the pathways underpinning Cdk5-mediated 
neurodegeneration is to identify the physiologically relevant substrates of Cdk5.  Examining the 
phosphoproteomes of p35-null and p35-OE flies and comparing them to an age-matched control 
phosphoproteome will reveal differentially phosphorylated proteins.  Screening of the sequences 
of these proteins for the Cdk5 target motif will suggest direct targets, which can then be 
biochemically validated and genetically tested.  One such substrate that has a well-documented 
interplay with Cdk5 is GSK3β.  These two proteins are known to phosphorylate one another, 
resulting in inhibition of the target.  Additional experiments are underway to test whether 
aberrant GSK3β activity can recapitulate any of the observed degenerative phenotypes, and if 
double mutants reveal any signs of rescue or exacerbation. 
 Experiments described here reveal that Cdk5 is capable of regulating a number of aging-
related processes, highlighting multiple pathways that are perturbed by Cdk5 dysfunction, and 
that could serve as potential therapeutic targets in diseases linked to altered Cdk5 activity.  
Further, our data show that perturbation of these processes precedes robust neurodegeneration 
and the onset of various degenerative phenotypes.  These findings upset the current view that 
aging causes degeneration by outlining a degenerative mechanism through which neuronal 
dysfunction itself can drive acceleration of aging.  Therapeutic advances for treating aging-
related and neurodegenerative diseases will hinge on our full understanding of this relationship, 
and the role of kinase regulation.  
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